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The first chapter of the book reports on the management of Langerhans cell 
histiocytosis (LCH)-induced central diabetes insipidus and its associated 
endocrinological/neurological sequelae in the national survey. The next chapter 
addresses DI and head injuries. Next, the management of neuroendocrine instability 
during maintenance of potential organ donors is described. Organ transplants have 
gradually increased worldwide. To have maintenance of appropriate potential organs, 
AVP is needed. Furthermore, nephrogenic DI-the potential therapeutic drugs and  
analysis of membrane protein stability is the topic of the next two chapters, followed 
by new insights into the diagnosis and management of pregnancy-related DI. The 
seventh chapter reports on the problems with differential diagnosis in a case of central 
DI in a female patient with bipolar disorder. The lithium treatment usually resulted 
in nephrogenic DI. Finally, over the last years, the development of MRI imaging on 
the pituitary gland with the stalk and hypothalamus has advanced. The final chapter 


















Edited by Kyuzi Kamoi
Contributors
Carmen Georgescu, Dirk Labudde, Florian Heinke, Anne Tuukkanen, Billy K.C. Chow, Jessica Y.S. Chu, Li-Wei Chou, Yi-
Chun Chou, Tzu-Yuan Wang, Luciana Mascia, Ilaria Mastromauro, Silvia Grottoli, Shinsaku Imashuku, Akira Morimoto, 
Tarun Pandey, Luis Alberto Flores, Cristina Gil-Diez, María Teresa Cańas, Rosa Sanguino
© The Editor(s) and the Author(s) 2011
The moral rights of the and the author(s) have been asserted.
All rights to the book as a whole are reserved by INTECH. The book as a whole (compilation) cannot be reproduced, 
distributed or used for commercial or non-commercial purposes without INTECH’s written permission.  
Enquiries concerning the use of the book should be directed to INTECH rights and permissions department 
(permissions@intechopen.com).
Violations are liable to prosecution under the governing Copyright Law.
Individual chapters of this publication are distributed under the terms of the Creative Commons Attribution 3.0 
Unported License which permits commercial use, distribution and reproduction of the individual chapters, provided 
the original author(s) and source publication are appropriately acknowledged. If so indicated, certain images may not 
be included under the Creative Commons license. In such cases users will need to obtain permission from the license 
holder to reproduce the material. More details and guidelines concerning content reuse and adaptation can be 
foundat http://www.intechopen.com/copyright-policy.html.
Notice
Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those 
of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published 
chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the 
use of any materials, instructions, methods or ideas contained in the book.
First published in Croatia, 2011 by INTECH d.o.o.
eBook (PDF) Published by  IN TECH d.o.o.
Place and year of publication of eBook (PDF): Rijeka, 2019.
IntechOpen is the global imprint of IN TECH d.o.o.
Printed in Croatia
Legal deposit, Croatia: National and University Library in Zagreb
Additional hard and PDF copies can be obtained from orders@intechopen.com
Diabetes Insipidus
Edited by Kyuzi Kamoi
p. cm.
ISBN 978-953-307-367-5
eBook (PDF) ISBN 978-953-51-6571-2
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
4,000+ 




Contributors from top 500 universities








the world’s leading publisher of 
Open Access books




Professor Kyuzi Kamoi was born August 28, 1943 in 
Tokyo, Japan. He received his MD in 1970 and his MSD 
in 1982, both from the Medical School of Niigata Uni-
versity, Niigata, Japan. He has received the following 
certificates: Japan Medical Diplomat (1970), Japan Board 
of Diabetes Mellitus (1990), Japan Board of Endocrinol-
ogy and Metabolism (1991), Certified Diabetes Mellitus 
Educator (1993), Certified Endocrine Educator (2004). From 1980 to 2010 
he was Chief of Internal Medicine, and from 2002 until 2010 the Director 
of Center of Diabetes Mellitus and Endocrine Disease at Nagaoka Red 
Cross Hospital, Japan. Since 2010 to the present he has been Professor of 
Niigata Prefecture University. He is a member of The Japanese Society of 
Internal Medicine, The Japan Endocrine Society, The Japanese Society of 
Hypertension, The Japan Society of Hypertension, the Endocrine Society, 
The American Society of Hypertension, The American Diabetes Associa-
tion, The International Diabetes Federation and the New York Academy of 











Chapter 1 Management of Langerhans Cell Histiocytosis  
(LCH)-Induced Central Diabetes Insipidus and 
Its Associated Endocrinological/Neurological Sequelae 1 
Shinsaku Imashuku and Akira Morimoto 
Chapter 2 Diabetes Insipidus and Traumatic Brain Injury 11 
Yi-Chun Chou, Tzu-Yuan Wang and Li-Wei Chou 
Chapter 3 Management of Neuroendocrine Instability 
During Maintenance of Potential Organ Donors 23 
Luciana Mascia, Ilaria Mastromauro and Silvia Grottoli 
Chapter 4 Nephrogenic Diabetes Insipidus 
– The Novelly Potential Therapeutic Drugs 41 
Jessica Y.S. Chu and Billy K.C. Chow 
Chapter 5 Analysis of Membrane Protein 
Stability in Diabetes Insipidus 53 
Florian Heinke, Anne Tuukkanen and Dirk Labudde 
Chapter 6 New Insights into the Diagnosis and 
Management of Pregnancy-Related Diabetes Insipidus 79 
Carmen Emanuela Georgescu 
Chapter 7 A Case of Central Diabetes Insipidus 
in a Female Patient with Bipolar Disorder, 
Lithium Consumer Over the Last Years 101 
Emilio González Pablos, Cristina Gil-Díez Usandizaga, 
Maite Cañas Cañas, Rosa Sanguino Andrés and Luis A. Flores 
Chapter 8 Imaging Manifestations and  
Techniques in Diabetes Insipidus 109 
Nirmal Phulwani, Tulika Pandey, Jyoti Khatri, 




Chapter 1 Management of Langerhans Cell Histiocytosis 
(LCH)-Induced Central Diabetes Insipidus and 
Its Associated Endocrinological/Neurological Sequelae 1 
Shinsaku Imashuku and Akira Morimoto 
Chapter 2 Diabetes Insipidus and Traumatic Brain Injury 11 
Yi-Chun Chou, Tzu-Yuan Wang and Li-Wei Chou 
Chapter 3 Management of Neuroendocrine Instability 
During Maintenance of Potential Organ Donors 23 
Luciana Mascia, Ilaria Mastromauro and Silvia Grottoli 
Chapter 4 Nephrogenic Diabetes Insipidus 
– The Novelly Potential Therapeutic Drugs 41
Jessica Y.S. Chu and Billy K.C. Chow 
Chapter 5 Analysis of Membrane Protein 
Stability in Diabetes Insipidus 53 
Florian Heinke, Anne Tuukkanen and Dirk Labudde 
Chapter 6 New Insights into the Diagnosis and 
Management of Pregnancy-Related Diabetes Insipidus 79 
Carmen Emanuela Georgescu 
Chapter 7 A Case of Central Diabetes Insipidus 
in a Female Patient with Bipolar Disorder, 
Lithium Consumer Over the Last Years 101 
Emilio González Pablos, Cristina Gil-Díez Usandizaga, 
Maite Cañas Cañas, Rosa Sanguino Andrés and Luis A. Flores 
Chapter 8 Imaging Manifestations and  
Techniques in Diabetes Insipidus 109 
Nirmal Phulwani, Tulika Pandey, Jyoti Khatri, 
Raghu H. Ramakrishnaiah, Tarun Pandey and Chetan C. Shah 
Preface 
This primary aim of this publication is to show recent scientific findings regarding
clinical problems of diabetes insipidus (DI) to all readers.
In a clinical setting, DI is divided into 4 types which are consisted of neurogenic,
nephrogenic, dipsogenic (primary polydipsia) and gestational types.
In 1794, DI was separated from diabetes mellitus by Dr. Frank JP who first defined DI
in the world. After that, the investigation of pathophysiology in DI has proceeded with
the development of science.
Secretions of blood vasopressin (AVP) are clarified by the developments of measuring
method and more adequate test for AVP secretion. Moreover, the development of MRI
imaging on the pituitary gland with the stalk and hypothalamus gives us more
evidentiary information. Non‐inflammatory diseases as pathophysiology of DI from
idiopathic causes are elucidated and the pathophysiology of nephrogenic DI and
gestational DI has been more clarified.
However, there are many unsolved problems in the field. For example, although adipsic
DI in neurogenic types is a rare disorder, its management is difficult. The main factor
may be caused by disturbance of the osmoreceptor. The osmoreceptor is a theoretical
concept and is not yet concretely established by recent scientific developments. Further,
it is crucial to measure plasma AVP in DI. However, as it is difficult to measure plasma
AVP easily in the world, other methods except plasma AVP have been searched. Among
the methods, there is hope in the measurement of plasma copeptin. Regarding clinical
problems, differential diagnosis of autoimmune diseases with other causes is not easy. It
needs to have a method for detecting the autoantibody for autoimmunity of DI simply
and trustworthily. In the gene, although some types have demonstrated relation to gene
abnormality, it is not clear to how the gene abnormality causes the DI.
The authors have contributed significant scientific findings and I hope that readers
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imaging  on  the  pituitary  gland  with  the  stalk  and  hypothalamus  gives  us  more 
evidentiary  information. Non‐inflammatory diseases  as pathophysiology of DI  from 
idiopathic  causes  are  elucidated  and  the  pathophysiology  of  nephrogenic  DI  and 
gestational DI has been more clarified. 
However, there are many unsolved problems in the field. For example, although adipsic 
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Management of Langerhans Cell 
Histiocytosis (LCH)-Induced Central 
Diabetes Insipidus and Its Associated 
Endocrinological/Neurological Sequelae 
Shinsaku Imashuku1 and Akira Morimoto2 
1Division of Pediatrics, Takasago-seibu Hospital, Takasago, 
2Department of Pediatrics, Jichi Medical University, Shimotsuke, 
Japan 
1. Introduction 
Central diabetes insipidus (CDI) is caused by a deficiency of arginine vasopressin (AVP), 
also known as antidiuretic hormone. Although CDI is rare in children and young adults, it 
should be kept in mind that it is associated with rare histiocytic disorders in the central 
nervous system (CNS), namely Langerhans cell histiocytosis (LCH), xanthogranulomatosis 
and Erdheim-Chester disease, all of which specifically affect the hypothalamus and pituitary 
stalk, thereby inducing CDI (1,2). In particular, CDI is the most frequently occurring CNS 
event in patients with multi-focal LCH, who often have multisystem lesions, including 
craniofacial bone lesions (3). LCH is a rare disorder that is characterized by the proliferation 
of cells that bear the activated Langerhans cell phenotype (4). Early studies reported that 
CDI occurs in 25–50% of LCH patients but this incidence appears to have dropped to 7–20% 
since the introduction of systemic chemotherapy (5). CDI can develop either before, 
simultaneously with, or subsequent to a diagnosis of LCH based on the presence of various 
extracranial lesions. It can also develop during chemotherapy for systemic LCH or after 
therapy. Patients with LCH-induced CDI show typical clinical symptoms, such as 
polyuria/polydispsia, in association with abnormal radiographic findings, such as a 
thickened pituitary stalk or a hypothalamic mass and the loss of a hot signal (T1 weighted) 
for the pituitary posterior lobe on brain magnetic resonance imaging (MRI) (5-8). Once CDI 
develops, it becomes irreversible in most patients, who will require life-long desmopressin 
replacement therapy with 1-desamino-8-D-arginine vasopressin(DDAVP). In addition, 30–
58% of patients with CDI exhibit anterior pituitary hormone deficiencies (APHD) during 
follow-up (1,7). LCH-associated APHD appears to be linked to a thickening of the pituitary 
stalk (6,7). In addition, patients with LCH-induced CDI can eventually develop 
neurodegenerative (ND) disease (9,10).  
Appropriate management of LCH-induced CDI involves (a) a prompt correct diagnosis; (b) 
early intervention with chemo/radiotherapy to reverse the CDI, if possible; (c) 
appropriately treating CDI to prevent the later development of APHD or ND disease; (d) 
good control of CDI, once it has become permanent, with DDAVP; and ideally (e) exploring 
future innovative measures that could prevent the occurrence of CDI in patients with LCH.  
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2. Diagnosis of LCH-related CDI 
2.1 Risk factors associated with the development of CDI 
CDI occurs most often among pediatric patients with multi-focal LCH, particularly those 
with multi-system disease with proptosis (11). Moreover, LCH lesions in the craniofacial 
bones are seen in >75% of CDI patients (7). We also found that LCH-induced CDI is 
associated significantly more frequently (p<0.001) with multi-system multi-focal bone 
lesions, particularly lesions in craniofacial bones (temporal bone, ear-petrous bone, orbita, 
and zygomatic bone), than with single system bone lesions (12). 
2.2 Diagnosis of CDI 
CDI is generally suspected on the basis of the characteristic symptoms of 
polyuria/polydipsia. To correctly diagnose CDI, the water deprivation with desmopression 
test has long been employed (13,14). At diagnosis, to confirm that CDI has developed, it is 
necessary to determine plasma osmolality (reference values, 276–292 mOsm/kg H2O) 
together with plasma AVP levels (reference values, 0.3–4.2 pg/ml by RIA 2 antibody 
method). The plasma osmolarity, AVP, and water deprivation test data are important for the 
early diagnosis of partial CDI, which is critical for preventing the progression into 
permanent CDI. However, sequential plasma osmolarity, AVP, and water deprivation test 
data are not available from the pre-CDI period to partial CDI and to complete CDI phase for 
patients.  
CDI may occur before, simultaneously with, or subsequent to a diagnosis of LCH that is 
made on the basis of biopsies of extra-cranial peripheral lesions such as those in the skin, 
bone, and soft tissues. The definite diagnosis of LCH is made on the basis of histopathology 
of granulomatous lesions that reveals the presence of CD1a-, Langerin (CD207)- and S100-
positive cells (15). If the initial and only lesion in patients with CDI is a thickened stalk, it 
may be necessary to biopsy the stalk since it has been reported that pituitary stalk 
thickening precedes the typical peripheral lesions of LCH by several months (16). However, 
the decision to biopsy should be made carefully, but it must be done promptly. The 
diagnosis and treatment of such cases are often delayed because physicians tend to follow a 
“wait and see” policy. 
2.3 Differential diagnosis 
CDI has various etiologies. Some are idiopathic while others are mass lesions on the 
hypothalamic-pituitary axis caused by germinoma, histiocytic disorders (including LCH), 
trauma, or inflammatory or infectious diseases (1,2,17,18). According to a large study by 
Maghnie et al.(1), the etiologies in 52% of CDI cases were idiopathic, while LCH accounted 
for another 15%. It should be noted that LCH should be suspected first in children with CDI, 
and that about 70% show pituitary stalk thickening while the remaining 30% may 
demonstrate a hypothalamic mass. In contrast, in adults, CDI is more frequently caused by 
inflammatory processes such as sarcoidosis or tuberculosis and neoplastic infiltrations that 
do not originate from neuronal tissue (2). Another possible cause in adults is lymphocytic 
hypophysitis, which is also termed infundibulo-neurohypophysitis or lymphocytic 
infundibulo-neurohypophysitis (19). Whenever this is suspected, the diagnosis is often 
delayed because a “wait and see” policy is adopted; this is because the disease is thought to 
be essentially self-limited. 
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2.4 Radiographic findings 
Abnormal radiographic findings that are associated with CDI are a thickened pituitary stalk 
or hypothalamic mass and the loss of a hot signal (on T1-weighted MRI) in the pituitary 
posterior lobe (Figure 1, 2). According to Grois et al. (7), by the time CDI is diagnosed in 
LCH patients, 71% already exhibit a thickened stalk, while MRIs performed more than 5 
years after CDI onset show that the stalk is still thickened in 24% of patients. Also, in a small 
percentage of patients, the stalk was already thickened several months before CDI onset. In 
addition, in the study of Maghnie et al. (1), where CDI cases with various etiologies were 
reviewed, 37% exhibited thickening of the pituitary stalk on the first MRI scan and, in 94%, 
the posterior pituitary was not hyper-intense. Moreover, when the course of CDI was 
examined in 18 patients who had a normal or thickened pituitary stalk at presentation, 
changes in the thickness of the stalk were observed over time: these included normalization, 
a decrease in thickness, further thickening, and thickening of a previously normal stalk  
Regarding the loss of the hot spot in the posterior pituitary lobe, we have often found it 
difficult to interpret the T1-weighted MRI findings because the hot signal in the posterior 
lobe is masked or overlapped by the hot signal of the dorsum sellae. This problem can be 
overcome if the slice on MRI is performed appropriately so that the posterior pituitary and 
the dorsum sellae are separated (8,20) (Figure 1). The high signal in the posterior lobe is due 
to the retention of AVP (8), while the high signal in the dorsum sellae reflects the dura 
membrane that covers the thin bony dorsum sellae. It has been suggested that the fat 
suppression technique and a horizontal direction of frequency encoding could help to 
differentiate the high signal of the neurohypophysis from that of the dorsum sella (20). In 
 
 
Fig. 1. MRI reveals normal and abnormal hypothalamic-pituitary regions. In two healthy 
controls, a hot signal in the pituitary lobe that is clearly separated from the dorsum sella can 
be observed (A,B: T1-weighted). A patient with LCH shows a thickened stalk and the loss of 
the hot spot in the posterior lobe (C: T1-weighted).  
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Fig. 2. Gadolinium-enhanced MRIs show a hypothalamic mass in two patients with LCH (A, 
B), each of which was histopathologically confirmed to be LCH by biopsy. 
addition, it is recommended that to confirm the diagnosis of CDI in patients with 
polyuria/polydipsia, an early survey of the hypothalamic-pituitary axis by Gadolinium-
enhanced MRI should be performed (Figure 2). 
2.5 CDI-related CNS complications - Anterior Pituitary Hormone Deficiencies (APHD) 
and Neurodegenerative (ND) Disease 
LCH-induced hypopituitarism has been described in children as well as in adults (21-24). 
Clinically, the symptoms start with CDI and then progress to anterior pituitary dysfunction, 
particularly growth hormone insufficiency. The 10-year risk of developing growth hormone 
deficiency is 54% in pediatric patients (25). However, sex hormone deficiency or 
hypogonadism has also been reported in both adult-onset cases of LCH and adults with 
childhood-onset LCH. Kaltsas et al.(23) found that at a median of 4.5 yr after the diagnosis of 
CDI in 12 adult cases, eight exhibited growth hormone deficiency, seven had FSH-LH 
deficiency, five showed TSH/ACTH deficiency, and five had panhypopituitarism. Similarly, 
in ten pediatric LCH cases with CDI, Amato et al.(24) reported growth hormone deficiency 
in four, obesity in three, and hypogonadism in two. Moreover, Maghnie et al. (1) found that 
the prevalence of growth hormone deficiency after the onset of CDI was 61% at a median of 
0.6 year after onset (range, 0.1 to 18.0). In advanced cases, panhypopituitarism develops.  
LCH-associated ND disease develops in 1–4% of LCH patients (9,10) but the correlation 
between CDI and ND disease is not as clear as the correlation between CDI and APHD. 
Grois et al. (7) reported that 76% of CDI patients with follow-up MRIs performed at least 5 
years after diagnosis exhibited neurodegenerative brain changes, showing a correlation 
between CDI and ND disease. On the other hand, we have noted in Japan that 50% of 
patients with LCH-induced ND disease had CDI but the other half did not (10). MRI is the 
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most sensitive and commonly used technique for the diagnosis and monitoring of lesions in 
the cerebellum and basal ganglia (Figure 3). Symptomatic patients with this disorder show 
neurological dysfunction such as clumsiness, tremor, dysarthria, dysphagia, nystagmus, 
dysmetria and ataxia (9,10). The eventual outcome of ND disease is dismal.  
 
 
Fig. 3. MRI of patients with neurodegenerative disease after treatment for multifocal LCH 
show high signals at the basal ganglia (A: Flair, TR=9000) and the cerebellar dentate nuclear 
area (B: Flair, TR=9000). 
3. Management of LCH-induced CDI 
3.1 Definition of CDI response to treatment 
Complete response (CR) could be defined as no further need for DDAVP therapy, while 
partial response (PR) could be defined as a reduction (>50%) in the DDAVP dosage. 
Although Minehan et al. (27) included improvement in computed tomography or MRI 
findings in their evaluation criteria, Grois et al. (7) concluded that the pituitary stalk 
thickness changes in a highly variable manner and does not correlate clearly with the 
treatment outcome. 
3.2 Detection of partial CDI 
Broadbent et al. (13) reported that ten of 14 children with LCH-induced CDI had "complete" 
CDI at onset, while the other four had "partial" CDI. This suggests that, in some cases of 
LCH, the early phase of CDI can be detected. Such conditions have also been described as 
partial, transient, or subclinical CDI. In one trial with 21 LCH patients who did not have 
CDI and had had LCH for less than four years (11), when the response of urinary AVP to 
water deprivation was measured every six months, it was found that 24% had subnormal 
responses during the initial test and CDI subsequently developed in two. However, it 






Fig. 2. Gadolinium-enhanced MRIs show a hypothalamic mass in two patients with LCH (A, 
B), each of which was histopathologically confirmed to be LCH by biopsy. 
addition, it is recommended that to confirm the diagnosis of CDI in patients with 
polyuria/polydipsia, an early survey of the hypothalamic-pituitary axis by Gadolinium-
enhanced MRI should be performed (Figure 2). 
2.5 CDI-related CNS complications - Anterior Pituitary Hormone Deficiencies (APHD) 
and Neurodegenerative (ND) Disease 
LCH-induced hypopituitarism has been described in children as well as in adults (21-24). 
Clinically, the symptoms start with CDI and then progress to anterior pituitary dysfunction, 
particularly growth hormone insufficiency. The 10-year risk of developing growth hormone 
deficiency is 54% in pediatric patients (25). However, sex hormone deficiency or 
hypogonadism has also been reported in both adult-onset cases of LCH and adults with 
childhood-onset LCH. Kaltsas et al.(23) found that at a median of 4.5 yr after the diagnosis of 
CDI in 12 adult cases, eight exhibited growth hormone deficiency, seven had FSH-LH 
deficiency, five showed TSH/ACTH deficiency, and five had panhypopituitarism. Similarly, 
in ten pediatric LCH cases with CDI, Amato et al.(24) reported growth hormone deficiency 
in four, obesity in three, and hypogonadism in two. Moreover, Maghnie et al. (1) found that 
the prevalence of growth hormone deficiency after the onset of CDI was 61% at a median of 
0.6 year after onset (range, 0.1 to 18.0). In advanced cases, panhypopituitarism develops.  
LCH-associated ND disease develops in 1–4% of LCH patients (9,10) but the correlation 
between CDI and ND disease is not as clear as the correlation between CDI and APHD. 
Grois et al. (7) reported that 76% of CDI patients with follow-up MRIs performed at least 5 
years after diagnosis exhibited neurodegenerative brain changes, showing a correlation 
between CDI and ND disease. On the other hand, we have noted in Japan that 50% of 
patients with LCH-induced ND disease had CDI but the other half did not (10). MRI is the 
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most sensitive and commonly used technique for the diagnosis and monitoring of lesions in 
the cerebellum and basal ganglia (Figure 3). Symptomatic patients with this disorder show 
neurological dysfunction such as clumsiness, tremor, dysarthria, dysphagia, nystagmus, 
dysmetria and ataxia (9,10). The eventual outcome of ND disease is dismal.  
 
 
Fig. 3. MRI of patients with neurodegenerative disease after treatment for multifocal LCH 
show high signals at the basal ganglia (A: Flair, TR=9000) and the cerebellar dentate nuclear 
area (B: Flair, TR=9000). 
3. Management of LCH-induced CDI 
3.1 Definition of CDI response to treatment 
Complete response (CR) could be defined as no further need for DDAVP therapy, while 
partial response (PR) could be defined as a reduction (>50%) in the DDAVP dosage. 
Although Minehan et al. (27) included improvement in computed tomography or MRI 
findings in their evaluation criteria, Grois et al. (7) concluded that the pituitary stalk 
thickness changes in a highly variable manner and does not correlate clearly with the 
treatment outcome. 
3.2 Detection of partial CDI 
Broadbent et al. (13) reported that ten of 14 children with LCH-induced CDI had "complete" 
CDI at onset, while the other four had "partial" CDI. This suggests that, in some cases of 
LCH, the early phase of CDI can be detected. Such conditions have also been described as 
partial, transient, or subclinical CDI. In one trial with 21 LCH patients who did not have 
CDI and had had LCH for less than four years (11), when the response of urinary AVP to 
water deprivation was measured every six months, it was found that 24% had subnormal 
responses during the initial test and CDI subsequently developed in two. However, it 
seemed difficult to predict precisely when CDI develops. Notably, Broadbent et al. (13) also 
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showed that CDI improved transiently during prednisolone therapy in one case and 
improved permanently after etoposide therapy in another. In addition, Ottaviano et al. (26) 
also successfully reversed partial CDI by using 2-chloro-deoxyadenosine (2-CDA). 
However, preventing the progression from partial CDI to complete CDI by treatment does 
not seem to be an easy task.  
3.3 Irradiation therapy of CDI 
LCH-induced CDI has been treated with irradiation with or without systemic chemotherapy 
(13, 27-29). In the past, hypothalamic-pituitary radiation therapy (HPRT) was the standard 
treatment for LCH-induced CDI in adults as well as in children (27). According to Minehan et 
al. (27), 36% of their HPRT-treated patients (10/28) responded (22% CR and 14% PR), whereas 
none in the untreated control group responded. It should be noted that five of the six complete 
responders were irradiated within 14 days of the diagnosis of CDI, and that three of the five 
patients (60%) who were treated with more than 15 Gy responded, as compared to seven of 23 
patients (30%) who were treated with less than 15 Gy. In addition, eight of the ten responders 
(80%) were female, whereas 16 of the 35 non-responders (46%) were female. Greenberger (28) 
emphasized that the most important variable in achieving a CR or PR is the speed with which 
therapy is initiated after the onset of symptoms: it was suggested that therapy should be 
instituted within 7 days, preferably sooner. However, while these observations indicate the 
importance and superiority of early intervention with irradiation in CDI, a risk/benefit ratio 
needs to be determined. In pediatric cases, HPRT is currently not recommended (30) and 
chemotherapy (such as 2-CDA) is preferred to irradiation (28, 30). In addition, prolonged low 
dose systemic chemotherapy is indicated (30). 
3.4 DDAVP 
A synthetic analog of arginine vasopressin is the drug of choice in the treatment of CDI. 
Nasal or oral administration of DDAVP, a long-acting vasopressin analog, reduces the daily 
urinary volume (31). To maintain normal urinary volume and control the symptoms of CDI, 
5–20 µg of nasal DDAVP is required per day. As little as 2.5µg may be sufficient, but the 
usual dose is 5–15µg/day. In oral DDAVP, the tablet contains 100µg of desmopressin acetate 
and the maximum plasma concentration after a single oral administration of 100µg DDAVP 
is obtained at 90 min (31). The average oral DDAVP dose required to obtain good control of 
CDI is about 20 times higher than the intranasal dose. Subcutaneous DDAVP is also 
available, which is useful for the treatment of infants with CDI and appears to be superior to 
oral or intranasal DDAVP therapy (32). Since the major complication of DDAVP therapy is 
water intoxication and hyponatremia, careful dose titration is required. 
3.5 Optimal measures for APHD and ND disease 
Growth hormone deficiency, thyroid dysfunction, and sex hormone (LH/FSH, testosterone) 
deficiency should be treated by hormonal replacement. In children, growth hormone 
deficiency is most common, whereas sex hormone deficiency is more frequent in adults. 
When the disease progresses into panhypopituitarism, cortisol replacement is also required. 
To date, while several reports have indicated that CDI can be reversed (as discussed above), 
this has not been observed for APHD (2,22,23). There is one exception: Makras et al. (33) 
reported that a 35-year-old female resumed normal menstrual cycling after steroid 
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administration. Since the hypothalamic-pituitary space-occupying mass lesions of LCH 
respond very well to 2-CDA (2, 26, 34), additional studies are needed to determine whether 
early administration of 2-CDA could reverse APHD as well as CDI.  
Established ND disease is very difficult to treat. Although several reports have suggested 
that all-trans retinoic acid or a combination of vincristine/AraC and intravenous high dose 
gamma-globulin (IVIG) may have some efficacy (35-37), it remains unclear whether any 
specific type of initial systemic chemotherapy for multifocal LCH patients can limit the later 
occurrence of ND disease (38). There is an urgent need for research that can identify an 
innovative therapy for such cases.  
4. CDI and other CNS complications experienced in the Japanese LCH study  
The cases of CDI, APHD and ND disease were analyzed in the cohort of patients treated 
with the JLSG-96/-02 protocols from 1996 to 2009 in Japan (39). CDI was detected in 12.4% 
(43/348) of pediatric multifocal LCH patients with a median follow-up of 5.0 (range, 0.2–
14.0) years, with the shortest follow-up of alive patients being 0.8 years from the initiation of 
treatment. Of these 43 cases, CDI was detected before LCH diagnosis in 13 cases, at the LCH 
diagnosis in 12 cases, during the induction/maintenance treatment in five cases, and after 
off therapy at a median of 21 months (range, 4–116) in the remaining 12 cases. The incidence 
of CDI after the initiation therapy was 5.6% in our JLSG protocols, which is lower than 9.3% 
by Grois et al. (5). Data indicate that our treatment protocol effectively reduces the incidence 
of CDI by preventing the new occurrence. Of the 43 CDI patients, APHD was noted in 30.2% 
(13/43), with growth hormone deficiency being observed in ten of these patients. Six 
patients developed ND disease. In total, chemotherapy completely resolved CDI in two 
patients, which suggests that early intervention with chemotherapy may be able to reverse 
CDI (39). 
5. Recommendations and future trials  
In practice, when LCH patients, particularly those with craniofacial bone lesions, are 
diagnosed, treated and followed up, they must be examined carefully for any signs 
suggesting that CDI is developing. In particular, inquiring about the symptoms of 
polydipsia/polyuria and occasional tests for plasma osmolarity with plasma AVP may help 
to diagnose CDI early after onset. Moreover, in young females, the presence of amenorrhea 
and/or morbid obesity could be a first sign of pituitary dysfunction together with CDI. 
Repeated brain MRI examinations are also useful for detecting the early signs of CDI and/or 
ND disease. Once the precise diagnosis of CDI has been made, nasal or oral DDAVP is a safe 
therapeutic option that effectively controls CDI. Patients with anterior pituitary dysfunction 
require other hormonal replacement therapies.  
Effective measures that can reverse CDI or other CDI-related neurological complications, or 
prevent them from newly occurring, remain elusive. Studies have shown that in LCH-
induced CDI cases, the CDI is already present at the start of chemotherapy in half of the 
cases, while the remaining half develop CDI during chemotherapy or after off therapy. 
Ideally, the early introduction of chemotherapy should be able to reverse pre-existing CDI 
and prevent the new occurrence of CDI. Unfortunately, however, therapeutic regimens for 
patients with LCH that consistently achieve these goals have not yet been identified. 
However, we recently found that IVIG may be able to prevent the progression of ND 
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disease in patients with LCH (10, 35). Given this observation and the fact that IVIG is also 
effective for other CNS inflammatory diseases, we have hypothesized that pre-emptive 
measures that include high dose IVIG may reduce the incidence of LCH-related CNS 
diseases, namely CDI and its related neurological complications, if they are given early and 
are combined with chemotherapy. To that end, we have proposed that the initial treatment 
of patients with “CNS-risk”-LCH should contain a high dose (2g/kg/dose) of IVIG 
combined with conventional induction chemotherapy (40). However, precise efficacy of 
immunomodulatory agents such as IVIG for treating LCH, particularly for preventing the 
development of LCH-related CNS diseases, needs to be explored by future studies.  
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1. Introduction  
Traumatic brain injury (TBI) is a leading cause of mortality and morbidity worldwide and is 
the major cause of disability among children and young adults in the United States (1999; 
Adekoya, Thurman et al. 2002). Recent data show that there are over a million emergency 
room visits for TBI in the United States annually. The majority of such emergency room 
visits are for patients with mild TBI, defined as a post-resuscitation Glasgow Coma Scale 
with a score of 13–15 (Teasdale and Jennett 1974). However, approximately 300,000 TBI 
victims are hospitalized annually. Of these, over 50,000 die and over half of the survivors 
have permanent neurobehavioral and quality of life problems, the most common being 
memory and concentration deficits, depression, anxiety, fatigue, and loss of emotional well-
being (Levin, Gary et al. 1990; Kraus and McArthur 1996; Hellawell, Taylor et al. 1999; Kelly, 
McArthur et al. 2006; Rutland-Brown, Langlois et al. 2006). 
Diabetes insipidus (DI) from post-TBI hypopituitarism was first reported in 1921 
(Rouvillois, Reverchon et al. 1921) and, in the 1970s, multiple case reports were published, 
documenting posterior pituitary dysfunction (Massol, Humbert et al. 1987; Halimi, Sigal et 
al. 1988). DI may be of a central (neurogenic), nephrogenic, gestational, dipsogenic, adipsic, 
or psychogenic type. The most common DI, the central type, which follows brain injury or 
surgery to the region of the pituitary and hypothalamus, is noted in previous literature 
review. DI is characterized by a diminished secretion of antidiuretic hormone, also known 
as arginine vasopressin (AVP). Neuroendocrine abnormalities following brain injury may 
occur with a much higher prevalence than previously realized, and represent an 
underdiagnosed consequence of brain injury.  
The prevalence of central DI among all kinds of neuroendocrine derangements after TBI in 
acute to chronic phases was 1.7%-26%. The development of DI seems to correlate with the 
severity of trauma in spite of more cases of permanent DI being reported in mild TBI cases. 
Central DI caused by brain injury is detectable because of polyuria and polydipsia in 
patients, but the occasions of DI are almost transient, leading to ignorance of its precise 
diagnosis and adequate treatment.  
In this chapter, diabetes insipidus was considered as central diabetes insipidus, which is a 
result of TBI. 
2. Epidemiology of diabetes insipidus after traumatic brain injury 
TBI involves, not only the primary mechanical event, but also secondary implications, such 
as pituitary insufficiency. Large neuropathological studies, including a total of 638 cases, 
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established a large frequency of 26.4% to 86% hypothalamic-pituitary damage in patients 
who died as a consequence of head injury (Ceballos 1966; Kornblum and Fisher 1969; 
Crompton 1971; Pierucci, Gherson et al. 1971; Harper, Doyle et al. 1986; Salehi, Kovacs et al. 
2007). Schneider et al. (Schneider, Kreitschmann-Andermahr et al. 2007) conducted 19 
studies, which included 1137 patients, and pointed out that the pooled prevalence of 
hypopituitarism in the chronic phase after TBI was 27.5% (95% confidence interval [CI], 
22.8%-28.9%). The prevalence of DI ranged 1.7% to 26% among all kinds of neuroendocrine 
derangements after brain injury in acute to chronic phases (Klose, Juul et al. 2007; Behan, 
Phillips et al. 2008). In a prospective cross-sectional and longitudinal study on posterior 
pituitary function after TBI, the prevalence of DI, diagnosed using the water deprivation test 
criterion standard, was 26% in the acute phase (Agha, Sherlock et al. 2005) and 6.9% among 
long-term survivors (Agha, Thornton et al. 2004). 
Literature regarding adults diagnosed with DI following TBI have flourished since 1998, and 
the findings of key studies are summarized in Table 1. Some observations are supported by 
a series of recent findings reported by Agha et al. In the study of 102 TBI survivors assessed 
at a median of 17 months following moderate to severe injury, acute DI and permanent DI 
were detected in 21.6% and 6.9% of patients, respectively. In 2003, Agha and colleagues also 
discovered a high frequency of DI (26%) in survivors (n=50) of moderate to severe TBI 
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- Boughey et al, 2004 
(Boughey, Yost et al. 
2004) 
888 USA 176 days <6 2.9% 
1998–2002 Alfonso Leal-Cerro, 
2005 (Leal-Cerro, 
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170 Male: 88% 
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2003-2005 Klose et al, 2007  
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2007) 
104 Male: 75% 








9–12: 19%  
<9: 38%  
2% 
2003 Aimaretti et al, 2004 
(Aimaretti, 
Ambrosio et al. 2004)




3 months  13–15: 55% 
9–12: 24%  
<9: 21%  
4% 
Table 1. Prevalence of diabetes insipidus after trauamtic brain injury across countries 
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2.1 Mechanism of diabetes insipidus after traumatic brain injury 
DI is characterized by a diminished release of AVP, resulting in variable degrees of 
hypotonic polyuria. Paucity of AVP may be caused by disorders that act at one or more of 
the sites involved in AVP secretion, namely, the hypothalamic osmoreceptors; the 
supraoptic or paraventricular nuclei; or the superior portion of the supraopticohypophyseal 
tract (Rose, Narins et al. 2001) (Fig. 1). Autopsy results have demonstrated different types of 
lesions, from damage to the pituitary capsule (the most frequent form of pituitary damage 
after TBI, occurring in 23.3%-59% of patients) to injury to the anterior and the posterior lobes 
and the pituitary stalk, in the form of hemorrhage, necrosis, and fibrosis (Ceballos 1966; 
Kornblum and Fisher 1969; Crompton 1971; Pierucci, Gherson et al. 1971; Harper, Doyle et 
al. 1986; Salehi, Kovacs et al. 2007). In contrast, damage to the tract below the median 
eminence or to the posterior pituitary generally induces only transient polyuria because 
AVP produced in the hypothalamus can still be secreted into the systemic circulation via the 
portal capillaries in the median eminence (Rose, Narins et al. 2001). Therefore, the severity 
of injury is unlikely to be the cause of hypopituitarism that would more likely be 
determined as trauma characteristics and/or unknown vascular mechanisms (Aimaretti, 
Ambrosio et al. 2004). There has ever been a report, showing that DI occurred secondary to 
penetrating spinal cord trauma (Kuzeyli, Cakir et al. 2001). 
 
 
Fig. 1. Arginine vasopressin is transported from the hypothalamus through the neural 
component of the pituitary stalk and stored in nerve terminals in the posterior pituitary. 
2.1.1 Imaging studies of the hypothalamic-pituitary region after traumatic brain injuy 
The posterior pituitary is known to be hyperintense on sagittal T1-weighted magnetic 
resonance imaging (MRI) of normal subjects. The absence of this finding serves as a 
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normal subjects (Brooks, el Gammal et al. 1989). The frequency of these radiologic 
abnormalities in patients with DI is poorly defined. Maghnie et al. (Maghnie, Cosi et al. 
2000) investigated the clinical presentation, the morphologic characteristics of the pituitary 
region on MRI, and the size of the pituitary stalk over time in patients who had DI from a 
variety of causes. The initial radiological findings, based on Marshall Classification, and/or 
the presence of cranial fractures did not predict the development of hypopituitarism 
(Bondanelli, De Marinis et al. 2004). 
With regard to the anatomical integrity of the hypothalamic-pituitary region, autopsy series 
from patients with fatal TBI displayed different degrees of damage to this region (Kornblum 
and Fisher 1969; Lieberman, Oberoi et al. 2001). This further supports the hypothesis that 
TBI severity is an important risk factor in the development of hypopituitarism. However, in 
the study made by Bondanelli et al. (Bondanelli, De Marinis et al. 2004), a significant 
number of patients with minimal TBI exhibited some degree of hypopituitarism. Also, in the 
Bondanelli study, the occurrence of anatomical lesions on MRI was low in patients with 
severe TBI and hypopituitarism. This was also seen in the series of studies made by Cytowic 
et al. (Cytowic, Smith et al. 1986). Therefore, in patients without radiological alteration, the 
functional damage to the hypothalamic-pituitary region may be due to a secondary hypoxic 
insult. Another possibility is diffused axonal injury caused by the acceleration-deceleration 
along rotational forces in motor vehicle crashes. Diffused axonal injury is the principal 
pathology in 40 to 50 percent of TBI hospital admissions, and is the predominant cause of 
loss of consciousness. Secondary to shearing injury, diffused axonal injury is seen in the 
midline structures. Most often, the initial CT and MRI scans have no specific findings and, 
therefore, it is only conclusively diagnosed microscopically (Cytowic, Smith et al. 1986). This 
explains why some patients with TBI, who undergo radiological scans, do not display any 
specific findings.  
However, recent MRI studies of the pituitary demonstrated pathological changes consistent 
with vascular injury. In the acute phase, the pituitary glands of TBI patients are significantly 
enlarged as compared with normal healthy control subjects. Many also demonstrate other 
abnormalities, such as hemorrhage, infarction, signal abnormalities, and/or partial stalk 
transection (Maiya, Newcombe et al. 2008). In the chronic phase, patients often demonstrate 
pituitary volume loss or empty sella, followed by abnormal pituitary gland signal 
heterogeneity, perfusion deficits, and/or lack of posterior pituitary signal (Schneider, 
Samann et al. 2007). The recently published study of 70 TBI patients with long-term follow-
up suggests that the degree of brain injury, as defined by acute CT (presence of diffused 
brain swelling and evacuated intracerebral hematoma or multiple contusions, in particular), 
is the strongest predictor of subsequent hypopituitarism (Bavisetty, McArthur et al. 2008).  
2.2 Differential diagnosis of diabetes insipidus following traumatic brain injury after 
neurosurgery 
Polyuria can be defined as a urine output exceeding 3 L/24 h in adults and 2 L/m2 in 
children. It must be differentiated from the more common complaints of frequency or 
nocturia, which are not associated with an increase in the total urine output. Differential 
diagnosis has to be kept in mind when TBI patients undergoing neurosurgery have huge 
amounts of urine output because most cases of polyuria, at this time, are not caused by DI 
(Seckl and Dunger 1989). The more common causes are excretion of excess fluid 
administered during surgery and an osmotic diuresis, resulting from treatment aimed at 
minimizing cerebral edema using mannitol or glucocorticoids (Bohn, Davids et al. 2005).  
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The diagnosis of DI following TBI in the immediate postoperative period may be more 
difficult because polyuria can occur during this period, secondary to a variety of causes. When 
polyuria begins, establish whether it is secondary to water or solute excretion. A solute 
diuresis may be a result of hyperglycemia; inability to retain sodium, secondary to 
corticosteroid deficiency; high urea levels; or the residual effect of osmotic diuretics so 
commonly used in neurosurgical procedures. When the diuresis is secondary to solute 
excretion, the urinary specific gravity is usually between 1.009 and 1.035; the urine osmolality 
is usually between 250 and 320 mOsm/kg; the serum sodium is normal or slightly decreased; 
and thirst is not usually a complaint. When the diuresis is secondary to water excretion, the 
urinary specific gravity is usually between 1.001 and 1.005; the urine osmolality is between 50 
and 150 mOsm/kg; the serum sodium is usually normal or increased; and thirst is usually a 
prominent feature. The latter picture is, of course, what is seen in diabetes insipidus. 
When it is determined that the diuresis is secondary to the excretion of a water load, the 
differential diagnosis includes the following: 
1. Diabetes insipidus. 
2. Chronic renal insufficiency. Renal function tests are abnormal and the patient is usually 
azotemic. 
3. Multiple myeloma, amyloidosis, sickle cell disease, and a peculiar phenomenon 
sometimes seen after relief of obstructive uropathy are rarer causes of an inability to 
concentrate urine. These problems usually cause little difficulty in the differential 
diagnosis. 
4. Recovery phase of acute tubular necrosis. The clinical sequence of events in this 
problem usually makes the diagnosis clear. 
5. Fluid overload. Careful attention must be paid to fluid administration during the 
intraoperative and the immediate postoperative periods when the patient may receive 
excessive amounts of parenteral fluids. If these fluids are electrolyte-free and do not 
cause a solute diuresis, the patient may retain excessive quantities of water. As the 
patient excretes this excessive water load, he may have an output which exceeds his 
intake. These conditions can be differentiated from DI by measuring urine osmolality, 
the response to water restriction, and the administration of AVP.  
You may conclude that a patient has DI if either 
1. The plasma sodium exceeds 150 mmol/ l in the presence of polyuria of > 3 L /24 h in an 
acute clinical setting; or 
2. Following an overnight water deprivation test or an 8-h observed water deprivation 
test, urine osmolality is less than 600 mOsmol/kg; or 
3. Considering a hypertonic saline water infusion test with measuring plasma AVP level 
while water deprivation test as a great burden to patients;  
4. If these do not occur, responsiveness of the renal tubule should be demonstrated by 
vasopressin administration. 
Once DI after TBI is adequately evaluated and accurately measured, the replacement of AVP 
may be considered. 
3. Outcome and association factors of diabetes insipidus after traumatic 
brain injury 
Admittedly, the pathophysiology of TBI is complex and is still poorly understood in many 
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The diagnosis of DI following TBI in the immediate postoperative period may be more 
difficult because polyuria can occur during this period, secondary to a variety of causes. When 
polyuria begins, establish whether it is secondary to water or solute excretion. A solute 
diuresis may be a result of hyperglycemia; inability to retain sodium, secondary to 
corticosteroid deficiency; high urea levels; or the residual effect of osmotic diuretics so 
commonly used in neurosurgical procedures. When the diuresis is secondary to solute 
excretion, the urinary specific gravity is usually between 1.009 and 1.035; the urine osmolality 
is usually between 250 and 320 mOsm/kg; the serum sodium is normal or slightly decreased; 
and thirst is not usually a complaint. When the diuresis is secondary to water excretion, the 
urinary specific gravity is usually between 1.001 and 1.005; the urine osmolality is between 50 
and 150 mOsm/kg; the serum sodium is usually normal or increased; and thirst is usually a 
prominent feature. The latter picture is, of course, what is seen in diabetes insipidus. 
When it is determined that the diuresis is secondary to the excretion of a water load, the 
differential diagnosis includes the following: 
1. Diabetes insipidus. 
2. Chronic renal insufficiency. Renal function tests are abnormal and the patient is usually 
azotemic. 
3. Multiple myeloma, amyloidosis, sickle cell disease, and a peculiar phenomenon 
sometimes seen after relief of obstructive uropathy are rarer causes of an inability to 
concentrate urine. These problems usually cause little difficulty in the differential 
diagnosis. 
4. Recovery phase of acute tubular necrosis. The clinical sequence of events in this 
problem usually makes the diagnosis clear. 
5. Fluid overload. Careful attention must be paid to fluid administration during the 
intraoperative and the immediate postoperative periods when the patient may receive 
excessive amounts of parenteral fluids. If these fluids are electrolyte-free and do not 
cause a solute diuresis, the patient may retain excessive quantities of water. As the 
patient excretes this excessive water load, he may have an output which exceeds his 
intake. These conditions can be differentiated from DI by measuring urine osmolality, 
the response to water restriction, and the administration of AVP.  
You may conclude that a patient has DI if either 
1. The plasma sodium exceeds 150 mmol/ l in the presence of polyuria of > 3 L /24 h in an 
acute clinical setting; or 
2. Following an overnight water deprivation test or an 8-h observed water deprivation 
test, urine osmolality is less than 600 mOsmol/kg; or 
3. Considering a hypertonic saline water infusion test with measuring plasma AVP level 
while water deprivation test as a great burden to patients;  
4. If these do not occur, responsiveness of the renal tubule should be demonstrated by 
vasopressin administration. 
Once DI after TBI is adequately evaluated and accurately measured, the replacement of AVP 
may be considered. 
3. Outcome and association factors of diabetes insipidus after traumatic 
brain injury 
Admittedly, the pathophysiology of TBI is complex and is still poorly understood in many 





injury patterns across all age ranges. In spite of more cases of permanent DI being reported 
in mild head injury cases (Segal-Lieberman, Karasik et al. 2000; Chou, Wang et al. 2009), the 
development of DI seems to correlate with the severity of trauma (Tsagarakis, Tzanela et al. 
2005). The pooled prevalence of hypopituitarism is greater in patients with severe TBI 
compared with those with mild or moderate TBI (Klose, Juul et al. 2007; Salehi, Kovacs et al. 
2007; Hadjizacharia, Beale et al. 2008). Recent prospective data suggest that the incidence of 
DI may be as high as 26% in the acute phase immediately following TBI, although up to 70% 
of cases fully recover from DI within 12 months (Agha, Sherlock et al. 2005). The incidence 
of acute DI in severe TBI is high, especially in penetrating injuries (Hadjizacharia, Beale et al. 
2008). Independent risk factors for DI include a Glasgow Coma Scale lower or equal to 8, 
cerebral edema, and a head Abbreviated Injury Score higher than 3 (Hadjizacharia, Beale et 
al. 2008). The risk of pituitary insufficiency increases in patients with severe TBI as opposed 
to those with mild TBI [odds ratio (OR) 10.1, 95% confidence interval (CI) 2.1-48.4, P = 
0.004], and in those patients with increased intracerebral pressure (OR 6.5, 95% CI 1.0-42.2, P 
= 0.03) (Klose, Juul et al. 2007). Posttraumatic DI was not associated with the presence of 
anterior hypopituitarism but was associated with more severe head trauma and the 
presence of cerebral edema on CT scan (Agha, Thornton et al. 2004). Moreover, severe TBI 
associated with basilar skull fracture, hypothalamic edema, prolonged unresponsiveness, 
hyponatremia, and/or hypotension is associated with a higher occurrence of 
endocrinopathy (Powner, Boccalandro et al. 2006).  
By contrast, Agha et al. reported in 2003 that the occurrence of post-trauma DI is unrelated 
to the severity of TBI, as assessed by  the Glasgow Coma Scale score. Lieberman et al. 
(Lieberman, Oberoi et al. 2001) also found no correlation between severity of head injury 
and pituitary dysfunction. Trauma severity was not uniformly identified as predictive of 
post-traumatic DI, which may be explained by a variety of reasons. The choice of diagnostic 
criteria, timing after TBI, identification of TBI severity, and thus of tests and cut-off limits, as 
well as that of inclusion and exclusion criteria, are of paramount importance in prevalence 
studies and the identification of predictors. For example, DI has been reported to occur in 
13% of patients in the late head injury period, with diagnosis made on the basis of random 
plasma and urine osmolalities, which are insufficiently accurate for either clinical or 
research purposes (Bohnen, Twijnstra et al. 1993). Also, alcohol and drug intoxication are 
serious confounders of the initial GCS scoring. Not all studies exclude patients with chronic 
alcohol or drug abuse and, as a result, this obvious confounder may have contributed to the 
observed inequalities. 
DI from post-traumatic hypopituitarism had been documented as a potential contributor to 
morbidity and, possibly, mortality. Boughey et al. (Boughey, Yost et al. 2004) reported that 
patients who develop DI early (in the first 3 days) have a higher mortality rate than those 
who develop DI later. The mean onset time of DI in nonsurvivors (1.5+-0.7 days) is shorter 
compared with survivors (8.9+-10.2 days) (P<0.001). The developement of DI after TBI 
carries a 69% mortality rate, and if the onset is within the first 3 days after injury, the 
mortality rate rises to 86%. 
3.1 Transient or persistent diabetes insipidus 
Actually, destruction of the hypothalamic centers or division of the supraoptic tract above 
the median eminence causes permanent DI. Transection below the median eminence, even 
removal of the posterior pituitary lobe, produces only a transient polyuria. However, DI, 
following brain injury or surgery in the hypothalamic-pituitary area, can follow a variety of 
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patterns in its development. Early prognostication as regards the permanence of DI should 
not be made because of a marked variation in the eventual outcome. Cerebral edema 
generally appears within 12 to 24 hours and is most marked at 48 to 72 hours. This edema 
may functionally impair cells which are structurally intact. A temporary DI can develop and 
is subsequently resolved as the edema clears. There are varying degrees of chronic 
antidiuretic hormone deficiency, with the urinary output being related to the number of 
viable cells. 
These initial insults, as well as transient events and treatments during the early injury phase, 
can evidently impact hypothalamic-pituitary function both acutely and chronically after 
injury. In most occasions, DI is transient, but persisting DI may develop with an incidence of 
6.9%-7.5% among TBI victims (Tsagarakis, Tzanela et al. 2005). Severe damage to the 
hypothalamus or the supraopticohypophyseal tract by neurosurgery or trauma often results 
in a typical triphasic response (Rose, Narins et al. 2001; Ghirardello, Hopper et al. 2006) (Fig. 
2). There is an initial polyuric phase, beginning within 24 hours and lasting 4 to 5 days. This 
phase reflects the inhibition of AVP release because of hypothalamic dysfunction (Seckl and 
Dunger 1989). This is followed, on days 6 to 11, by an antidiuretic phase, in which stored 
hormone is slowly released from the degenerating posterior pituitary. During this stage, 
excessive water intake can lead to hyponatremia in a manner similar to that in the syndrome 
of inappropriate AVP secretion. Permanent DI may then ensue after the posterior pituitary 
stores are depleted. 
 
 
Fig. 2. Tri-phases of central diabetes insipidus after severe damage to the hypothalamus or 
supraopticohypophyseal tract 
There was rarely any statement or discussion associated with the factors implicated in the 
persistence and the duration of post-trauma DI. Although one study has discovered that 
postoperative hypernatremia (higher than 145 mmol/L) within the first five days has a high 
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phases of post-head injury were presented with various amounts of urine output clinically. 
Post-traumatic DI is often transient, and suggests that patients need to be followed up to 
determine the true prevalence of late DI following TBI (Edwards and Clark 1986). 
4. Management of diabetes insipidus after traumatic brain injury 
The probability of developing hypopituitarism is based on the severity of the TBI. However, 
discrepancies in recent studies indicate that minimal TBI can also result in hypopituitarism. 
Thus, patients with moderate to severe TBI must be screened, and those with minimal TBI 
must be monitored for hypopituitarism. Alterations in pituitary hormones may develop 
subtly or generate clinical manifestations similar to those attributed to head trauma. 
Therefore, pituitary dysfunction may be overlooked or viewed as a result of 
postconcussional causes and escape diagnosis (Edwards and Clark 1986; Benvenga, 
Campenni et al. 2000). The modern therapeutic paradigm for moderate and severe TBI 
victims is centered on the concepts of rapidly treating the primary brain injury, correcting or 
avoiding secondary brain insults, and optimizing cerebral blood flow and metabolism 
(Edwards and Clark 1986; Benvenga, Campenni et al. 2000; Kelly, Gonzalo et al. 2000; Agha, 
Rogers et al. 2004; Dimopoulou, Tsagarakis et al. 2004). The temporal relationship between 
TBI and the occurrence of hypopituitarism is observed in three phases, namely, acute, 
recovery, and chronic. Agha et al. examined the prevalence of anterior and posterior 
pituitary dysfunctions in the acute (7–21 days) phase following TBI, and those series-
identified deficiencies in need of immediate replacement, such as ACTH deficiency and 
posterior pituitary dysfunction (Agha, Rogers et al. 2004). 
Adequate secretion of AVP is crucial in water homeostasis. Inadequate AVP secretion leads 
to varying degrees of water loss. Water intake may be inadequate to compensate for the 
water loss because of impaired cognition, physical disability, or coexistent hypodipsia that 
may occur in the early post-TBI period. This may lead to hypernatraemic dehydration with 
increased morbidity and impairment of recovery (Maggiore, Picetti et al. 2009). Therefore, 
daily sodium measurements and fluid charts are indicated in all TBI patients during the 
early post-injury period. Therapeutic intervention with desmopressin is indicated in 
patients with severe forms of this disorder. Caution is required for the occasional 
development of the syndrome involving inappropriate AVP release that may also occur as a 
result of brain trauma, and increase the likelihood of seizures. If polyuria persists during the 
late-phase of TBI, a persistent DI should be appropriately diagnosed and treated. 
4.1 Drugs for diabetes insipidus after traumatic brain injury 
Considering that the primary problem in DI is the deficient secretion of AVP, control of the 
polyuria can be achieved by hormone replacement. In the past, intramuscular injections of 
vasopressin (Pitressin) tannate in oil was used to control, which is no longer available. This 
preparation had two problems, namely, the requirement of intramuscular administration 
and the occasional development of antivasopressin antibodies, with a secondary increase in 
urine output that appear AVP resistant (Vokes, Gaskill et al. 1988). Pitressin has many side 
effects of anaphylaxis (cardiac arrest and/or shock), circumoral pallor, arrhythmias, 
decreased cardiac output, angina, myocardial ischemia, peripheral vasoconstriction, 
gangrene, abdominal cramps, nausea, vomiting, passage of gas, tremor, vertigo, pounding 
in head, bronchial constriction, sweating, urticaris, cutaneous gangrene et al. Otherwise, 
pitressin has two actions with V1 and V2 receptors. As DI is caused by decreased V2 
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receptor function owing to paucity of AVP secretion, it is better to have V2 receptor action 
alone without V1 receptor action as drug. Consequently, using DDAVP (desmopressin 
acetate) instead of Pitressin is better. Desmopressin comes in liquid form. That is, it is 
usually administered intranasally and in an oral tablet form. The usual daily maintenance 
dose is 10 to 20 µg once or twice a day. 
An oral tablet preparation of desmopressin is also available (Stenberg and Lackgren 1994). 
The absorption of desmopressin in normal persons is decreased by 40 to 50 percent when 
taken with meals (Rittig, Jensen et al. 1998). The oral form has about one-tenth to one-
twentieth the potency of the nasal form because only about five percent is absorbed from the 
gut. Thus, a 0.1 mg tablet is the equivalent of 2.5 to 5 µg of the nasal spray. Although 
patients generally prefer the oral preparation because of ease of administration, not all 
patients have an adequate response. As a result, we recommend starting with the intranasal 
preparation. This ensures that the patient understands what constitutes a good antidiuretic 
response prior to performing a trial of oral therapy. If DDAVP cannot be administered 
intranasally or orally, it can be given subcutaneously. A usual antidiuretic dose is 1 µg, 
administered subcutaneously every 12 hours. Alternatively, in patients with decreased 
subcutaneous absorption, 2 µg of desmopressin acetate is given intravenously over one 
minute, and the duration of action, as judged by increased urine osmolality, is 12 hours or 
more (Rembratt, Graugaard-Jensen et al. 2004). DDAVP is safe for both the mother and the 
fetus when administered during pregnancy (Ray 1998). 
For the vast majority of patients with DI, desmopressin is readily available, safe, and 
effective. Nevertheless, with partial DI and/or if the amount of available desmopressin is 
limited (Thurman, Halterman et al. 2003), the addition of other drugs that increase AVP 
release, enhance AVP effect on the kidneys (both of which require at least some endogenous 
AVP secretion), or directly decrease the urine output independent of AVP is rarely 
necessary. However, these agents, such as chlorpropamide, carbamazepine, clofibrate, 
thiazide diuretics, or NSAID, are less effective and associated with more adverse effects than 
desmopressin. 
5. Conclusion 
DI from post-traumatic hypopituitarism is documented as a potential contributor to 
morbidity and, possibly, mortality. As the above discussion shows, we suggest and note that 
1. Greater awareness of these possible complications of TBI and appropriate testing are 
encouraged. 
2. Assessment of the integrity of AVP secretion, and hypothalamic-pituitary axis is crucial 
to ensure the survival and the optimal rehabilitation of TBI patients. 
3. Physicians should also present clinical symptoms of anterior or posterior pituitary 
dysfunction, not only for patients with severe TBI who need to be screened, but also for 
patients with minimal brain injury (Estes and Urban 2005). 
4. The identification and the appropriate timely management of hormone deficiencies, 
such as the replacement and supplementation of desmopressin, are crucial to optimize 
patient recovery from brain injury, improve quality of life, and avoid long-term adverse 
outcomes of untreated hypopituitarism.   
5. By monitoring pituitary function over time, planning appropriate hormonal 
replacement for brain-injured patients who acquired hypopituitarism is possible. This 
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morbidity and, possibly, mortality. As the above discussion shows, we suggest and note that 
1. Greater awareness of these possible complications of TBI and appropriate testing are 
encouraged. 
2. Assessment of the integrity of AVP secretion, and hypothalamic-pituitary axis is crucial 
to ensure the survival and the optimal rehabilitation of TBI patients. 
3. Physicians should also present clinical symptoms of anterior or posterior pituitary 
dysfunction, not only for patients with severe TBI who need to be screened, but also for 
patients with minimal brain injury (Estes and Urban 2005). 
4. The identification and the appropriate timely management of hormone deficiencies, 
such as the replacement and supplementation of desmopressin, are crucial to optimize 
patient recovery from brain injury, improve quality of life, and avoid long-term adverse 
outcomes of untreated hypopituitarism.   
5. By monitoring pituitary function over time, planning appropriate hormonal 
replacement for brain-injured patients who acquired hypopituitarism is possible. This 
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1. Introduction 
Solid organ transplantation is the treatment of choice for patients with end-stage cardiac, 
pulmonary or liver disease. This form of surgical treatment has enjoyed increasing success, 
with better early and late survival for lung, liver and cardiac transplantation, while renal 
transplantation is both cost effective and improves the quality of life for the recipient 
receiving dialysis. The main limiting factor for this successful procedure is the shortage of 
suitable donor organs, resulting in longer waiting list for patients with a substantial risk of 
mortality before transplantation (Keegan M.T. 2009). 
The majority of organs come from patients who suffered an acute neurologic injury, such as 
traumatic brain injury or cerebrovascular accidents, including spontaneous intracerebral 
bleeding and thrombosis that progresses to brainstem death. Unfortunately, not all 
brainstem dead patients become potential organ donors and organ are ultimately harvested 
from only 15-20% of individuals who satisfy organ donor criteria (Mascia et al 2010). Many 
reasons contribute to the paucity of donor organs, such as the sub-optimal critical care 
management of potential organ donors, lack of consent, logistical problems and the use of 
strict donor criteria (Mascia et al 2006). 
In the present chapter we will discuss neuroendocrine alterations which occur in acute brain 
injured patients evolving to brain death. Since most of the data available has been collected 
in acute neurological patients with varying impairment of the conscious state, we will first 
summarize the pathophysiology, clinical signs, diagnosis and treatment of endocrine 
abnormalities in severe brain injury patients and then we will focus on the consequences of 
neuroendocrine alterations in brain dead subjects. These abnormalities contribute to the 
hemodynamic and metabolic instability of the potential organ donors and may affect organs 
availability for transplantation. 
In severe acute brain injury patients evolving to brain death, hypothalamic-pituitary-adrenal 
insufficiency occurs in 30-50% (Behan et al 2008; Corneli et al 2007) of patients and a high 
prevalence of neuroendocrine deficiency is present in brain dead patients (Howlett et al 
1989; Salim et al 2006). These endocrine alterations lead to metabolic abnormalities and 
hemodynamic instability with deleterious effects on these potential organ donors (Ullah et 
al 2006). Adequate organ donor management is therefore mandatory to prevent, reduce or 
reverse these alterations and to maintain the functional integrity of potentially 
transplantable organs. Since all donors are treated in intensive care units an optimal clinical 
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practice. Nevertheless a substantial variability between medical centres and a consequent 
sub-optimal clinical management exists in the field of organ donors treatment (Mascia et al 
2009). Regarding the neuroendocrine alterations most of the studies have been performed in 
neurological patients looking at the long term effects of these abnormalities. 
When we treat acute neurological patients with a preserved conscious status who develop 
endocrine alterations such as anti-diuretic hormone depletion, details from the clinical history 
are collected, symptoms developed over time frame of weeks or even months are recorded, 
then clinical signs are identified and laboratory tests are required to confirm the clinical 
diagnosis. Finally a therapeutic strategy is implemented and the clinical prognosis is proposed 
according to the severity of symptoms and signs as well as the response to treatment. When 
we treat acute neurological patients with a severe impairment in the conscious state and 
endocrine alterations, the clinical history, symptoms and signs are not easily evaluated, 
although severe hemodynamic and metabolic alterations usually occur in a time frame of 
hours or few days. Laboratory tests are required to confirm the clinical diagnosis, a therapeutic 
strategies must be readily implemented and the severity of clinical status will have a 
prognostic value. When we treat potential organ donors with neuroendocrine alterations, 
clinical signs develop within minutes or few hours with a dramatic impairment in systemic 
hemodynamics and metabolism. Therefore, clinical diagnosis, laboratory test confirmation and 
implementation of the specific therapy are required in a time frame of minutes or few hours. 
Moreover, no prognostic evaluation is required, while hemodynamic stability and prompt 
correction of metabolic alterations are mandatory in order to guarantee an optimal organ 
perfusion and metabolic homeostasis for organ donation. 
2. Neuroendocrine alterations in severe acute neurological patients 
Several studies have demonstrated that brain injury such as traumatic brain injury (TBI) or 
subarachnoid hemorrhage (SAH) is a frequent cause of hypopituitarism, with an incidence 
that is much greater than previously reported.  
First of all, we have to introduce a distinction between acute and prolonged critical illness in 
term of metabolic and neuroendocrine paradigms. The initial endocrine response consists 
primarily of an activated release of anterior pituitary hormone and peripheral inactivation 
of anabolic pathways. In the chronic phase there is a uniformly impaired pulsatile secretion 
of anterior pituitary hormones at least in part due to hypothalamic origin (Van den Berghe 
et al 1998), which is correlated with reduced activity of target tissue. However, this specific 
pituitary-dependent axis can be reactivated with preserved peripheral responsiveness. 
Another mandatory issue to underline is that there is sufficient data from the literature 
concerning long term effects at hypothalamic or pituitary level of TBI or SAH, while data 
regarding the short term effects of severe acute neurological injuries in terms of 
neuroendocrine activity are very scanty.   
The first report of TBI–induced hypopituitarism was published in 1918 (Cyran 1918). Then 
several retrospective studies and case reports identified additional conditions of 
hypopituitarism following head injury (Altman and Pruzanski 1961; Edwards and Clark 
1986; Kusanagi et al 2000). In particular, more than ten years ago Benvenga et al. confirmed 
the relationship between TBI and hypopituitarism (Benvenga et al 2000). These authors 
reported that in 70% of cases hypopituitarism was diagnosed within 1 year of injury. Indeed 
there are reports of patients with total, multiple or isolated hypopituitarism whose clinical 
history revealed the occurrence of TBI many years before the diagnosis.  
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Subarachnoid hemorrhage produces a pattern of deficits similar to that of TBI. Patients with 
aneurysmal SAH frequently present persistent physical, psychosocial, cognitive and emotional 
deficits similar to those of patients with untreated partial or complete hypopituitarism, even if 
clinicians do not normally relate these symptoms to pituitary insufficiency.  
In the field of intensive care medicine, several studies show that critically ill patients with 
TBI frequently exhibited an abnormal pituitary hormonal response in the immediate post-
injury period (Agha et al 2004b; Aimaretti et al 2004; Bondanelli et al 2005; Dimopoulou et al 
2004). On the other hand, the critical illness itself has profound effects on the pituitary 
function (Van den Berghe and de Zegher 1996) that is characterized by protein 
hypercatabolism, preservations of fat depots and immune dysfunction. Since the anterior 
pituitary gland is the first regulator of human metabolism and immune function, the 
presence of an extensive interaction between these three players is not surprising. 
Interestingly, the critical illness may be associated with reduced levels of activity in the 
different pituitary axes, except for the corticotropic axis (Van den Berghe and de Zegher 
1996). Furthermore, in the critical care scenario some therapeutic strategies such as the 
infusion of dopamine has been found to be associated with an impaired pituitary function, 
which has raised the hypothesis that dopamine may play a role in the pathogenesis of the 
pituitary dysfunction present in critical illness (Van den Berghe and de Zegher 1996). 
2.1 Epidemiology 
TBI-related hypopituitarism remains largely under-diagnosed, mostly due to the lack of 
awareness among physicians who take care of these patients. Indeed, considering the 
epidemiology of TBI (91–332/100,000 inhabitants all over the world) and the high risk to 
develop the most severe form of multiple or total hypopituitarism (at least 10–15% of 
patients), it has became more evident that many patients misdiagnosed hypopituitarism 
induced by brain injury may experience a poor quality of life and a low life expectancy.  
The estimated incidence rates for SAH are between 10 to 25 per 100,000 per year. Morbidity 
and mortality in the acute phase are due to the pathophysiological changes related to the 
initial bleeding, such as the abrupt increase in intracranial pressure, impairment of cerebral 
perfusion and focal or global cerebral ischemia. In studies which included both SAH and 
TBI patients, an incidence different degrees of hypopituitarism was reported to be 27% and 
47% respectively (Schneider et al 2007). 
2.2 Pathophysiology 
Pituitary function is at particular risk because of the vulnerable anatomic location of the 
gland within the sella turcica as well as its delicate infundibular hypothalamic structure and 
its fragile vascular supply (Kelly et al 2000). In several neuropathological studies 
haemorrhage, necrosis, and fibrosis of the pituitary gland and hypothalamus have been 
recorded after TBI or SAH. Stalk lesions can produce anterior-lobe infarction by damaging 
the portal blood supply (Daniel et al 1959; Kornblum and Fisher 1969). Hypothalamic 
lesions consisting of areas of ischemic necrosis, macro and micro-haemorrhages were noted 
in two-thirds of the patients who died shortly after SAH (Bondanelli et al 2006).  
Growth hormonal deficiency is most often seen in patients with TBI since the growth 
hormone-secreting somatotrope cells are located in the wings of the pituitary gland and the 
vascular supply and oxygen they receive come out of the hypothalamic-pituitary portal 
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in cell death. In contrast, the cells that secrete adrenocorticotropin hormone and thyroid-
stimulating hormone are located ventrally in the more protected, medial portion of the 
pituitary, and they receive blood from the portal vessels and the anterior pituitary artery 
branch, which provides nutrients and oxygen to this area and to all the cells located in the 
sub-capsular part (Kelly et al 2000). However, data from literature show that the frequency 
of growth hormone deficiency and low cortisol levels are 15% and 46% respectively in TBI 
while in SAH the risk of hypopituitarism may be even higher (Agha et al 2004b; Aimaretti et 
al 2004; Casanueva et al 2004; Kreitschmann-Andermahr et al 2004).  
Disorders of salt and water balance, in particular diabetes insipidus (DI) and the syndrome of 
inappropriate antidiuretic hormone secretion, are common complications in the acute phase of 
TBI (Kaufman et al 1993). Available information on the frequency of post-traumatic DI are 
mainly derived from retrospective data (Boughey et al 2004; Wong et al 1998), while few 
prospective studies have accurately defined the natural history of DI following TBI. In the first 
prospective study Agha and collegues (Agha et al 2005) investigated the sequential posterior 
pituitary function after TBI and reported a frequency of early post-traumatic DI equal to 26%. 
Further studies reported a negative correlation between Glasgow Coma Scale and plasmatic 
levels of both osmolality and sodium, and a positive correlation between Glasgow Coma Scale 
and peak urine osmolality in the acute phase of TBI, suggesting that acute DI is associated with 
the severity of injury. Post-traumatic DI may result from inflammatory oedema around the 
hypothalamus or posterior pituitary, with recovery as the swelling resolves. It can also result 
from direct damage to the paraventricular and supraoptic hypothalamic neurones, the 
pituitary stalk or axon terminals in the posterior pituitary. These abnormalities may be either 
transient, if the supraoptic and paraventricular neurones form new vascular connections, or 
become permanent if gliosis occurs (Yuan and Wade 1991).  
Finally, pituitary function is impaired in 50% of patients with primary brain tumors, as a 
consequence of surgery and radiotherapy. Hypopituitarism in patients with primary brain 
tumors often includes severe growth hormone deficiency. However, the efficacy of 
treatment of hypopituitarism in patients with primary brain tumours has never been 
demonstrated (Schneider et al 2006). 
2.3 Clinical signs and symptoms of hypopituitarism  
In acute neurological patients with a preserved conscious level hypopituitarism is associated 
with a number of non-specific signs and symptoms. Fatigue is a major symptom (Kreutzer 
et al 2001; LaChapelle and Finlayson 1998) although this symptom may also be related to 
TBI. Other signs, symptoms and laboratory abnormalities include decreased lean body mass 
with increased body fat and dyslipidaemia, reduced exercise tolerance and muscle strength 
(Carroll et al 1998), DI (Edwards and Clark 1986), decreased thyroid-stimulating hormone 
and free tyroxine levels and adrenal insufficiency (Benvenga et al 2000; Carroll et al 1998; 
Lieberman et al 2001), amenorrhea/infertility, erectile dysfunction and hyperprolactinaemia 
(Benvenga et al 2000; Cytowic et al 1986), diminished cardiovascular function, impaired 
cognitive function, memory loss, decreased concentration, mood disturbances, increased 
anxiety and depression, irritability, insomnia (Deijen et al 1996; Howlett et al 1989; Leon-
Carrion et al 2001) and a feeling of social isolation (Carroll et al 1998). A deficiency of 
growth hormone produces metabolic effects in different organs with consequences in both 
physical and emotional areas. These signs and symptoms of hypopituitarism are the same in 
hypopituitaric patients after TBI. These symptoms and signs of hypopituitarism are also 
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present in TBI in the sub-acute phase. The overlap of clinical manifestations due to the 
sequelae of TBI or to the presence of hypopituitarism induced by trauma may result in a 
sub-optimal rehabilitation of TBI patients with hypopituitarism. 
Traditionally, the onset of DI was considered a useful indicator of hypopituitarism because 
it is routinely attributed to pituitary insult. However, reports of the incidence of DI 
following brain injury vary widely, with Benvenga et al. (Benvenga et al 2000) reporting as 
many as 30% of cases compared to Aimaretti et al. (Aimaretti et al 2004) who reported only 
5.5%. In a recent retrospective study, the incidence of severe hypernatremic cases of DI was 
2.9% but the incidence of less severe forms seems to be much higher. Agha et al, in a 
retrospective study reported an incidence of 21.6% in the immediate period following TBI, 
which was related to the severity of the traumatic insult but not related to the development 
of anterior pituitary abnormalities (Agha et al 2004a). The discrepancy between anterior and 
posterior pituitary altered function has been recently confirmed in a prospective study 
which reported a high incidence of DI (26%) (Agha et al 2004a).   
Likewise, reports on the incidence of hyperprolactinaemia, another marker of hypothalamus-
pituitary derangement, following brain injury vary even more dramatically (Aimaretti et al 
2004; Benvenga et al 2000; Lieberman et al 2001). While these findings provide evidence that 
TBI is associated with derangement of the hypothalamus-pituitary unit, it underscores the fact 
that a full endocrinologic assessment is necessary to determine the extent of the hormonal 
alterations after TBI and the need for a global endocrine evaluation. Aimaretti and co-workers 
(Aimaretti et al 2005) in a multicentered study prospectively investigated the risk to develop 
hypopituitarism in brain injured patients. Pituitary function was evaluated in 100 patients 
with TBI and in 40 patients with SAH after 3 and 12 months to evaluate the incidence of 
hypopituitarism and the effect of pituitary deficits on outcome one year after the brain injury. 
The 3 month study showed some degree of hypopituitarism in 35% of TBI patients. Total, 
multiple and isolated deficits were present in 4, 6 and 25% respectively. DI was present in 4%, 
secondary adrenal, thyroid and gonadal deficit was present in 8, 5 and 17%, respectively. 
Severe growth hormone deficiency was the most frequent pituitary defect (25%). In SAH 
patients some degree of hypopituitarism was reported in 37.5%. Multiple and isolated deficits 
were present in 10 and 27.5% respectively. DI was present in 7.5%, secondary adrenal, thyroid  
and gonadal deficits was present in 2.5, 7.5 and 12.5%, respectively. Severe growth hormone 
deficiency was the most frequent defect (25%). The 12 months retesting demonstrated that 
some degree of hypopituitarism was still present in 22.7% of the TBI patients. Total 
hypopituitarism was always confirmed at 12 months while multiple and isolated 
hypopituitarism was confirmed in 25%, DI was present in 2.8%. In SAH after 12 months 
retesting hypopituitarism was present in 37.5% with multiple or isolated deficits in 6.2 and 
31.3% respectively. No multiple deficits were confirmed at 12 months but in 2 patients new 
deficits were diagnosed. It is important to note that 30.7% of SAH with isolated deficits at 3 
months displayed normal pituitary function at 12 months and the most common deficit was 
severe growth hormone deficiency in both TBI and SAH.  
These data indicate that pituitary function may improve over time and that hypopituitarism 
is transient in most cases and would reflect effective repair of the hypothalamic-pituitary 
damage induced by brain injuries.  
Considering the topic of this chapter it is important to note that the acute phase is 
characterized by a high incidence of hypopituitarism as sign of the acute brain damage in 
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2.4 Diagnosis  
Diagnosis of hypopituitarism due to brain injury does not differ from that of 
hypopituitarism due to other causes. Test of pituitary hormones function and their target 
glands should be always performed.  
Diabetes insipidus is demonstrated by the presence of massive dilute urine volume (>3 
L/24 h) with low urine osmolality (<300 mmol/kg) (Aimaretti et al 1998a; Aimaretti et al 
1998b; Lamberts et al 1998; Lissett CA 1996). 
Secondary adrenal insufficiency is demonstrated by early-morning (at 9:00 am) cortisol 
concentrations less than 30 μg/L (or < 100 pmol/L) and morning ACTH below upper 
reference range, associated with another pituitary deficit (Aimaretti et al 1998a; Aimaretti et 
al 1998b; Lamberts et al 1998; Lissett CA 1996). 
Secondary hypothyroidism is demonstrated by low free tyroxine (<8 ng/l) concentrations 
with normal or low thyroid-stimulating hormone levels (Aimaretti et al 1998a; Aimaretti et 
al 1998b; Lamberts et al 1998; Lissett CA 1996). 
Secondary hypogonadism is demonstrated by: (1) in premenopausal women low estradiol 
levels (<20 pg/ml) with normal or low follicle-stimulating hormone and luteinizing 
hormone levels; (2) in men by low testosterone levels (<3 μg/l) with low or normal follicle-
stimulating hormone and luteinizing hormone levels (Aimaretti et al 1998a; Aimaretti et al 
1998b; Lamberts et al 1998; Lissett CA 1996). 
GH deficiency is demonstrated by peak growth hormone response to growth hormone 
releasing hormone + arginine below 16.5 μg/L (3rd centile limit of normal growth hormone 
response). A peak growth hormone response below 9.0 μg/L (1st centile limit) indicates 
severe growth hormone deficiency (Aimaretti et al 1998a; Ghigo et al 2001; Lamberts et al 
1998). Insulin-like growth factor-I levels were considered with respect to the 25th centile 
age-related normal limits (Aimaretti et al 1998a; Ghigo et al 2001; Hartman et al 2002; 
Lamberts et al 1998). From an endocrinological point of view, TBI patients in coma or in 
vegetative state should not be evaluated. The reason is that no data are now available 
showing that an early diagnosis and appropriate replacement for the different forms of 
hypopituitarism can be of any benefit for patients in such extreme conditions.  
Therefore endocrinologists should perform a neuroendocrine assessment in: 1) patients who 
develop an acute form of hypopituitarism in the early phases after TBI (i.e. DI and 
electrolyte abnormalities in particular) 2) patients with abnormalities in the brain imaging 
techniques like hemorrhagic lesions (on CT or MRI scan). Although a neuroendocrine 
assessment is not a priority in severe neurological patients, an optimal hemodynamic 
management of severe brain injured patients is crucial to guarantee adequate perfusion to 
the brain during the repair process. Therefore, a prompt diagnosis and treatment of anti-
diuretic hormone, cortisol and insulin depletion in severe brain injured patients may play a 
relevant role in stabilizing hemodynamic and electrolyte abnormalities. When these patients 
evolve to brain death hemodynamic stability remains a crucial part of the clinical 
management to optimize peripheral organ perfusion.  
2.5 Therapeutic strategy  
2.5.1 Who 
The severity of TBI or SAH has been suggested as a risk factor for the development of 
hypopituitarism. Although some discrepancies are present in the literature, the degree of 
severity of the brain lesion is considered a limiting factor for treatment of endocrine 
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diffuse brain swelling on initial CT and hypotensive or hypoxic insults as significant 
predictors for the development of hypopituitarism. Bondanelli et al. (Bondanelli et al 2004) 
confirmed that hypopituitarism was more prevalent in TBI patients with low Glasgow coma 
scale although the CT scan abnormalities based on the Marshall classification did not predict 
the development of pituitary abnormalities. Indeed, Lieberman et al (Lieberman et al 2001) 
and Aimaretti et al. (Aimaretti et al 2004; Aimaretti et al 2005) did not confirm any 
correlation between Glasgow coma scale and pituitary dysfunction. Because of these 
discrepancies regarding the risk factors for pituitary abnormalities after TBI, it is difficult to 
identify which patients should be screened for these alterations. However it is well known 
that: 1) hemodynamic instability (hypotension and low cerebral perfusion) and electrolyte 
abnormalities may affect neurological outcome after TBI; and 2) pituitary abnormalities may 
have a relevant impact on hemodynamic and metabolic homeostasis. Therefore, in order to 
guarantee the optimal clinical management of severe brain injured patients it is wise to plan 
a basic screening test for the presence of endocrine abnormalities after TBI. 
2.5.2 When  
It is well known that hormonal secretion from the pituitary is altered immediately 
following TBI (Chiolero and Berger 1994). However, because of the use of drugs, 
metabolic abnormalities, and functional alterations, a condition of hypopituitarism is 
difficult to assess (Dimopoulou et al 2004). Agha et al. (Agha et al 2004a) examined the 
prevalence of anterior and posterior pituitary dysfunction in the acute (7–21 days) phase 
following TBI. The authors identified adrenocorticotropin hormone deficiency and 
posterior pituitary dysfunction as the main abnormalities which required immediate 
replacement therapy. In the recovery phase, Aimaretti et al. (Aimaretti et al 2004; 
Aimaretti et al 2005) established that early diagnosis of pan-hypopituitarism is always 
confirmed at one year and thus treatment is required at the time of diagnosis. In the 
chronic phase, Bondanelli et al. (Bondanelli et al 2004) observed a high prevalence of 
growth hormonal deficiency and hypogonadotrophic hypogonadism but not 
corticotrophic and posterior dysfunction.  
2.5.3 How 
To date there are no conclusive data on this topic in severe brain injured patients. In cases 
with a clear indication of hormonal deficiency, the treatment should be conducted by an 
endocrinologist as defined by the international guidelines. DI, adrenal insufficiency, thyroid 
dysfunction and hypogonadism should be treated along with appropriate follow up. 
Diabetes insipidus The general goals of treatment are the correction of pre-existing water 
deficits and reduction in ongoing excessive urinary water losses; however, the specific 
therapy varies with the clinical situation. Ambulatory patients with DI and normal thirst 
have little body water deficit and may be helped from relief of the polyuria and polydipsia 
that disrupt normal activities. In contrast, comatose patients with or without DI are unable 
to drink in response to thirst, and in these patients progressive hypertonicity may be a life-
threatening situation. A variety of anti-diuretic agents have been used to treat central DI, but 
desmopressina is the treatment of choice for this disorder. Desmopressina is an anti-diuretic 
hormone analogue, which particularly useful because it has a much longer half-life than 
anti-diuretic hormone and is devoid of the pressor activity of anti-diuretic hormone at 
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24 hours), but can be given parenterally in acute situations (1–2 mg intravenously, 
intramuscularly or subcutaneously). For both oral and parenteral preparations, the increase 
of the administered dose generally has the effect to prolong the duration of anti-diuresis 
rather than increasing its magnitude; consequently, altering the dose can be useful to reduce 
the required frequency of administration. Synthetic anti-diuretic hormone (Pitressin) can 
also be used to treat central DI, but its use is limited by a much shorter half-life, requiring 
frequent doses or a continuous infusion, and carries a side effect of increased blood pressure 
due to vasoconstriction. 
Secondary adrenal insufficiency Conventional treatment is represented by 10–25 mg of 
hydrocortisone per day (2–3 doses per day) or 25–37.5 mg of cortisone acetate. It is essential 
to use the lowest possible dose. In stress situations (psyco-emotional, surgery, transient 
diseases, infections etc.) the dose should be increased to 25-50 hydrocortisone per day or 50-
75 mg of cortisone acetate or if reduction of intestinal absorption is expected parenteral 
hydrocortisone 100-50 mg should be administered.  
Secondary hypothyroidism L-thyroxine is considered the drug of choice. The usual 
replacement dose is age-dependent and varies from 1.3 µg/kg (< 60 yrs) to 1.1 µg/kg (> 60 
yrs). The most common route of administration is oral, even through nasogastric tube, but in 
acute situations when this is not possible, parenteral administration can be used (50-300 
µg/daily iv). Because thyroid hormone replacement increases the rate of metabolism of 
glucocorticoids, which can lead to an adrenal crisis, replacement therapy should begin after 
hydrocortisone substitution has been initiated. 
Hypogonadism In male patients testosterone substitution (testosterone gel 25–50 mg/day or 
testosterone undecanoate 1000 mg every 3 months) returned bone and muscle mass, sexual 
function and haematocrit to normal levels.  
In pre-menopausal female patients sex hormone substitution (20–35 μg ethinyl oestradiol or 
oestradiol valerate 2–4 mg/day plus progesterone unless hysterectomised) can return libido, 
well being and bone mass to normal levels. In post menopausal women sex hormone 
therapy is not indicated because a significant increased risk of cardiovascular and neoplastic 
diseases.  
3. Neuroendocrine alterations in brain dead patients 
Brain death results from damage to the brain stem with a complete irreversible loss of its 
function. This devastating insult to the brain stem is immediately followed by a 
“sympathetic storm”. In addition, brain death causes significant endocrine alterations 
involving the hypothalamic-pituitary axis and triggers an inflammatory reaction. The 
catecholamine storm, the endocrine disturbances and the systemic inflammatory reaction 
represent the first insult with consequential organ insufficiency and metabolic 
derangement (Avlonitis et al 2003). Sub-optimal management of potential organ donors 
leading to a further impairment of the cardiovascular and respiratory function represents 
an additional damage to potentially transplantable organs (Fisher et al 1999; 
Venkateswaran et al 2009a). Any intervention in each of these three phases in order to 
prevent or treat these insults may have an impact on the functional outcome of 
transplanted organs (figure 1). In this prospective a prompt recognition and treatment of 
neuroendocrine alterations represent one of the possible therapeutic strategies able to 
optimise organ availability for transplantation. 
 




Fig. 1. Pathophysiology of hormonal deficiency in brain death and its implication on organ 
donors maintainance 
3.1 Pathophysiology 
Brain death has an important impact on endocrine function leading to profound metabolic 
abnormalities and hemodynamic instability with deleterious effects on the potential organ 
donors (Chamorro et al 2009; Smith 2004). The most important endocrine disturbances are a 
reduction in anti-diuretic hormone secretion, thyroid dysfunction, reduction in 
adenocorticotrophic hormone and insulin levels (Ullah et al 2006). In experimental animal 
models of brain death, the pituitary gland hormones vasopressin and adenocorticotrophic 
hormone decreased significantly after 15 and 45 minutes of brain death respectively (Bittner 
et al 1995). Circulating triiodothyronine, thyroxine, glucagons and insulin concentrations 
were significantly reduced within a few hours after brain death (Bittner et al 1995; Chen et al 
1996). The significant reduction in circulating concentrations of stress hormones was 
associated with a severe hemodynamic instability (Chen et al 1996; Hing et al 2007; 
Novitzky et al 2006). In a prospective randomized experimental study of brain death, Hing 
et al. showed that hormonal replacement therapy including triiodothyronine, 
methylprednisolone, vasopressin and insulin reduced norepinephrine requirements and 
improved hemodynamics and cardiac function (Hing et al 2007). 
An interesting study by Ishikawa et al. (Ishikawa et al 2009) compared, in autoptic cases, 
morphological results as well as endocrine function in brain death (within 24 hours post 
mortem), acute death (< 3 h) and delayed death (survival time 4-51 days). Histology and 
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fluid levels of adrenocorticotropin hormone, growth hormone and thyroid-stimulating 
hormone were measured. Morphological and microscopic studies revealed partial necrosis 
of central anterior lobe but preservation of its periphery, autolysis in the hypothalamus, 
swelling of mitochondria and dilation of smooth endoplasmatic reticulum and golgi 
apparatus suggesting that pituitary is preserved without blood supply after brain death but 
the integrity of hypothalamus pituitary axis is lost. Regarding pituitary secretion, no 
peculiar findings were demonstrated after brain death different from cases of delayed death. 
In fact, serum adrenocorticotropin hormone levels were similar to the clinical reference 
values in both brain death, acute or delayed death cases, while serum growth hormone, 
cerebralspinal fluid growth hormone and adrenocorticotropin hormone levels were lower in 
brain and delayed death than in acute cases and serum thyroid-stimulating hormone  levels 
were comparable in both brain death and delayed death cases (Ishikawa et al 2009).  
In observational clinical studies, an early depletion of arginine vasopressin and 
development of DI is present in almost 45-80% of brain death organ donors (Gramm et al 
1992; Howlett et al 1989; Salim et al 2006). Arginine vasopressin is one of the most important 
endogenously released stress hormones. It is also named anti-diuretic hormone based on its 
effects on the distal tubule of the kidney. It is synthesized in the hypothalamus and released 
into the bloodstream from posterior pituitary. Vasopressin has several important 
physiological functions including water retention by the V2 receptors on the kidney and 
constriction by V1 receptors on vascular smooth muscle on the systemic and pulmonary 
circulation. In addition to its anti-diuretic action, vasopressin is important in maintaining 
arterial blood pressure during episodes of hypotension (Gordon et al 2010). In brain dead 
patients there is a deficiency of vasopressin levels in systemic circulation due to 
supraventricular and paraventricular hypothalamic nuclei ischaemia (Agha et al 2007) or 
pituitary stalk damage that disrupts the hypothalamic pituitary axis associated to a defect in 
the baroreflex-mediated secretion of vasopressin levels in systemic circulation (Chen et al 
1999; Gordon et al 2010). Therefore, the depletion of vasopressin may contribute to the 
hemodynamic instability associated with diabetes insipidus. In brain dead patients, low 
dose arginine vasopressin infusion, in addition to treating diabetes insipidus, results in 
significant reduction of inotropic support and has been associated with good kidney, liver 
and heart graft function (Pennefather et al 1995). Comparing the treatment of brain-dead 
patients with epinephrine alone versus epinephrine plus vasopressin the authors obtained a 
prolonged hemodynamic stabilization in brain-dead donors treated with vasopressin 
(Yoshioka et al 1986). In brain dead patients without clinical signs of DI, Chen et al obtained 
a significant reduction in cathecolamine doses (dopamine and/or norepinephrine) using 
arginine vasopressin at low dosage (0.04 to 1.0 U/min) with a significant increase in mean 
arterial pressure and better organ perfusion (Chen et al 1999). A complete weaning from 
catecholamine has been demonstrated in up to 40% of the donors with the use of 
vasopressin. Indeed a more extensive use of vasopressin as an alternative to norepinephrine 
has been suggested in a prospective randomised double blind trial (Venkateswaran et al 
2009b). 
Thyroid dysfunction is another event of brain death. This decrease of thyroid function is not 
caused by a primary failure of the thyroid or pituitary glands. It has been defined “sick 
euthyroid syndrome” and has also been described in cardiopulmonary by-pass. It is 
postulated that proinflammatory cytokines may play a role in inhibiting the conversion of 
thyroxine to the active form of thyroid hormone, and instead, convert it to the non-active 
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form, reverse- thyroid hormone (Ullah et al 2006). In an animal model of brain death, 
Novitzky et al. showed that levels of thyroid hormones were severely depleted (Novitzky et 
al 1988). In interventional clinical studies the following results have been reported: 1) 
administration of thyroid hormone to donor and recipient improved cardiac allograph 
function; 2) therapy with thyroid hormone reversed donor myocardial dysfunction, 
promoted hemodynamic stability and reduced inotropic support (Novitzky et al 1990; Salim 
et al 2001).  However a randomized clinical trial in a small number of potential organ donors 
using low dose of thyroid hormone was unable to confirm the positive effect of hormonal 
therapy on cardiac function (Goarin et al 1996). Conversely, in pediatric patients following 
cardiac surgery triidothyronine administration improved cardiac function (Bettendorf et al 
2000). Therefore, there is still a considerable debate whether the sick euthyroid syndrome 
requires treatment. 
Insulin levels fall after brain stem death, leading to a decrease in intracellular glucose 
concentration, the development of an cellular energy deficit, and a shift toward anaerobic 
metabolism and acidosis (Ullah et al 2006).  
In brain dead patients there is also a significant decreases in cortisol levels that, in 
association with decreases in thyroid hormone, may contribute to the cardiovascular 
instability. The decrease in plasma cortisol may be associated with a decrease in the release 
of its stimulating factors adrenocorticotropic hormone from the anterior lobe of the pituitary 
gland (Gramm et al 1992). High dose steroid administration has a beneficial role in 
attenuating the effects of pro-inflammatory cytokines released after brain death. Steroids 
significantly improved oxygenation and simultaneously increased lung recovery (Follette et 
al 1998). A beneficial effect is described also in cases of liver transplantation involving donor 
treatment with methylprednisolone (Kotsch et al 2008).  
3.2 Therapy of neuroendocrine dysfunction in potential organ donors 
Several studies have suggested that the use of Hormonal Replacement Therapy (HRT) in 
donor management may serve a crucial role in helping to maintain metabolic stability and 
prevent hemodynamic instability (Rosendale et al 2003b). Rosendale et al. showed an 
increase of the mean number of organs from HRT donors (22.5%) when compared to non-
hormonal resuscitation donors, which led to a significant increase in organs transplanted 
per donor (Rosendale et al 2003a; Rosendale et al 2003b). HRT allowed substantial 
improvement in mean arterial pressure and consequently in organ prefusion, and left 
ventricular stroke work index combined with reduction in central venous and wedge 
pressure and a reduction of inotropic support (Wheeldon et al 1995).  
The selection of donors who are predicted to benefit from HRT was outlined at the Cristal 
City Consensus Conference Report (Rosengard et al 2002). After conventional management 
to adjust volume status, anemia and metabolic abnormalities, the guidelines recommended 
to perform an echocardiogram to rule out the structural abnormalities and document the 
ejection fraction. If the ejection fraction is less than 45%, a pulmonary artery catheter should 
be placed and HRT should be started. The four hormones commonly used are: 
methylprednisolone, triiodothyronine, arginine vasopressin titrated to obtain  systemic 
vascular resistances of 800-1200 dynes/sec-cm) and insulin titrated to maintain blood sugar 
at 120 to 180 mg/dL (Rosengard et al 2002). However the use of HRT is not supported by a 
strong level of evidence. Clinical studies of HRT have been observational, retrospective, 
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2000). Therefore, there is still a considerable debate whether the sick euthyroid syndrome 
requires treatment. 
Insulin levels fall after brain stem death, leading to a decrease in intracellular glucose 
concentration, the development of an cellular energy deficit, and a shift toward anaerobic 
metabolism and acidosis (Ullah et al 2006).  
In brain dead patients there is also a significant decreases in cortisol levels that, in 
association with decreases in thyroid hormone, may contribute to the cardiovascular 
instability. The decrease in plasma cortisol may be associated with a decrease in the release 
of its stimulating factors adrenocorticotropic hormone from the anterior lobe of the pituitary 
gland (Gramm et al 1992). High dose steroid administration has a beneficial role in 
attenuating the effects of pro-inflammatory cytokines released after brain death. Steroids 
significantly improved oxygenation and simultaneously increased lung recovery (Follette et 
al 1998). A beneficial effect is described also in cases of liver transplantation involving donor 
treatment with methylprednisolone (Kotsch et al 2008).  
3.2 Therapy of neuroendocrine dysfunction in potential organ donors 
Several studies have suggested that the use of Hormonal Replacement Therapy (HRT) in 
donor management may serve a crucial role in helping to maintain metabolic stability and 
prevent hemodynamic instability (Rosendale et al 2003b). Rosendale et al. showed an 
increase of the mean number of organs from HRT donors (22.5%) when compared to non-
hormonal resuscitation donors, which led to a significant increase in organs transplanted 
per donor (Rosendale et al 2003a; Rosendale et al 2003b). HRT allowed substantial 
improvement in mean arterial pressure and consequently in organ prefusion, and left 
ventricular stroke work index combined with reduction in central venous and wedge 
pressure and a reduction of inotropic support (Wheeldon et al 1995).  
The selection of donors who are predicted to benefit from HRT was outlined at the Cristal 
City Consensus Conference Report (Rosengard et al 2002). After conventional management 
to adjust volume status, anemia and metabolic abnormalities, the guidelines recommended 
to perform an echocardiogram to rule out the structural abnormalities and document the 
ejection fraction. If the ejection fraction is less than 45%, a pulmonary artery catheter should 
be placed and HRT should be started. The four hormones commonly used are: 
methylprednisolone, triiodothyronine, arginine vasopressin titrated to obtain  systemic 
vascular resistances of 800-1200 dynes/sec-cm) and insulin titrated to maintain blood sugar 
at 120 to 180 mg/dL (Rosengard et al 2002). However the use of HRT is not supported by a 
strong level of evidence. Clinical studies of HRT have been observational, retrospective, 





HRT but not the complete hormonal replacement advocated in the United Network for 
Organ Sharing guidelines (http://www.ccdt:ca/english/home.html ; Rosendale et al 2003a; 
Rosendale et al 2003b; Rostron et al 2008; Venkateswaran et al 2009a; Venkateswaran et al 
2009b). In addition, the contribution of other changes in donor management such as 
invasive hemodynamic monitoring make it difficult to judge the relative contribution of 
combined hormonal resuscitation to the improvements in donor organs outcome reported in 
these studies. These observations have provided the foundation for prospective clinical 
trials to examine the efficacy and optimal timing of HRT. However, until these results are 
not available it remains prudent to reserve HRT for unstable donors requiring high doses of 
dopamine or with an ejection fraction of less than 45% (Rosengard et al 2002; Wood et al 
2004; Zaroff et al 2002). 
The diagnosis of DI in brain death patients does not differ from other clinical situations. DI 
must be differentiated from the polyuria induced by mannitol, hyperglicemia or diuretic 
agents. Assessment of diuresis (> 40 ml/kg body weight/day or 3000 cc/day), plasma (> 
295 mOsm/kg) and urine (< 200 Osm/kg) osmolality and sodium levels (> 146 mEq/l) are 
key elements for its diagnosis (Mascia et al 2009). Plasma anti-diuretic hormone levels have 
little importance due to the poor reliability of the assay, the extreme high variability of anti-
diuretic hormone plasma levels and the relatively long turn-around time (4–10 days) for 
results. The clinical goals are primarily based on the stabilization of the volume status by 
hypotonic fluid replacement with 5% dextrose or nasogastric water, serum sodium and 
osmolality and then on an adequate urine output. When urine volume loss are large, anti-
diuretic hormone replacement therapy is required (Mascia et al 2009). A vasopressin 
infusion acts on the V1 and V2 receptors and induces vasoconstriction and anti-diuretic 
effects (Mutlu and Factor 2004). Low dose arginine vasopressin decreases serum osmolarity 
and sodium levels, maintains blood pressure and reduces the need for vasoactive 
medications in potential organ donors, with no deleterious short-term or long-term effects 
on the function of the donated kidney to the recipient (Guesde et al 1998; Rosendale et al 
2003a; Wood et al 2004). Intermittent treatment with synthetic analogue anti-diuretic 
hormone desmopressin can also be used. Synthetic analogue anti-diuretic hormone 
desmopressin was synthesized as a selective antagonist of vasopressin V2 receptors. In brain 
death patients synthetic analogue anti-diuretic hormone desmopressin is administered 
parenterally (1–2 mg intravenously, intramuscularly or subcutaneously); increasing the 
administered dose generally has the effect of prolonging the duration of anti-diuresis rather 
than increasing its magnitude (Wood et al 2004).  
4. Conclusion 
In conclusion, hypothalamic-pituitary-adrenal insufficiency occurs in 30-50% of patients 
after traumatic and non-traumatic brain injury and has a high prevalence in brain dead 
patients. These endocrine alterations lead to metabolic abnormalities and hemodynamic 
instability with deleterious effects on potential organ donors. To optimize clinical 
management of potential organ donors and therefore guarantee the availability of 
transplantable organs, recent guidelines advocate the use of standardized hormonal therapy 
(l-thyroxine, methylprednisolone, vasopressin and insulin). This replacement therapy is 
suggested to stabilize brain death patients who present hemodynamic instability 
unresponsive to standard cardiovascular treatment. Despite available experimental data and 
increased interest for HRT in the management of potential organ donors, there are no 
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prospective randomized controlled clinical studies testing combined HRT and examining its 
effects on donor cardiac function, hemodynamics and vasopressor requirements. Therefore 
in our opinion the HRT with particular attention to the antidiuretic hormone represents a 
valid component of the treatment choices to stabilize hemodynamics in potential organ 
donors. In the sub-group of brain death patients with a clear diagnosis of DI, the 
replacement therapy with low dose of arginine vasopressin is the treatment of choice.  
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Nephrogenic Diabetes Insipidus 
– The Novelly Potential Therapeutic Drugs 
Jessica Y.S. Chu and Billy K.C. Chow 
School of Biological Sciences, The University of Hong Kong, Hong Kong, 
China 
1. Introduction 
Water reabsorption in the kidney represents a critical physiological event in the 
maintenance of body water homeostasis. This highly regulated process relies largely on the 
antidiuretic hormone, vasopressin (VP), and on the VP-sensitive aquaporin-2 (AQP2) water 
channel that is expressed in the principal cells of kidney collecting duct. Under normal 
condition, AQP2 resides in the intracellular vesicles of the principal cells. Apical plasma 
membrane facing the primary urine of these cells therefore contains only low amounts of 
water channels and is relatively water impermeable. When there is increased plasma 
osmolality or hypovolemia, VP released from the neurohypophysis binds to its cognate VP 
type 2 receptor (V2R) that is expressed on the basolateral membrane of the collecting duct 
principal cells. This elevates intracellular cAMP concentration and promotes protein kinase 
A (PKA) activity that lead to phosphorylation of AQP2 at Ser256 (Christensen et al., 2000), as 
well as phosphorylation of Rho at Ser188 (Tamma et al., 2001; Tamma et al., 2003). AQP2 
phosphorylation allows their redistribution from intracellular location to apical plasma 
membrane, whereas Rho phosphorylation results in a subsequent attenuation of Rho 
activity that favors the depolymerization of F-actin (Tamma et al., 2001; Tamma et al., 2003). 
This latter action allows removal of the cytoskeleton barrier that blocks the passage of AQP2 
to the plasma membrane. Therefore, with the presence of AQP2 on the apical membrane of 
principal cells, a strong increase of water permeability of this membrane compartment is 
resulted. This allows acceleration of water reabsorption from primary urine, thus 
compensating for body water loss during hypovolemic or hypernatremic state. 
Defects in the function of V2R and/or in AQP2 cell surface expression (known as 
nephrogenic diabetes insipidus or NDI) may perpetuate alteration of the biological 
boundaries that maintain plasma osmolality within a well defined, but very narrow 
physiological range. Patients having which are unable to concentrate their urine despite 
normal or elevated plasma concentrations of VP, thereby at the risk of hypernatremic 
dehydration and having manifestations including polyuria, polydipsia, hyposthenuria, 
recurrent episodes of dehydration, fever, and even growth failure. Despite the molecular 
defects underlying this disorder has now been revealed and has enabled a successful 
diagnosis, no cure is currently exists for NDI. Instead, this condition is managed by 
restriction in sodium intake combined with the administration of hydrochlorothiazide 
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hypokalemia (Blanchard et al., 2008). The search for more effective therapeutic strategies for 
NDI therefore is needed. Consistent with this notion, identifying V2R-independent 
mechanisms that regulate AQP2 trafficking could definitely be beneficial for the exploration 
of novel therapeutic strategies in the treatment of NDI, as this disorder is most commonly 
resulted from mutations in V2R gene (~90%).  
2. Factors involved in V2R-independent cAMP pathway 
2.1 Secretin 
Apart from VP, various other physiological factors that modulate AQP2 cell-surface 
localization via the cAMP pathway have been uncovered. One of such factors is secretin 
(SCT), a 27-amino acid peptide hormone that modulates transepithelial movement of water 
and electrolyte in varies tissues. Clinically, serum concentration of SCT was found to 
increase significantly in hemodialysis patients (Grekas et al., 1984) and in patients with 
chronic renal failure (Hansky, 1979) in comparison to controls, indicating that the peptide 
might be associated with clinical-pathological status of the kidney. Morphologically, the 
kidneys of SCT receptor (SCTR)-deficient (SCTR-/-) mice were abnormal, characterized by 
increased mesangial area, enlarged urinary space, and frequent tubular dilation and 
hypertrophy in the collecting tubules of the medullary region (Chu et al., 2007), suggesting 
they might have altered water absorption and filtration processes. Consistent with this 
notion, in vitro treatment of SCT was found to induce a dose-dependent increase in AQP2 
expression on the plasma membrane and a dose-dependent decrease in AQP2 expression in 
the intracellular vesicles (Cheng et al., 2009; Chu et al., 2007). This induced translocation of 
AQP2 was mediated via a cAMP/PKA-dependent pathway (Cheng et al., 2009), and was 
shown to be absent in the medullary tubules isolated from SCTR-/- (Chu et al., 2007), hence 
indicating that the peptide induces the movement of AQP2 upon binding with its receptor. 
Because SCT can be released from the hypothalamo-pituitary axis (Chu et al., 2009), and that 
SCTR-/- mice exhibit normal levels of plasma VP as well as V2R in their kidney when 
compared to their wild-type littermates (Chu et al., 2007), these data collectively indicated a 
role of SCT in VP-independent stimulation of the expression and movement of AQP2s in the 
kidney. This concept was further substantiated by the fact that Charlton et al. (Charlton et 
al., 1986) was able to show an antidiuretic effect of SCT as potent as VP in homozygous VP-
deficient Brattleboro rats, whereas Chu et al. (Chu et al., 2007) detected an altered response 
in AQP2 movement to the plasma membrane during hyperosmolality in SCTR-/- mice. 
Therefore, all these data suggested that SCT could also be of great interest to the NDI 
community as it shows a direction of study for developing therapies to treat NDI that are 
independent of the VP pathway. 
2.2 Calcitonin 
The second factor that has been proven to by-pass the VP-dependent simulation of AQP2 
translocation via the cAMP pathway is calcitonin, which is a 32-amino acid peptide 
hormone that was found to have its plasma concentration increase in acute and chronic 
renal failure (Ardaillou, 1975; Ardaillou et al., 1975). Early work by de Rouffignac and 
Elalouf (de Rouffignac and Elalouf, 1983) proposed that the peptide hormone could exert a 
VP-like effect on electrolyte transport by the thick ascending limb and/or on the water 
permeability of the cortical collecting ducts. This observation has recently been confirmed 
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by another group showing a stimulation of the membrane accumulation of AQP2 by 
calcitonin in the LLC-PK1 cells as well as in the cortical collecting ducts on rat kidney slices 
(Bouley et al., 2011). Using osmotic pumps implanted into VP-deficient Brattleboro rats, they 
also discovered that calcitonin-treated rats urinate less, and their urine was more 
concentrated than in the control group, indicating that the peptide could play a direct role in 
the urinary concentrating mechanism. Additional studies therefore are required to further 
examining the antidiuretic effect of calcitonin as well as to determine whether this peptide 
might be beneficial to patients suffering from X-linked NDI. 
3. Factors involved in nitric oxide/cGMP pathway 
Together with the canonical cAMP-induced pathway, the nitric oxide (NO)/cGMP signaling 
pathway has been shown to play a role in AQP2 trafficking/expression, prompting 
investigation of this signaling pathway as a means to develop alternative therapies for 
treatment of NDI. NO is a very active free radical that produced enzymatically by one of the 
three (i.e. endothelial, neuronal, and inducible) intracellularly located nitric oxide synthase 
(NOS) isoforms that convert L-arginine to citrulline. It plays an important role in overall 
excretory function of the kidney (Majid and Navar, 2001) and is involved in the 
development of kidney dysfunction in several diseases, including diabetes and hypertension 
(Palm et al., 2009). In the classical NO signaling pathway, NO acts on the soluble guanylyl 
cyclase (GC), leading to an increased production of the second messenger cyclic guanosine 
monophosphate (cGMP). This then influences various intracellular functions via activation 
of the protein kinase G. cGMP, however, can also affects cAMP signals (Stangherlin et al., 
2011) as well as PKA activity (Yamada et al., 2006), which are both mediated via cGMP-
regulated phosphodiesterases (PDEs) (Stangherlin et al., 2011). By binding to the regulatory 
GAF-B domain at the N-terminus of PDE2, cGMP potently activates its cAMP hydrolyzing 
activity (Martinez et al., 2002). Through such a regulatory mechanism, stimuli that elevate 
cGMP could attenuate cAMP-dependent signaling pathway (Michie et al., 1996). 
Conversely, cGMP could also act effectively as a competitive inhibitor of PDE3 cAMP-
degrading activity (Shakur et al., 2001). As a consequence, PDE3 provides a means by which 
an increase in cGMP may lead to an increase in cAMP. 
The components of the NO-cGMP signaling pathway were found to be expressed 
throughout the kidney (Bachmann et al., 1995; Tojo et al., 1994; Ujiie et al., 1994), supporting 
the notion that the NO-cGMP signaling pathway plays a key role in renal physiology, 
including fluid transport. In consistent with this notion, Bouley et al. (Bouley et al., 2000) 
found that AQP2 insertion could be accomplished by the activation of the cGMP-dependent 
pathway. They showed that NO donors, such as sodium nitroprusside and NONOate, as 
well as the NOS substrate L-arginine, appeared to induce AQP2 translocation from 
intracellular vesicles to the apical membrane by increasing cGMP levels in rat kidney slices 
and AQP2-transfected LLC-PK1 cells. Similarly, another study by Martin et al. (Martin et al., 
2002) showed that water deprivation induced the expression of endothelial NOS and 
neuronal NOS in the outer medulla as well as both the outer medulla and the papilla, 
respectively, which could be subsequently decreased by water loading. Other evidence 
further supporting the idea that NO-cGMP plays a role in water homeostatic mechanisms 
came from the fact that 1) VP specifically increases neuronal NOS expression levels in the 
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by another group showing a stimulation of the membrane accumulation of AQP2 by 
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within the kidneys of cirrhotic rats was found to correlate with the increasing activities of 
NOS (Jun et al., 2010), and 3) simultaneous disruption of all three NOS isoforms led to 
reduce membranous AQP2 expression associated with tubuloglomerular lesion formation, 
as well as marked hypotonic polyuria, polydipsia, and renal unresponsiveness to VP 
(Morishita et al., 2005), all of which are characteristics consistent with NDI. Thus, AQP2 
expression and trafficking, which is chiefly regulated by VP, may be additionally stimulated 
by NO-cGMP activity. 
3.1 Atrial Natriuretic Peptide (ANP) 
ANP is a 28-amino acid peptide that is well established to activate membrane-bound GC 
and modulates cellular functions via the intracellular second messenger cGMP. Consistent 
with this, studies have provided evidence for stimulation of cGMP production in various 
renal tubule segments in response to ANP (Nonoguchi et al., 1987; Takeda et al., 1986) and 
for the expression of the cGMP-coupled ANP receptor in these segments (Terada et al., 
1991). However, the effect of ANP (through an increase in cGMP) on sodium and fluid 
transport in the collecting duct is still controversial. Some earlier studies showed that it 
decreases both sodium reabsorption and vasopressin-induced water transport in collecting 
ducts (Dillingham and Anderson, 1986; Nonoguchi et al., 1988; Nonoguchi et al., 1989), 
whereas later studies do not confirm these inhibitory effects (Bouley et al., 2000; Rouch et al., 
1991). This might probably due to the fact that ANP has a biphasic effects on renal water 
reabsorption process. Wang et al. (Wang et al., 2006) in a more recent study demonstrated 
that ANP infusion (0.5 μg/kg/min) evoked a transient (peak at 10 min) but significant 
diuresis (~5 fold), with no changes in GFR as well as the subcellular localization of AQP2, 
followed by a decrease in water excretion, accompanied by a marked increase in apical 
targeting of AQP2, 90 min after infusion. This effect of ANP on AQP2 was further confirmed 
by both Bouley et al. (Bouley et al., 2000) and Wang et al. (Wang et al., 2006) in in-vitro 
studies using AQP2-expressing LLC-PK1 cells and AQP2-transfected HEK 293 cells, 
respectively. The former group also postulated that Ser256 of AQP2 is the target motif for 
stimulation by ANF. Because there are marked changes in water excretion seen in response 
to acute (10 min) and subacute (90 min) ANP treatment, a detail understanding of the 
underlying mechanisms that governs these processes is needed before considering whether 
ANP could be use as a therapeutic strategy for the treatment of NDI. 
3.2 Sildenafil citrate (Viagra) 
The use of Viagra, a selective PDE5 inhibitor, as potential therapeutic agents for NDI has 
been described. Bouley et al. (Bouley et al., 2005) found that 45-min exposure of AQP2-
transfected LLC-PK1 cells to either Viagra or 4-{[3',4'-methylene-dioxybenzyl]amino}-6-
methoxyquinazoline elevates intracellular cGMP levels and results in the plasma membrane 
accumulation of AQP2. They also demonstrated that exposure to PDE5 inhibitors for 60 min 
could induce an apical accumulation of AQP2 in renal medullary collecting duct principal 
cells both in tissue slices incubated in-vitro as well as in-vivo after intravenous injection of 
Viagra into rats. While Viagra has been successfully used in the clinical treatment of erectile 
dysfunction and that research data suggested that PDE inhibition by this drug may offer a 
promising approach for X-linked NDI therapy, further studies are needed in order to 
determine whether prolonged viagra or cGMP inhibition, or a combined therapeutic 
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approach, can improve water reabsorption in patients suffering from NDI who may express 
variable amounts of AQP2 in their principal cells. 
4. Factors involved in AQP2 endocytosis and exocytosis 
About 10% of NDI cases are associated with AQP2 mutations rather than with defects of 
V2R signalling. Interestingly, most mutations identified in the AQP2 gene in NDI are 
manifested as mis-routing errors rather than as structural defects that affect their ability in 
conducting water across the membrane. Some of these mutations, including L22V, L28P, 
A47V, V71M, T126M, A147T, V168M, P185A, R187C, E258K, and P262L have been 
characterized in Xenopus oocytes, yeast, and/or mammalian cells, and have been shown to 
have impaired folding, resulting in recognition by the endoplasmic reticulum (ER) quality 
control machinery, ubiquitination, and degradation by the 26S proteasome (Boccalandro et 
al., 2004; de Mattia et al., 2004; Deen et al., 1995; Kamsteeg et al., 2008; Kamsteeg et al., 2009; 
Levin et al., 2001; Marr et al., 2002; Mulders et al., 1997; Tamarappoo and Verkman, 1998). 
However, these AQP2 mutants are found to be intrinsically functional water channels when 
being characterized. In light of the fact that AQP2 rapidly and constitutively recycle 
between the plasma membrane and intracellular vesicles, even in the absence of any 
stimulation (Lu et al., 2004), and that channel gating of AQP2 is independent of the 
membrane insertion/trafficking process (Moeller et al., 2009), therapeutic strategies for NDI 
caused by AQP2 mutation could be bought either by agents that stimulate AQP2 
excytosis, or agents that causes a reduction in the rate of AQP2 endocytosis. Consistent 
with this notion, an extensive accumulation of AQP2 at the cell surface was successfully 
accomplished within 30 min after inhibition of endocytosis by treatment with cholesterol-
depleting drug, methyl-β-cyclodextrin (Lu et al., 2004; Russo et al., 2006), which prevents 
the formation and budding of clathrin-coated pits. This implies that while we are looking 
for V2R-independent signalling pathways to induce an increase translocation of AQP2 to 
the cell surface, any agent that inhibits the endocytosis of intrinsically functional AQP2 
mutant may consequently represent an alternative strategy for therapeutic intervention in 
NDI. 
4.1 Chemical chaperones 
Chemical chaperones, which are protein-folding enhancers, have already been shown to act 
as the potential therapeutic agents for the control of many of the protein conformational 
diseases, including Alzheimer’s disease (Evans et al., 2006), Prion’s disease (Tatzelt et al., 
1996), and cystic fibrosis (Brown et al., 1996). As most of the AQP2 mutants are associated 
with defect in folding, leading to their accumulation within intracellular compartment, an 
observation of the corrective effect of chemical chaperones on defective AQP2 trafficking in 
NDI is therefore not peculiar. In this regards, Tamarappoo and Verkman (Tamarappoo and 
Verkman, 1998) found that incubating chemical chaperones, including glycerol, 
trimethylamine oxide (TMAO), and dimethyl sulfoxide (DMSO), to AQP2 mutant-
expressing cells could produced a nearly complete redistribution of the mutants from 
endoplasmic reticulum to membrane/endosome fractions, achieving functional correction 
of the processing defect. Similarly, another group also showed that Hsp90 inhibitor, 17-
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mutant may consequently represent an alternative strategy for therapeutic intervention in 
NDI. 
4.1 Chemical chaperones 
Chemical chaperones, which are protein-folding enhancers, have already been shown to act 
as the potential therapeutic agents for the control of many of the protein conformational 
diseases, including Alzheimer’s disease (Evans et al., 2006), Prion’s disease (Tatzelt et al., 
1996), and cystic fibrosis (Brown et al., 1996). As most of the AQP2 mutants are associated 
with defect in folding, leading to their accumulation within intracellular compartment, an 
observation of the corrective effect of chemical chaperones on defective AQP2 trafficking in 
NDI is therefore not peculiar. In this regards, Tamarappoo and Verkman (Tamarappoo and 
Verkman, 1998) found that incubating chemical chaperones, including glycerol, 
trimethylamine oxide (TMAO), and dimethyl sulfoxide (DMSO), to AQP2 mutant-
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defective AQP2 cellular processing in transfected kidney cells (Yang et al., 2009). They also 
observed an increase urine osmolality in AQP2 mutant-expressing mice when 
intraperitoneally injected with 17-AAG, demonstrating a function of this chemical 
chaperones in improving urinary concentrating function. As 17-AAG is currently in phase 2 
clinical trials for several cancer targets (Pacey et al., 2010), and that recent data showing 
promising therapeutic activity of the compound (Kurashina et al., 2009; Yao et al., 2010), 17-
AAG or other chemical chaperones may be useful for therapy of some forms of NDI. 
4.2 Simvastatin 
Simvastatin, a family of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, was 
originally developed as therapeutic agents for reducing cholesterol and hence the 
prevention and treatment of cardiovascular diseases (O'Driscoll et al., 1997; Olsson et al., 
2011). Recent studies, however, have revealed more of its pleiotropic effects including 
cognition enhancement (Douma et al., 2011), anti-inflammation (Nezic et al., 2009; Zhang et 
al., 2011), and anti-cancer activity (Miller et al., 2011). More interestingly, studies in-vitro also 
suggested that it could inhibit the endocytosis of proteins in proximal tubule cells via its 
inhibitory effects on prenylation and thereby the function of one or more GTP-binding 
proteins (Sidaway et al., 2004), suggesting a similar role of its in regulating AQP2 membrane 
presentation. Consistent with this notion, simvastatin was shown to induces AQP2 
membrane accumulation via its inhibitory effect on AQP2 endocytosis, which was 
independent of cAMP/PKA activation and also Ser256 phosphorylation of AQP2 (Li et al., 
2011). These authors also found that intraperitoneal injection of simvastatin to VP-deficient 
Brattleboro rats resulted in decreased urinary volume with simultaneously increased 
urinary osmolality, hence its effect on renal water reabsorption and urinary concentration. 
Therefore, even though the total reduction of urine output may seem to be modest with 
simvastatin-treated animals, simvastatin treatment might still be significant for NDI patients 
who may produce up to 10-15 liters of urine each day. 
 
Factors involved in V2R-independent cAMP pathway 
Secretin 
Calcitonin 
Factors involved in nitric oxide/cGMP pathway 
Atrial natriuretic peptide 
Sildenafil citrate (Viagra) and other PDE inhibitors 
Factors involved in AQP2 endocytosis and exocytosis 
Chemical chaperones 
• Glycerol 
• Trimethylamine oxide (TMAO) 
• Dimethyl sulfoxide (DMSO) 




Table 1. List of the potential therapeutic drugs that increase membrane presentation of 
AQP2. 
 




Recent advances in the understanding of AQP2 recycling and the signaling pathways that 
lead to the membrane accumulation of AQP2 in renal collecting tubular principal cells have 
opened up several possible strategies for inducing this process in the absence of 
conventional VP signaling via its receptor, which is defective in X-linked NDI (Table 1). 
Some of these strategies are potential to serve as basis for the development of novel 
therapies that may ultimately improve life quality of NDI patients. Therefore, identifying 
analogs of these potential agents with reduced cytoxicity and also improved 
pharmacological properties are necessary for preclinical development. Depending on the 
nature of the defect leading to this disorder, it is very likely that a combination of different 
approaches, directed by the basic research endeavors that are ongoing in many labs, will be 
needed to achieve a positive clinical outcome. 
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2011). These authors also found that intraperitoneal injection of simvastatin to VP-deficient 
Brattleboro rats resulted in decreased urinary volume with simultaneously increased 
urinary osmolality, hence its effect on renal water reabsorption and urinary concentration. 
Therefore, even though the total reduction of urine output may seem to be modest with 
simvastatin-treated animals, simvastatin treatment might still be significant for NDI patients 
who may produce up to 10-15 liters of urine each day. 
 
Factors involved in V2R-independent cAMP pathway 
Secretin 
Calcitonin 
Factors involved in nitric oxide/cGMP pathway 
Atrial natriuretic peptide 
Sildenafil citrate (Viagra) and other PDE inhibitors 
Factors involved in AQP2 endocytosis and exocytosis 
Chemical chaperones 
• Glycerol 
• Trimethylamine oxide (TMAO) 
• Dimethyl sulfoxide (DMSO) 




Table 1. List of the potential therapeutic drugs that increase membrane presentation of 
AQP2. 
 




Recent advances in the understanding of AQP2 recycling and the signaling pathways that 
lead to the membrane accumulation of AQP2 in renal collecting tubular principal cells have 
opened up several possible strategies for inducing this process in the absence of 
conventional VP signaling via its receptor, which is defective in X-linked NDI (Table 1). 
Some of these strategies are potential to serve as basis for the development of novel 
therapies that may ultimately improve life quality of NDI patients. Therefore, identifying 
analogs of these potential agents with reduced cytoxicity and also improved 
pharmacological properties are necessary for preclinical development. Depending on the 
nature of the defect leading to this disorder, it is very likely that a combination of different 
approaches, directed by the basic research endeavors that are ongoing in many labs, will be 
needed to achieve a positive clinical outcome. 
6. Acknowledgment 
The authors thank the research supported by the HK government RGC grant 
HKU7501/05 M and HKU7384/04 M to BKCC. 
7. References 
Ardaillou, R., 1975. Kidney and calcitonin. Nephron. 15, 250-60. 
Ardaillou, R., Beaufils, M., Nivez, M.P., Isaac, R., Mayaud, C., Sraer, J.D., 1975. Increased 
plasma calcitonin in early acute renal failure. Clin Sci Mol Med. 49, 301-4. 
Bachmann, S., Bosse, H.M., Mundel, P., 1995. Topography of nitric oxide synthesis by 
localizing constitutive NO synthases in mammalian kidney. Am J Physiol. 268, 
F885-98. 
Blanchard, A., Vargas-Poussou, R., Peyrard, S., Mogenet, A., Baudouin, V., Boudailliez, B., 
Charbit, M., Deschesnes, G., Ezzhair, N., Loirat, C., Macher, M.A., Niaudet, P., 
Azizi, M., 2008. Effect of hydrochlorothiazide on urinary calcium excretion in dent 
disease: an uncontrolled trial. Am J Kidney Dis. 52, 1084-95. 
Boccalandro, C., De Mattia, F., Guo, D.C., Xue, L., Orlander, P., King, T.M., Gupta, P., Deen, 
P.M., Lavis, V.R., Milewicz, D.M., 2004. Characterization of an aquaporin-2 water 
channel gene mutation causing partial nephrogenic diabetes insipidus in a Mexican 
family: evidence of increased frequency of the mutation in the town of origin. J Am 
Soc Nephrol. 15, 1223-31. 
Bouley, R., Breton, S., Sun, T., McLaughlin, M., Nsumu, N.N., Lin, H.Y., Ausiello, D.A., 
Brown, D., 2000. Nitric oxide and atrial natriuretic factor stimulate cGMP-
dependent membrane insertion of aquaporin 2 in renal epithelial cells. J Clin 
Invest. 106, 1115-26. 
Bouley, R., Pastor-Soler, N., Cohen, O., McLaughlin, M., Breton, S., Brown, D., 2005. 
Stimulation of AQP2 membrane insertion in renal epithelial cells in vitro and in 
vivo by the cGMP phosphodiesterase inhibitor sildenafil citrate (Viagra). Am J 
Physiol Renal Physiol. 288, F1103-12. 
Bouley, R., Lu, H.A., Nunes, P., Da Silva, N., McLaughlin, M., Chen, Y., Brown, D., 2011. 
Calcitonin has a vasopressin-like effect on aquaporin-2 trafficking and urinary 





Brown, C.R., Hong-Brown, L.Q., Biwersi, J., Verkman, A.S., Welch, W.J., 1996. Chemical 
chaperones correct the mutant phenotype of the delta F508 cystic fibrosis 
transmembrane conductance regulator protein. Cell Stress Chaperones. 1, 117-
25. 
Charlton, C.G., Quirion, R., Handelmann, G.E., Miller, R.L., Jensen, R.T., Finkel, M.S., 
O'Donohue, T.L., 1986. Secretin receptors in the rat kidney: adenylate cyclase 
activation and renal effects. Peptides. 7, 865-71. 
Cheng, C.Y., Chu, J.Y., Chow, B.K., 2009. Vasopressin-independent mechanisms in 
controlling water homeostasis. J Mol Endocrinol. 43, 81-92. 
Christensen, B.M., Zelenina, M., Aperia, A., Nielsen, S., 2000. Localization and regulation of 
PKA-phosphorylated AQP2 in response to V(2)-receptor agonist/antagonist 
treatment. Am J Physiol Renal Physiol. 278, F29-42. 
Chu, J.Y., Chung, S.C., Lam, A.K., Tam, S., Chung, S.K., Chow, B.K., 2007. Phenotypes 
developed in secretin receptor-null mice indicated a role for secretin in regulating 
renal water reabsorption. Mol Cell Biol. 27, 2499-511. 
Chu, J.Y., Lee, L.T., Lai, C.H., Vaudry, H., Chan, Y.S., Yung, W.H., Chow, B.K., 2009. Secretin 
as a neurohypophysial factor regulating body water homeostasis. Proc Natl Acad 
Sci U S A. 106, 15961-6. 
de Mattia, F., Savelkoul, P.J., Bichet, D.G., Kamsteeg, E.J., Konings, I.B., Marr, N., Arthus, 
M.F., Lonergan, M., van Os, C.H., van der Sluijs, P., Robertson, G., Deen, P.M., 
2004. A novel mechanism in recessive nephrogenic diabetes insipidus: wild-type 
aquaporin-2 rescues the apical membrane expression of intracellularly retained 
AQP2-P262L. Hum Mol Genet. 13, 3045-56. 
de Rouffignac, C., Elalouf, J.M., 1983. Effects of calcitonin on the renal concentrating 
mechanism. Am J Physiol. 245, F506-11. 
Deen, P.M., Croes, H., van Aubel, R.A., Ginsel, L.A., van Os, C.H., 1995. Water channels 
encoded by mutant aquaporin-2 genes in nephrogenic diabetes insipidus are 
impaired in their cellular routing. J Clin Invest. 95, 2291-6. 
Dillingham, M.A., Anderson, R.J., 1986. Inhibition of vasopressin action by atrial natriuretic 
factor. Science. 231, 1572-3. 
Douma, T.N., Borre, Y., Hendriksen, H., Olivier, B., Oosting, R.S., 2011. Simvastatin 
improves learning and memory in control but not in olfactory bulbectomized rats. 
Psychopharmacology (Berl). 
Evans, C.G., Wisen, S., Gestwicki, J.E., 2006. Heat shock proteins 70 and 90 inhibit early 
stages of amyloid beta-(1-42) aggregation in vitro. J Biol Chem. 281, 33182-91. 
Grekas, D.M., Raptis, S., Tourkantonis, A.A., 1984. Plasma secretin, pancreozymin, and 
somatostatin-like hormone in chronic renal failure patients. Uremia Invest. 8, 117-
20. 
Hansky, J., 1979. Effect of renal failure on gastrointestinal hormones. World J Surg. 3, 
463-7. 
Jun, D.W., Park, J.H., Park, Y.S., Kang, J.S., Kim, E.K., Kim, K.T., Son, B.K., Kim, S.H., Jo, Y.J., 
2010. The role of nitric oxide in the expression of renal aquaporin 2 in a cirrhotic rat 
model: does an AVP-independent mechanism exist for the regulation of AQP2 
expression? Dig Dis Sci. 55, 1296-304. 
Kamsteeg, E.J., Savelkoul, P.J., Hendriks, G., Konings, I.B., Nivillac, N.M., Lagendijk, A.K., 
van der Sluijs, P., Deen, P.M., 2008. Missorting of the Aquaporin-2 mutant E258K to 
 
Nephrogenic Diabetes Insipidus – The Novelly Potential Therapeutic Drugs 
 
49 
multivesicular bodies/lysosomes in dominant NDI is associated with its 
monoubiquitination and increased phosphorylation by PKC but is due to the loss 
of E258. Pflugers Arch. 455, 1041-54. 
Kamsteeg, E.J., Stoffels, M., Tamma, G., Konings, I.B., Deen, P.M., 2009. Repulsion 
between Lys258 and upstream arginines explains the missorting of the AQP2 
mutant p.Glu258Lys in nephrogenic diabetes insipidus. Hum Mutat. 30, 1387-
96. 
Kurashina, R., Ohyashiki, J.H., Kobayashi, C., Hamamura, R., Zhang, Y., Hirano, T., 
Ohyashiki, K., 2009. Anti-proliferative activity of heat shock protein (Hsp) 90 
inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells. Cancer 
Lett. 284, 62-70. 
Levin, M.H., Haggie, P.M., Vetrivel, L., Verkman, A.S., 2001. Diffusion in the endoplasmic 
reticulum of an aquaporin-2 mutant causing human nephrogenic diabetes 
insipidus. J Biol Chem. 276, 21331-6. 
Li, W., Zhang, Y., Bouley, R., Chen, Y., Matsuzaki, T., Nunes, P., Hasler, U., Brown, D., Lu, 
H.A., 2011. Simvastatin Enhances Aquaporin 2 Surface Expression and Urinary 
Concentration in Vasopressin Deficient Brattleboro Rats through Modulation of 
Rho GTPase. Am J Physiol Renal Physiol. 
Lu, H., Sun, T.X., Bouley, R., Blackburn, K., McLaughlin, M., Brown, D., 2004. Inhibition of 
endocytosis causes phosphorylation (S256)-independent plasma membrane 
accumulation of AQP2. Am J Physiol Renal Physiol. 286, F233-43. 
Majid, D.S., Navar, L.G., 2001. Nitric oxide in the control of renal hemodynamics and 
excretory function. Am J Hypertens. 14, 74S-82S. 
Marr, N., Bichet, D.G., Hoefs, S., Savelkoul, P.J., Konings, I.B., De Mattia, F., Graat, M.P., 
Arthus, M.F., Lonergan, M., Fujiwara, T.M., Knoers, N.V., Landau, D., Balfe, W.J., 
Oksche, A., Rosenthal, W., Muller, D., Van Os, C.H., Deen, P.M., 2002. Cell-biologic 
and functional analyses of five new Aquaporin-2 missense mutations that cause 
recessive nephrogenic diabetes insipidus. J Am Soc Nephrol. 13, 2267-77. 
Martin, P.Y., Bianchi, M., Roger, F., Niksic, L., Feraille, E., 2002. Arginine vasopressin 
modulates expression of neuronal NOS in rat renal medulla. Am J Physiol Renal 
Physiol. 283, F559-68. 
Martinez, S.E., Beavo, J.A., Hol, W.G., 2002. GAF domains: two-billion-year-old molecular 
switches that bind cyclic nucleotides. Mol Interv. 2, 317-23. 
Michie, A.M., Lobban, M., Muller, T., Harnett, M.M., Houslay, M.D., 1996. Rapid regulation 
of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of 
the T cell antigen receptor on thymocytes: analysis using the selective inhibitors 
erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram. Cell Signal. 8, 97-
110. 
Miller, T., Yang, F., Wise, C.E., Meng, F., Priester, S., Munshi, M.K., Guerrier, M., Dostal, 
D.E., Glaser, S.S., 2011. Simvastatin stimulates apoptosis in cholangiocarcinoma by 
inhibition of Rac1 activity. Dig Liver Dis. 43, 395-403. 
Moeller, H.B., MacAulay, N., Knepper, M.A., Fenton, R.A., 2009. Role of multiple 
phosphorylation sites in the COOH-terminal tail of aquaporin-2 for water 






Brown, C.R., Hong-Brown, L.Q., Biwersi, J., Verkman, A.S., Welch, W.J., 1996. Chemical 
chaperones correct the mutant phenotype of the delta F508 cystic fibrosis 
transmembrane conductance regulator protein. Cell Stress Chaperones. 1, 117-
25. 
Charlton, C.G., Quirion, R., Handelmann, G.E., Miller, R.L., Jensen, R.T., Finkel, M.S., 
O'Donohue, T.L., 1986. Secretin receptors in the rat kidney: adenylate cyclase 
activation and renal effects. Peptides. 7, 865-71. 
Cheng, C.Y., Chu, J.Y., Chow, B.K., 2009. Vasopressin-independent mechanisms in 
controlling water homeostasis. J Mol Endocrinol. 43, 81-92. 
Christensen, B.M., Zelenina, M., Aperia, A., Nielsen, S., 2000. Localization and regulation of 
PKA-phosphorylated AQP2 in response to V(2)-receptor agonist/antagonist 
treatment. Am J Physiol Renal Physiol. 278, F29-42. 
Chu, J.Y., Chung, S.C., Lam, A.K., Tam, S., Chung, S.K., Chow, B.K., 2007. Phenotypes 
developed in secretin receptor-null mice indicated a role for secretin in regulating 
renal water reabsorption. Mol Cell Biol. 27, 2499-511. 
Chu, J.Y., Lee, L.T., Lai, C.H., Vaudry, H., Chan, Y.S., Yung, W.H., Chow, B.K., 2009. Secretin 
as a neurohypophysial factor regulating body water homeostasis. Proc Natl Acad 
Sci U S A. 106, 15961-6. 
de Mattia, F., Savelkoul, P.J., Bichet, D.G., Kamsteeg, E.J., Konings, I.B., Marr, N., Arthus, 
M.F., Lonergan, M., van Os, C.H., van der Sluijs, P., Robertson, G., Deen, P.M., 
2004. A novel mechanism in recessive nephrogenic diabetes insipidus: wild-type 
aquaporin-2 rescues the apical membrane expression of intracellularly retained 
AQP2-P262L. Hum Mol Genet. 13, 3045-56. 
de Rouffignac, C., Elalouf, J.M., 1983. Effects of calcitonin on the renal concentrating 
mechanism. Am J Physiol. 245, F506-11. 
Deen, P.M., Croes, H., van Aubel, R.A., Ginsel, L.A., van Os, C.H., 1995. Water channels 
encoded by mutant aquaporin-2 genes in nephrogenic diabetes insipidus are 
impaired in their cellular routing. J Clin Invest. 95, 2291-6. 
Dillingham, M.A., Anderson, R.J., 1986. Inhibition of vasopressin action by atrial natriuretic 
factor. Science. 231, 1572-3. 
Douma, T.N., Borre, Y., Hendriksen, H., Olivier, B., Oosting, R.S., 2011. Simvastatin 
improves learning and memory in control but not in olfactory bulbectomized rats. 
Psychopharmacology (Berl). 
Evans, C.G., Wisen, S., Gestwicki, J.E., 2006. Heat shock proteins 70 and 90 inhibit early 
stages of amyloid beta-(1-42) aggregation in vitro. J Biol Chem. 281, 33182-91. 
Grekas, D.M., Raptis, S., Tourkantonis, A.A., 1984. Plasma secretin, pancreozymin, and 
somatostatin-like hormone in chronic renal failure patients. Uremia Invest. 8, 117-
20. 
Hansky, J., 1979. Effect of renal failure on gastrointestinal hormones. World J Surg. 3, 
463-7. 
Jun, D.W., Park, J.H., Park, Y.S., Kang, J.S., Kim, E.K., Kim, K.T., Son, B.K., Kim, S.H., Jo, Y.J., 
2010. The role of nitric oxide in the expression of renal aquaporin 2 in a cirrhotic rat 
model: does an AVP-independent mechanism exist for the regulation of AQP2 
expression? Dig Dis Sci. 55, 1296-304. 
Kamsteeg, E.J., Savelkoul, P.J., Hendriks, G., Konings, I.B., Nivillac, N.M., Lagendijk, A.K., 
van der Sluijs, P., Deen, P.M., 2008. Missorting of the Aquaporin-2 mutant E258K to 
 
Nephrogenic Diabetes Insipidus – The Novelly Potential Therapeutic Drugs 
 
49 
multivesicular bodies/lysosomes in dominant NDI is associated with its 
monoubiquitination and increased phosphorylation by PKC but is due to the loss 
of E258. Pflugers Arch. 455, 1041-54. 
Kamsteeg, E.J., Stoffels, M., Tamma, G., Konings, I.B., Deen, P.M., 2009. Repulsion 
between Lys258 and upstream arginines explains the missorting of the AQP2 
mutant p.Glu258Lys in nephrogenic diabetes insipidus. Hum Mutat. 30, 1387-
96. 
Kurashina, R., Ohyashiki, J.H., Kobayashi, C., Hamamura, R., Zhang, Y., Hirano, T., 
Ohyashiki, K., 2009. Anti-proliferative activity of heat shock protein (Hsp) 90 
inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells. Cancer 
Lett. 284, 62-70. 
Levin, M.H., Haggie, P.M., Vetrivel, L., Verkman, A.S., 2001. Diffusion in the endoplasmic 
reticulum of an aquaporin-2 mutant causing human nephrogenic diabetes 
insipidus. J Biol Chem. 276, 21331-6. 
Li, W., Zhang, Y., Bouley, R., Chen, Y., Matsuzaki, T., Nunes, P., Hasler, U., Brown, D., Lu, 
H.A., 2011. Simvastatin Enhances Aquaporin 2 Surface Expression and Urinary 
Concentration in Vasopressin Deficient Brattleboro Rats through Modulation of 
Rho GTPase. Am J Physiol Renal Physiol. 
Lu, H., Sun, T.X., Bouley, R., Blackburn, K., McLaughlin, M., Brown, D., 2004. Inhibition of 
endocytosis causes phosphorylation (S256)-independent plasma membrane 
accumulation of AQP2. Am J Physiol Renal Physiol. 286, F233-43. 
Majid, D.S., Navar, L.G., 2001. Nitric oxide in the control of renal hemodynamics and 
excretory function. Am J Hypertens. 14, 74S-82S. 
Marr, N., Bichet, D.G., Hoefs, S., Savelkoul, P.J., Konings, I.B., De Mattia, F., Graat, M.P., 
Arthus, M.F., Lonergan, M., Fujiwara, T.M., Knoers, N.V., Landau, D., Balfe, W.J., 
Oksche, A., Rosenthal, W., Muller, D., Van Os, C.H., Deen, P.M., 2002. Cell-biologic 
and functional analyses of five new Aquaporin-2 missense mutations that cause 
recessive nephrogenic diabetes insipidus. J Am Soc Nephrol. 13, 2267-77. 
Martin, P.Y., Bianchi, M., Roger, F., Niksic, L., Feraille, E., 2002. Arginine vasopressin 
modulates expression of neuronal NOS in rat renal medulla. Am J Physiol Renal 
Physiol. 283, F559-68. 
Martinez, S.E., Beavo, J.A., Hol, W.G., 2002. GAF domains: two-billion-year-old molecular 
switches that bind cyclic nucleotides. Mol Interv. 2, 317-23. 
Michie, A.M., Lobban, M., Muller, T., Harnett, M.M., Houslay, M.D., 1996. Rapid regulation 
of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of 
the T cell antigen receptor on thymocytes: analysis using the selective inhibitors 
erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram. Cell Signal. 8, 97-
110. 
Miller, T., Yang, F., Wise, C.E., Meng, F., Priester, S., Munshi, M.K., Guerrier, M., Dostal, 
D.E., Glaser, S.S., 2011. Simvastatin stimulates apoptosis in cholangiocarcinoma by 
inhibition of Rac1 activity. Dig Liver Dis. 43, 395-403. 
Moeller, H.B., MacAulay, N., Knepper, M.A., Fenton, R.A., 2009. Role of multiple 
phosphorylation sites in the COOH-terminal tail of aquaporin-2 for water 






Morishita, T., Tsutsui, M., Shimokawa, H., Sabanai, K., Tasaki, H., Suda, O., Nakata, S., 
Tanimoto, A., Wang, K.Y., Ueta, Y., Sasaguri, Y., Nakashima, Y., Yanagihara, N., 
2005. Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase 
isoforms. Proc Natl Acad Sci U S A. 102, 10616-21. 
Mulders, S.M., Knoers, N.V., Van Lieburg, A.F., Monnens, L.A., Leumann, E., Wuhl, E., 
Schober, E., Rijss, J.P., Van Os, C.H., Deen, P.M., 1997. New mutations in the AQP2 
gene in nephrogenic diabetes insipidus resulting in functional but misrouted water 
channels. J Am Soc Nephrol. 8, 242-8. 
Nezic, L., Skrbic, R., Dobric, S., Stojiljkovic, M.P., Jacevic, V., Satara, S.S., Milovanovic, Z.A., 
Stojakovic, N., 2009. Simvastatin and indomethacin have similar anti-inflammatory 
activity in a rat model of acute local inflammation. Basic Clin Pharmacol Toxicol. 
104, 185-91. 
Nonoguchi, H., Knepper, M.A., Manganiello, V.C., 1987. Effects of atrial natriuretic factor 
on cyclic guanosine monophosphate and cyclic adenosine monophosphate 
accumulation in microdissected nephron segments from rats. J Clin Invest. 79, 
500-7. 
Nonoguchi, H., Sands, J.M., Knepper, M.A., 1988. Atrial natriuretic factor inhibits 
vasopressin-stimulated osmotic water permeability in rat inner medullary 
collecting duct. J Clin Invest. 82, 1383-90. 
Nonoguchi, H., Sands, J.M., Knepper, M.A., 1989. ANF inhibits NaCl and fluid absorption in 
cortical collecting duct of rat kidney. Am J Physiol. 256, F179-86. 
O'Driscoll, G., Green, D., Taylor, R.R., 1997. Simvastatin, an HMG-coenzyme A 
reductase inhibitor, improves endothelial function within 1 month. Circulation. 
95, 1126-31. 
Olsson, A.G., Lindahl, C., Holme, I., Fayyad, R., Faergeman, O., Kastelein, J.J., Tikkanen, 
M.J., Larsen, M.L., Pedersen, T.R., 2011. LDL cholesterol goals and cardiovascular 
risk during statin treatment: the IDEAL study. Eur J Cardiovasc Prev Rehabil. 18, 
262-9. 
Pacey, S., Gore, M., Chao, D., Banerji, U., Larkin, J., Sarker, S., Owen, K., Asad, Y., Raynaud, 
F., Walton, M., Judson, I., Workman, P., Eisen, T., 2010. A Phase II trial of 17-
allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with 
metastatic melanoma. Invest New Drugs. 
Palm, F., Teerlink, T., Hansell, P., 2009. Nitric oxide and kidney oxygenation. Curr Opin 
Nephrol Hypertens. 18, 68-73. 
Rouch, A.J., Chen, L., Troutman, S.L., Schafer, J.A., 1991. Na+ transport in isolated rat CCD: 
effects of bradykinin, ANP, clonidine, and hydrochlorothiazide. Am J Physiol. 260, 
F86-95. 
Russo, L.M., McKee, M., Brown, D., 2006. Methyl-beta-cyclodextrin induces vasopressin-
independent apical accumulation of aquaporin-2 in the isolated, perfused rat 
kidney. Am J Physiol Renal Physiol. 291, F246-53. 
Shakur, Y., Holst, L.S., Landstrom, T.R., Movsesian, M., Degerman, E., Manganiello, V., 
2001. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) 
gene family. Prog Nucleic Acid Res Mol Biol. 66, 241-77. 
Sidaway, J.E., Davidson, R.G., McTaggart, F., Orton, T.C., Scott, R.C., Smith, G.J., Brunskill, 
N.J., 2004. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce 
 
Nephrogenic Diabetes Insipidus – The Novelly Potential Therapeutic Drugs 
 
51 
receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol. 15, 
2258-65. 
Stangherlin, A., Gesellchen, F., Zoccarato, A., Terrin, A., Fields, L.A., Berrera, M., Surdo, 
N.C., Craig, M.A., Smith, G., Hamilton, G., Zaccolo, M., 2011. cGMP Signals 
Modulate cAMP Levels in a Compartment-Specific Manner to Regulate 
Catecholamine-Dependent Signaling in Cardiac Myocytes. Circ Res. 108, 929-
39. 
Takeda, S., Kusano, E., Murayama, N., Asano, Y., Hosoda, S., Sokabe, H., Kawashima, H., 
1986. Atrial natriuretic peptide elevates cGMP contents in glomeruli and in distal 
tubules of rat kidney. Biochem Biophys Res Commun. 136, 947-54. 
Tamarappoo, B.K., Verkman, A.S., 1998. Defective aquaporin-2 trafficking in nephrogenic 
diabetes insipidus and correction by chemical chaperones. J Clin Invest. 101, 2257-
67. 
Tamma, G., Klussmann, E., Maric, K., Aktories, K., Svelto, M., Rosenthal, W., Valenti, G., 
2001. Rho inhibits cAMP-induced translocation of aquaporin-2 into the apical 
membrane of renal cells. Am J Physiol Renal Physiol. 281, F1092-101. 
Tamma, G., Klussmann, E., Procino, G., Svelto, M., Rosenthal, W., Valenti, G., 2003. cAMP-
induced AQP2 translocation is associated with RhoA inhibition through RhoA 
phosphorylation and interaction with RhoGDI. J Cell Sci. 116, 1519-25. 
Tatzelt, J., Prusiner, S.B., Welch, W.J., 1996. Chemical chaperones interfere with the 
formation of scrapie prion protein. EMBO J. 15, 6363-73. 
Terada, Y., Moriyama, T., Martin, B.M., Knepper, M.A., Garcia-Perez, A., 1991. RT-PCR 
microlocalization of mRNA for guanylyl cyclase-coupled ANF receptor in rat 
kidney. Am J Physiol. 261, F1080-7. 
Tojo, A., Gross, S.S., Zhang, L., Tisher, C.C., Schmidt, H.H., Wilcox, C.S., Madsen, K.M., 
1994. Immunocytochemical localization of distinct isoforms of nitric oxide synthase 
in the juxtaglomerular apparatus of normal rat kidney. J Am Soc Nephrol. 4, 1438-
47. 
Ujiie, K., Yuen, J., Hogarth, L., Danziger, R., Star, R.A., 1994. Localization and regulation of 
endothelial NO synthase mRNA expression in rat kidney. Am J Physiol. 267, F296-
302. 
Wang, W., Li, C., Nejsum, L.N., Li, H., Kim, S.W., Kwon, T.H., Jonassen, T.E., Knepper, 
M.A., Thomsen, K., Frokiaer, J., Nielsen, S., 2006. Biphasic effects of ANP infusion 
in conscious, euvolumic rats: roles of AQP2 and ENaC trafficking. Am J Physiol 
Renal Physiol. 290, F530-41. 
Yamada, T., Matsuda, K., Uchiyama, M., 2006. Atrial natriuretic peptide and cGMP activate 
sodium transport through PKA-dependent pathway in the urinary bladder of the 
Japanese tree frog. J Comp Physiol B. 176, 203-12. 
Yang, B., Zhao, D., Verkman, A.S., 2009. Hsp90 inhibitor partially corrects nephrogenic 
diabetes insipidus in a conditional knock-in mouse model of aquaporin-2 mutation. 
FASEB J. 23, 503-12. 
Yao, J.Q., Liu, Q.H., Chen, X., Yang, Q., Xu, Z.Y., Hu, F., Wang, L., Li, J.M., 2010. Hsp90 
inhibitor 17-allylamino-17-demethoxygeldanamycin inhibits the proliferation of 





Morishita, T., Tsutsui, M., Shimokawa, H., Sabanai, K., Tasaki, H., Suda, O., Nakata, S., 
Tanimoto, A., Wang, K.Y., Ueta, Y., Sasaguri, Y., Nakashima, Y., Yanagihara, N., 
2005. Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase 
isoforms. Proc Natl Acad Sci U S A. 102, 10616-21. 
Mulders, S.M., Knoers, N.V., Van Lieburg, A.F., Monnens, L.A., Leumann, E., Wuhl, E., 
Schober, E., Rijss, J.P., Van Os, C.H., Deen, P.M., 1997. New mutations in the AQP2 
gene in nephrogenic diabetes insipidus resulting in functional but misrouted water 
channels. J Am Soc Nephrol. 8, 242-8. 
Nezic, L., Skrbic, R., Dobric, S., Stojiljkovic, M.P., Jacevic, V., Satara, S.S., Milovanovic, Z.A., 
Stojakovic, N., 2009. Simvastatin and indomethacin have similar anti-inflammatory 
activity in a rat model of acute local inflammation. Basic Clin Pharmacol Toxicol. 
104, 185-91. 
Nonoguchi, H., Knepper, M.A., Manganiello, V.C., 1987. Effects of atrial natriuretic factor 
on cyclic guanosine monophosphate and cyclic adenosine monophosphate 
accumulation in microdissected nephron segments from rats. J Clin Invest. 79, 
500-7. 
Nonoguchi, H., Sands, J.M., Knepper, M.A., 1988. Atrial natriuretic factor inhibits 
vasopressin-stimulated osmotic water permeability in rat inner medullary 
collecting duct. J Clin Invest. 82, 1383-90. 
Nonoguchi, H., Sands, J.M., Knepper, M.A., 1989. ANF inhibits NaCl and fluid absorption in 
cortical collecting duct of rat kidney. Am J Physiol. 256, F179-86. 
O'Driscoll, G., Green, D., Taylor, R.R., 1997. Simvastatin, an HMG-coenzyme A 
reductase inhibitor, improves endothelial function within 1 month. Circulation. 
95, 1126-31. 
Olsson, A.G., Lindahl, C., Holme, I., Fayyad, R., Faergeman, O., Kastelein, J.J., Tikkanen, 
M.J., Larsen, M.L., Pedersen, T.R., 2011. LDL cholesterol goals and cardiovascular 
risk during statin treatment: the IDEAL study. Eur J Cardiovasc Prev Rehabil. 18, 
262-9. 
Pacey, S., Gore, M., Chao, D., Banerji, U., Larkin, J., Sarker, S., Owen, K., Asad, Y., Raynaud, 
F., Walton, M., Judson, I., Workman, P., Eisen, T., 2010. A Phase II trial of 17-
allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with 
metastatic melanoma. Invest New Drugs. 
Palm, F., Teerlink, T., Hansell, P., 2009. Nitric oxide and kidney oxygenation. Curr Opin 
Nephrol Hypertens. 18, 68-73. 
Rouch, A.J., Chen, L., Troutman, S.L., Schafer, J.A., 1991. Na+ transport in isolated rat CCD: 
effects of bradykinin, ANP, clonidine, and hydrochlorothiazide. Am J Physiol. 260, 
F86-95. 
Russo, L.M., McKee, M., Brown, D., 2006. Methyl-beta-cyclodextrin induces vasopressin-
independent apical accumulation of aquaporin-2 in the isolated, perfused rat 
kidney. Am J Physiol Renal Physiol. 291, F246-53. 
Shakur, Y., Holst, L.S., Landstrom, T.R., Movsesian, M., Degerman, E., Manganiello, V., 
2001. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) 
gene family. Prog Nucleic Acid Res Mol Biol. 66, 241-77. 
Sidaway, J.E., Davidson, R.G., McTaggart, F., Orton, T.C., Scott, R.C., Smith, G.J., Brunskill, 
N.J., 2004. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce 
 
Nephrogenic Diabetes Insipidus – The Novelly Potential Therapeutic Drugs 
 
51 
receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol. 15, 
2258-65. 
Stangherlin, A., Gesellchen, F., Zoccarato, A., Terrin, A., Fields, L.A., Berrera, M., Surdo, 
N.C., Craig, M.A., Smith, G., Hamilton, G., Zaccolo, M., 2011. cGMP Signals 
Modulate cAMP Levels in a Compartment-Specific Manner to Regulate 
Catecholamine-Dependent Signaling in Cardiac Myocytes. Circ Res. 108, 929-
39. 
Takeda, S., Kusano, E., Murayama, N., Asano, Y., Hosoda, S., Sokabe, H., Kawashima, H., 
1986. Atrial natriuretic peptide elevates cGMP contents in glomeruli and in distal 
tubules of rat kidney. Biochem Biophys Res Commun. 136, 947-54. 
Tamarappoo, B.K., Verkman, A.S., 1998. Defective aquaporin-2 trafficking in nephrogenic 
diabetes insipidus and correction by chemical chaperones. J Clin Invest. 101, 2257-
67. 
Tamma, G., Klussmann, E., Maric, K., Aktories, K., Svelto, M., Rosenthal, W., Valenti, G., 
2001. Rho inhibits cAMP-induced translocation of aquaporin-2 into the apical 
membrane of renal cells. Am J Physiol Renal Physiol. 281, F1092-101. 
Tamma, G., Klussmann, E., Procino, G., Svelto, M., Rosenthal, W., Valenti, G., 2003. cAMP-
induced AQP2 translocation is associated with RhoA inhibition through RhoA 
phosphorylation and interaction with RhoGDI. J Cell Sci. 116, 1519-25. 
Tatzelt, J., Prusiner, S.B., Welch, W.J., 1996. Chemical chaperones interfere with the 
formation of scrapie prion protein. EMBO J. 15, 6363-73. 
Terada, Y., Moriyama, T., Martin, B.M., Knepper, M.A., Garcia-Perez, A., 1991. RT-PCR 
microlocalization of mRNA for guanylyl cyclase-coupled ANF receptor in rat 
kidney. Am J Physiol. 261, F1080-7. 
Tojo, A., Gross, S.S., Zhang, L., Tisher, C.C., Schmidt, H.H., Wilcox, C.S., Madsen, K.M., 
1994. Immunocytochemical localization of distinct isoforms of nitric oxide synthase 
in the juxtaglomerular apparatus of normal rat kidney. J Am Soc Nephrol. 4, 1438-
47. 
Ujiie, K., Yuen, J., Hogarth, L., Danziger, R., Star, R.A., 1994. Localization and regulation of 
endothelial NO synthase mRNA expression in rat kidney. Am J Physiol. 267, F296-
302. 
Wang, W., Li, C., Nejsum, L.N., Li, H., Kim, S.W., Kwon, T.H., Jonassen, T.E., Knepper, 
M.A., Thomsen, K., Frokiaer, J., Nielsen, S., 2006. Biphasic effects of ANP infusion 
in conscious, euvolumic rats: roles of AQP2 and ENaC trafficking. Am J Physiol 
Renal Physiol. 290, F530-41. 
Yamada, T., Matsuda, K., Uchiyama, M., 2006. Atrial natriuretic peptide and cGMP activate 
sodium transport through PKA-dependent pathway in the urinary bladder of the 
Japanese tree frog. J Comp Physiol B. 176, 203-12. 
Yang, B., Zhao, D., Verkman, A.S., 2009. Hsp90 inhibitor partially corrects nephrogenic 
diabetes insipidus in a conditional knock-in mouse model of aquaporin-2 mutation. 
FASEB J. 23, 503-12. 
Yao, J.Q., Liu, Q.H., Chen, X., Yang, Q., Xu, Z.Y., Hu, F., Wang, L., Li, J.M., 2010. Hsp90 
inhibitor 17-allylamino-17-demethoxygeldanamycin inhibits the proliferation of 





Zhang, S., Rahman, M., Qi, Z., Thorlacius, H., 2011. Simvastatin antagonizes CD40L 
secretion, CXC chemokine formation, and pulmonary infiltration of neutrophils in 




Analysis of Membrane Protein 
Stability in Diabetes Insipidus 
Florian Heinke, Anne Tuukkanen and Dirk Labudde  
University of Applied Sciences Mittweida 
 Germany 
1. Introduction 
Diabetes insipidus (DI) is a rare endocrine disorder, with an incidence in the general  
population assessed on one case per 25,000-30,000 people (Robertson, 1995; 
Ananthakrishnan, 2009; Krysiak, et al., 2010). It is a disease characterized by polyuria and 
compensatory polydipsia. The underlying causes of DI are diverse and can be central 
defects, in which no functional arginine-vasopressin is released from the pituitary, or may 
becaused by defects in the kidney (nephrogenic DI, NDI). Four different types of NDI are 
known. First, acquired NDI can originate as a side-effect of drugs, with the most prominent 
being the antibipolar drug lithium. Second and third, autosomal recessive and dominant 
inheritable NDI, are caused by gene mutations in the AQP2 gene encoding aquaporin-2. 
Finally, mutations in the AVPR2 gene (Deen et al., 1994; Mulders, 1998), which encodes the 
V2 vasopressin receptor (V2R), are the cause of the X-linked inheritable form of NDI (Fig. 1 
right) (Van den Ouweland et al., 1992; Rosenthal, 1992).  
 
   
Fig. 1. Transcellular water transport in renal collecting principal duct cells and molecular 
cause of X-linked nephrogenic diabetes insipidus (NDI) 
(Left) Vasopressin binding to its type 2 receptor (V2R) triggers a cAMP cascade that leads to 
the insertion of aquaporin-2 water channels in the apical membrane. This allows water to pass 
through this membrane and transcellular water transport to balance concentration of the pro-
urine and, there by antidiuresis. (Right) In the X-linked form, NDI is often caused by V2R 
mutants trapped in the endoplasmic reticulum as a result of their misfolding, making them 
unavailable for binding arginine-vasopressin (AVP) at the basolateral plasma membrane. As a 
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The X-linked inheritable form of nephrogenic diabetes insipidus is a disorder in which 
patients are unable to concentrate their urine despite the presence of the hormone arginine-
vasopressin (AVP). This antidiuretic hormone regulates the process of the water 
reabsorption, according to the body’s need, from the pro-urine that is formed by 
ultrafiltration in the kidney. It binds to its type 2 receptor in the kidney (Fig. 1, A). 
Mutations in the gene encoding the V2R often lead to NDI. Many of these mutations do not 
interfere with the intrinsic functionality of V2R, but cause its retention in the endoplasmic 
reticulum (ER) making it unavailable for AVP binding. 
As a consequence of the inability of the kidneys to concentrate the pro-urine in response to 
AVP, diseased adult patients may have a daily output of 15–20 l of highly dilute (usually < 
100 mOsmol  kg) urine. In newborn infants, NDI is characterized by irritability, poor 
feeding, poor weight gain and dehydration symptoms. 
Classically, the diagnosis NDI was made after a dehydration test (Los et al., 2010) but it has 
become possible in clinical practice to apply direct analysis of the arginine vasopressin V2 
receptor gene (AVPR2) and the aquaporin-2 gene for the diagnosis and differential 
diagnosis of nephrogenic diabetes insipidus (Fujiwara & Bichet, 2005). 
To date, over 200 mutations have been described in the AVPR2 gene, which can be 
categorized into classes according to their cellular fate (Robben et al. 2006). 
Another gene for the diagnosis of Diabetes insipidus is WFS1. It encodes a transmembrane 
protein which induces the Wolfram Syndrom (Hardy et al. 1999), a rare autosomal recessive 
disorder characterized by juvenile-onset non-autoimmune Diabetes mellitus, optic atrophy, 
sensorineural deafness and Diabetes insipidus (Wolfram & Wagener, 1938). In addition, 
psychiatric illnesses such as depression and impulsive behavior are frequently observed in 
affected individuals (Swift & Swift, 2001). 
The minimal criteria for diagnosis are Diabetes mellitus and optic atrophy. Diabetes 
insipidus, sensorineural deafness, urinary tract anatomy, ataxia, peripheral neuropathy, 
mental retardation and psychiatric illness are additional symptoms seen in the majority of 
patients (Strom, 1998a). 
The WFS1 protein, also called wolframin, consists of 890 amino acids and was predicted to 
have nine or ten membrane spanning domains (Inoue et al., 1998; Strom et al., 1998b). More 
than 100 mutations of the WFS1 gene have been identified to date in Wolfram syndrome 
patients. Most are inactivating mutations, suggesting loss of function to be responsible for 
the disease phenotype (Cryns et al., 2003). The WFS1 protein is expressed in various tissues 
but at higher levels in the brain, heart, lung and pancreas (Inoue et al., 1998; Strom et al., 
1998b). The literature shows that the WFS1 protein is to be localized predominantly in the 
endoplasmic reticulum and suggested a possible role of this protein in membrane 
trafficking, protein processing and/or regulation of cellular calcium homeostasis (Takeda et 
al, 2001). A recent study showed this protein to contain nine transmembrane domains and to 
be embedded in the ER membrane with the amino-terminus in the cytosol and the carboxy-
terminus in the ER lumen (Hofmann et al., 2003). 
The short introduction shows the correlation of Diabetes insipidus with mutations in 
different membrane proteins. Membrane proteins play essential roles in cellular processes. 
Despite the central importance of transmembrane proteins, the number of high-resolution 
structures remains small due to the practical difficulties in crystalizing them. Many human 
disease-linked point mutations occur in transmembrane proteins. These mutations cause 
structural instabilities in a transmembrane protein leading it to unfold or missfold in an 
alternative conformation. 
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However, the analysis of this stability plays an important part concerning the 
understanding process of these diseases, especially for Diabetes insipidus. In this chapter, 
we demonstrate two different approaches on membrane protein stability analysis, results 
from single-molecule force spectroscopy (SMFS) on aquaporin-1 and a new method based 
on so called energy profiles.  
2. Description of the investigated membrane proteins  
The points of interest in this work are the membrane proteins: aquaporins -2, -3 and -4 as 
well as the arginine vasopressin V2 receptor.  
2.1 Aquaporins 
For a better understanding of the relationship between mutations and changes in the stability 
of membrane proteins, we summarize in this section the structural characteristics of water 
cannels. Knowledge of these aquaporins derived by experimental data revealed the affiliation 
of aquaporins to a family of related water channels from many species. Aquaporins provide 
highly permeable pores for water to cross membranes. Four identical subunits form a stable 
tetramer in the plane of membrane. Each subunit has a narrow pore that is selective for water 
passing through the middle of a bundle of α-helices. About 10 water molecules line up in a 
pore about 0.3 nm in diameter. Hydrophobic bonding of water with a pair of asparagine 
residues (Fig. 2: Asn 76 and Asn 192, human aquaporin-1 numbering) at a narrow point in the 
pore allows the channel to be selective for water. The monomers of the protein arose by gene 
duplication, since their sequences are remarkably similar. Various human tissues express 12 
different aquaporin isoforms. Aquaporin-1 (Fig. 2) is found in red blood cells, retinal proximal 
tubules, blood vessel endothelial cells, and the choroid plexus. Aquaporin-2 is required for 
renal collecting ducts to reabsorb water (King et al. 2004).  
 
 
Fig. 2. Structure of an aquaprin-1 protein (PDB_ID 1ih5); The lined up water molecules are 
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Antidiuretic hormone controls the insertion of aquaporin-2 in the collecting duct membrane. It 
activates a seven-helix receptor, causing cytoplasmic vesicles storing aquaporin-2 to fuse with 
the plasma membrane. This increases the permeability of apical plasma membranes to water, 
allowing it to move from the urine into the hypertonic extracellular space of the renal medulla. 
The water selectivity can appreciate by the protein structure. The figure 3 illustrates the 
network of the involved residues in the process. Additional to the exposed residue pair (Asn 
76 and Asn 192) we observed Arg 195 and His 180 on the top of the pore, both closing the pore 
for bigger molecules or ions. The pore is hydrophobic inside. The peptide bonds of the 
residues Gly 188 and Ile 191 can form h-bonds with water molecules. The reaction of sensitive 
Cys 189 with mercuric ions closes the water pore (King et al. 2004; Pollard & Earnshaw, 2007).  
 
 
Fig. 3. Aquaporin 1 and the residue network for water transport. The following residues are 
involved: His 180, Gly 188, Cys 189, Gly 190, Ile 191, Asn 192, Arg 195 and Phe 56, Asn 76.  
Furthermore, it is shown that two of the seven helices hold a highly conserved Asn-Pro-Ala 
motif (Chen et al., 2006). These two motifs meet in opposite α-helical orientation. This 
conformation induces a bipolar electric field changing the water molecule orientation and 
preventing protons to move through the channel. Further molecular simulation study has 
revealed a secondary free energy-barrier induced by Phe 56, His 180 and Arg 195. This 
barrier is located at the extracellular side, about 8 Å apart from the bipolar field. It forms a 
constriction region with a diameter of approximately 2 Å which allows only a single water 
molecule to pass the pore. Thus, the secondary free-energy barrier plays a main role in 
transport selectivity. Additionally, molecular dynamics simulation of Arg 195 mutants 
showed a significant decrease of the secondary energy-barrier leading to the loss of 
selectivity. This indicates that conformational changes or mutations of Arg 195 have a main 
influence on the transport behavior of aquaporin (de Groot et al. 2004; Chakrabarti et al., 
2004a; Chakrabarti et al., 2004b; Ilan et. al, 2004). 
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The focus of this chapter is the analyses of the stability of membrane proteins. To collect a 
reliable dataset and to gather information about existing protein structures, we checked the 
Protein Data Bank (PDB) and the ModBase for aquaporin entries. Table 1 and  table 2 give an 


















Aqp1/1fqy 230 273 7 36 84 
Aqp4/3gd8 227 328 31 70 69 
Aqp5/3d9s 251 269 1 17 93 
Table 1. Overview of aquaporin structure   
 





Aqp2: 3d9sA 2.00E-99 x 3d9sA good 68% 
Aqp3: 1ldfA 2.00E-46 x 3ldfA average 43% 
Table 2. Overview of models in the ModBase for the structural unknown aquaporin proteins.  
The highlighted (bold) PDB_ID 1ldf is the structure of a glycerol channel from E.coli.   
While the structures of aquaporin-1, -4 and -5 have been clarified by electron 
crystallography (aquaporin-1) or x-ray diffraction (aquaporin-4 and -5) respectively, the 
structures of aquaporin-2 and -3 have been predicted by homology modeling. In homology 
modeling, the sequence of a structural unknown protein is queried to a protein structure 
database (such as the Protein Data Bank or Protein Data Bank of Transmembrane Proteins). 
The structure with adequate sequence identity (usually greater than 25-30%, depending on 
the length of the query sequence) is used as the modeling template. By simulations with 
force fields, using rotamer libraries and machine learning techniques, the query sequence is 
modeled into the given structure template and the resulting model can be evaluated. 
Unsuccessful modeling is caused by low sequence identity and leads to short modeled 
fragments or no model at all. Many of those successfully modeled structures are stored and 
organized in protein model databases (e.g. Modbase and Protein Model Portal). Because of 
the relatively low number of known structures finding an appropriate template is still a 
bottleneck in structure homology modeling. 
As seen in table 2, the structure model of aquaporin-2 has been produced by using the 
structure of aquaporin-5 as modeling template. The most reliable structure of aquaporin-3 
was modeled on the basis of a glycerol channel of E. coli. The neighbor joining tree (see 
figure 4) of aquaporin 1-5 and the glycerol channel gives insight to sequence similarity of the 
involved proteins and, in case of aquaporin-2 and -3 their modeling template sequences. As 
seen by branch length, aquaporin-2 and aquaporin-5 share the highest sequence identity in 
the entire tree which confirms the applicability of the aquaporin-5 structure of modeling a 
high reliable aquaporin-2 structure. Aquaporin-3 and the glycerol channel form a single 
isolated monophyletic cluster with a branch length of about 600 indicating the moderate 
sequence identity of 43% given in table 2. However, this sequence identity is high enough 
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The focus of this chapter is the analyses of the stability of membrane proteins. To collect a 
reliable dataset and to gather information about existing protein structures, we checked the 
Protein Data Bank (PDB) and the ModBase for aquaporin entries. Table 1 and  table 2 give an 


















Aqp1/1fqy 230 273 7 36 84 
Aqp4/3gd8 227 328 31 70 69 
Aqp5/3d9s 251 269 1 17 93 
Table 1. Overview of aquaporin structure   
 





Aqp2: 3d9sA 2.00E-99 x 3d9sA good 68% 
Aqp3: 1ldfA 2.00E-46 x 3ldfA average 43% 
Table 2. Overview of models in the ModBase for the structural unknown aquaporin proteins.  
The highlighted (bold) PDB_ID 1ldf is the structure of a glycerol channel from E.coli.   
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Unsuccessful modeling is caused by low sequence identity and leads to short modeled 
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was modeled on the basis of a glycerol channel of E. coli. The neighbor joining tree (see 
figure 4) of aquaporin 1-5 and the glycerol channel gives insight to sequence similarity of the 
involved proteins and, in case of aquaporin-2 and -3 their modeling template sequences. As 
seen by branch length, aquaporin-2 and aquaporin-5 share the highest sequence identity in 
the entire tree which confirms the applicability of the aquaporin-5 structure of modeling a 
high reliable aquaporin-2 structure. Aquaporin-3 and the glycerol channel form a single 
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Fig. 4. The neighbor joining tree of aquaporin 1-5 and the glycerol channel of E. coli (PDB_ID 
1ldf) indicates the sequence similarities of aquaporin-2,-3 and their modeling templates 
aquaporin-5 and 1ldf, respectively. The direct neighborhood of the involved proteins and 
their template structures point to the adequate reliability of the existing aquaporin-2 and 
aquaporin-3 models. 
Mutations in aquaporin are correlated with NDI. For the detailed analyses of mutations in 
aquaporin-2, we concentrated on two well-defined point mutations. Characterization of 
D150E and G196D aquaporin-2 mutations are responsible for nephrogenic diabetes 
insipidus: importance of a mild phenotype. These two mutations were compared with the 
wild-type protein (aquaporin-2-wt) for functional activity (water flux analysis), protein 
maturation, and plasma membrane targeting. As shown by Guyon et al (2009) the D150E 
mutant induces an intermediate water flux compared to the aquaporin-2 –wt whereas the 
G196D mutant leads to no water flux. This observation is consistent with results from 
immunocytochemical experiments and Western blotting which indicate partial targeting of 
D105E in plasma membrane and complete sequestration of G196D within intracellular 
compartments. When coinjecting aquaporin-2-wt with mutants, no (aquaporin-2-wt + 
D150E) or partial (aquaporin-2-wt + G196D) reduction of water flux were observed 
compared with aquaporin-2-wt alone, whereas complete loss of function was found when 
both mutants were coinjected (Guyon, et al., 2009). 
2.2 Model of V2 receptor 
The V2 receptor belongs to the class A of G-protein-coupled receptors containing seven 
membrane spanning helices which are connected by extracellular and intracellular loops of 
varying length. The function of V2R is coupled to the G-protein activating adenyl cyclase 
(Barberis et al. 1998). If an agonist arginine vasopressin binds to V2R, the receptor becomes 
activated which leads to allosteric structural rearrangements. These structural changes then 
enable interactions with the cytosolic G-protein. The binding site of arginine vasopressin on 
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the V2 receptor is formed within the transmembrane helices II –VII (Slusarz et al. 2006). 
Regions between residues 88-96, 119-127, 284-291 and 311-317 contain most of the residues 
involved in binding. The selectivity of vasopressin was proposed to be connected with non-
conserved residue Q180 whose carboxamide forms hydrogen bonds with carboxamide of 
Asn5 in the peptide. The stability of the hormone in the bound state is ensured by two 
hydrogen bonds between peptide backbone atoms of Tyr 2 and Asn 5. In general, hydrogen 
bonding and salt bridges were identified as the most important interactions contribution to 
the arginine vasopressin binding (Slusarz et al. 2006). Significant hydrophobic interactions 
were not detected.  
A three-dimensional structural model of human V2 receptor (Fig. 5) was produced using I-
TASSER protein structure modeling pipeline (Roy et al. 2010). I-TASSER builds protein 
models using multiple threading alignments on template structures and iterative assembly. 
The top three structural templates used in the structure prediction were PDB_ID 2ks9 
(Substance-P receptor) with sequence identity of 19 %, PDB_ID 2rh1 (B2-adrenergic G 
protein-coupled receptor) with sequence identity of 22 % and PDB_ID 1l9h (bovine 
rhodopsin) with sequence identity of 18 %  to VR2 receptor. The modeled structure was 
subjected first to conjugate gradient minimization and then MD simulation using the 
program NAMD2 (Phillips et al. 2005) and the CHARMM27 force-field (MacKerrel et al. 
1998). The TIP3P solvent model represented the water molecules (Joergensen et al. 1983). 
Simulations assumed constant particle number, constant pressure and constant temperature 
(NpT) ensembles. Langevin dynamics was used to maintain constant temperature and 
pressure was controlled using a hybrid Nose-Hoover Langevin piston method. Extensive 
molecular dynamics simulations were done on the modeled structure in order to study its 
quality and structural stability. The average root-mean-square-deviation of the backbone 
atoms of the modeled structure during the simulation was found to be 2.7 Å. The model 
structure has seven helical segments: helix I 34 -64, helix II 73 – 101, helix III 109 – 142, helix 
IV 153-175, helix V 202-230, helix VI 248-296, helix VII 304-328. 
Molecular dynamics (MD) simulation is one of the most common methods to study 
computationally protein function, conformational flexibility, and interactions. It is a 
technique to calculate the equilibrium and transport properties of a classical many-body 
system (Frenkel, 2002). In MD simulations, particles obey the laws of classical mechanics 
and the technique show how the system of particles evolves in time. The first MD 
simulation of a protein was done in the 1970s in vacuum for duration of 10ps (McCammon 
et al. 1977). Nowadays, the computational power allows simulation of about one million 
atoms, up to 100 Å in size and time scale up to 1 microsecond. Even single membrane 
proteins in the native lipid environment can be studied. Simulations of large biomolecular 
systems are becoming more feasible as demonstrated by the work on the MD-based 
structure prediction of the ribosome complex from E. coli (Villa, 2009), the simulation of the 
assembly of lipids and proteins into lipoprotein particles (Shih, 2007), the MD studies of 
viral capsid self-assembly (Freddolino, 2006; Miao, 2010) and vesicle fusion simulations 
(Kasson, 2010). MD simulations are used to gain information about the conformational 
changes of protein structure, i.e. sample the configuration space. In addition, MD 
simulations provide thermal averages of molecular properties such as the free energy 
change upon binding or atomic mean square fluctuation amplitudes. According to the 
ergodic hypothesis all microstates of a system are equally probable for a particle over a long 
period of time. Hence, the average of a process parameter over time and the average over 
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system in detail by observing the conformational states that are accessible in a given 
temperature. Ab initio structure prediction starting from amino acid sequence of a protein 
using MD simulations is computationally feasible only for very small proteins, but 
simulations can be used to improve computational predicted protein structures obtained by 
homology modeling or fold recognition. The limitations of MD simulations are still 
relatively short time scale, inaccuracies in the description of physical interactions and the 
size limitation of the simulation system. 
 
 
Fig. 5. Structure model of the V2 receptor (left). On the right side a result from Molecular 
Docking Server. The AVP hormone is highlighted in orange and is bound to the V2 receptor 
(right). 
 
Mutation  Effect  
A84D 
This mutation not only affects receptor folding in such a way as to lead to its 
retention inside the intracellular compartments but, as expected, also has 
profound effects on its binding and coupling properties (pubmed_Id 
10820167). 
I130F 
Functional analysis of I46K and I130F revealed reduced maximum agonist-
induced cAMP responses as a result of an improper cell surface targeting 
(pubmed_Id 10770218,16006591) 
P322S P322S mutation of AVPR2 gene leads to a mild form of CNDI. (pubmed_Id 10026830,9402087) 
Table 3. Overview of mutations in the V2 receptor and a short description of the biological 
effect. (More mutants in the appendix.) 
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In this work we address only a repertory. We do not analyses mutations cause constitutive 
activation of the receptor in this work (such as: Feldman et al, 2005). The table 3 shows the 
position and the molecular description of the investigated mutations of the V2 receptor be 
focused on this work.  
3. SMFS – Stability and experiments 
Atomic force microscopy (AFM) is mostly known for its imaging capabilities (Müller & 
Engel, 1999; Müller, et al, 1999; Seelert et.al, 2003). Recently, single-molecule force 
spectroscopy (SMFS) has proven to be a tool for detecting and locating inter- and intra-
molecular forces on a single molecule level. SMFS experiments allow measuring the stability 
of membrane proteins and also probing the energy landscapes (Janshoff et al., 2000; Janovjak 
et al, 2004). In Fig. 6A a schematic representation of the force spectroscopy instrumentation 
is shown. Molecules with complex three-dimensional structures, such as proteins, can be 
unfolded in a controlled way. When transmembrane proteins are unfolded in force 
spectroscopy experiments, during continuous stretching of the molecule the applied force is 
 
 
Fig. 6. A: Schematic representation of AFM. The sample is mounted on a piezo-electric 
element and scanned under a sharp tip attached to the cantilever. The voltage difference of 
the photodetector is proportional to the deflection of the cantilever.  
B: Unfolding of a transmembrane protein. A single molecule is attached between the tip and 
the sample while the distance between tip and sample is continuously increased.  
C: Typical spectrum obtained from an unfolding experiment of bR with the main peaks 
fitted by a hyperbolic function (WLC model) and correlated to the unfolding of secondary 





system in detail by observing the conformational states that are accessible in a given 
temperature. Ab initio structure prediction starting from amino acid sequence of a protein 
using MD simulations is computationally feasible only for very small proteins, but 
simulations can be used to improve computational predicted protein structures obtained by 
homology modeling or fold recognition. The limitations of MD simulations are still 
relatively short time scale, inaccuracies in the description of physical interactions and the 
size limitation of the simulation system. 
 
 
Fig. 5. Structure model of the V2 receptor (left). On the right side a result from Molecular 
Docking Server. The AVP hormone is highlighted in orange and is bound to the V2 receptor 
(right). 
 
Mutation  Effect  
A84D 
This mutation not only affects receptor folding in such a way as to lead to its 
retention inside the intracellular compartments but, as expected, also has 
profound effects on its binding and coupling properties (pubmed_Id 
10820167). 
I130F 
Functional analysis of I46K and I130F revealed reduced maximum agonist-
induced cAMP responses as a result of an improper cell surface targeting 
(pubmed_Id 10770218,16006591) 
P322S P322S mutation of AVPR2 gene leads to a mild form of CNDI. (pubmed_Id 10026830,9402087) 
Table 3. Overview of mutations in the V2 receptor and a short description of the biological 
effect. (More mutants in the appendix.) 
 
Analysis of Membrane Protein Stability in Diabetes Insipidus 
 
61 
In this work we address only a repertory. We do not analyses mutations cause constitutive 
activation of the receptor in this work (such as: Feldman et al, 2005). The table 3 shows the 
position and the molecular description of the investigated mutations of the V2 receptor be 
focused on this work.  
3. SMFS – Stability and experiments 
Atomic force microscopy (AFM) is mostly known for its imaging capabilities (Müller & 
Engel, 1999; Müller, et al, 1999; Seelert et.al, 2003). Recently, single-molecule force 
spectroscopy (SMFS) has proven to be a tool for detecting and locating inter- and intra-
molecular forces on a single molecule level. SMFS experiments allow measuring the stability 
of membrane proteins and also probing the energy landscapes (Janshoff et al., 2000; Janovjak 
et al, 2004). In Fig. 6A a schematic representation of the force spectroscopy instrumentation 
is shown. Molecules with complex three-dimensional structures, such as proteins, can be 
unfolded in a controlled way. When transmembrane proteins are unfolded in force 
spectroscopy experiments, during continuous stretching of the molecule the applied force is 
 
 
Fig. 6. A: Schematic representation of AFM. The sample is mounted on a piezo-electric 
element and scanned under a sharp tip attached to the cantilever. The voltage difference of 
the photodetector is proportional to the deflection of the cantilever.  
B: Unfolding of a transmembrane protein. A single molecule is attached between the tip and 
the sample while the distance between tip and sample is continuously increased.  
C: Typical spectrum obtained from an unfolding experiment of bR with the main peaks 
fitted by a hyperbolic function (WLC model) and correlated to the unfolding of secondary 





measured by the deflection of the cantilever and plotted against extension (tip-sample 
separation), yielding a characteristic force-distance curve (F-D curve) (see Fig. 6). From the 
analysis of single molecule force spectra it is possible to associate the peaks to individual 
stable structural segments within membrane proteins. For a given protein under study, the 
F-D curves exhibit certain patterns, which contain information about the strength and 
location of molecular forces established within the molecule, stable intermediates and 
reaction pathways, and the probability with which they occur. For membrane proteins the 
sequence of the unfolding peaks follow the amino acid sequence of the protein. Fitting each 
peak to a hyperbolic function, the worm-like chain model (WLC), gives the number of 
already unfolded amino acids (Rief et al. 1997).  
Consequently, with the peaks and the predicted secondary structure, it is possible to 
associate the peaks to structural domains (see Fig. 7 and Fig. 8). Force curves show specific 
and unspecific interactions which lead to different unfolding pathways.  
To draw biologically relevant conclusions on molecular interactions about how strong they 
are and where they occur, or whether they are independent or occur only in presence with 
other events, one must analyze many F-D curves by identical objective procedures. Thus, 
there is an increasing demand for data analysis techniques that offer fully automated 
processing of many datasets with identical analysis procedures. To discriminate force 
spectra showing specific and non-specific interactions and different unfolding/unbinding 
pathways, classification and pattern recognition algorithms are urgently needed (Marcico et 
al. 2007; Sapra et al., 2008). 
One aim of the analyses of experimental data from SMFS measurements is the detection of 
possible unfolding pathways. Furthermore, we can identify different groups in hierarchical 
trees, which relate to different unfolding events. These events correspond to secondary 
structure elements and stabilized regions in the investigated protein.  
3.1 SMFS experiments on aquaporin-1  
Here, we work on data from SMFS experiments for human aquaporin-1 from the literature 
In the work of (Möller et al, 2003) 26 F-D curves were measured and manually aligned. The 
individual hAQP1 molecules were unfolded by pulling at their C-termini. The author 
created an overlay of all investigated curves (Fig. 7).  
 
 
Fig. 7. Overlay of 26 F-D curves of the human aquaporin-2 and fitted using the WLC model 
(continuous curves). The numbers on the WLC fits indicate the contour lengths used to 
obtain the fit, in amino acids (Möller et al, 2003). 
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The next step is the mapping of the unfolding results of the known structure of aquaporin-1. 
This leads to a correlation of unfolding events and the secondary structure of the membrane 













Grey marker  
(Fig. 8) 
40 ±  8 26 (100%) 206 ± 64 end of helix H6 1 
58  ± 6 24 (92%) 157 ± 49 end of helix HE 2 
70  ± 8 17 (65%) 125 ± 63 end of helix H5 3 
91  ± 7 22 (85%) 156 ± 44 Helix H5 4 
113  ± 7 13 (50%) 98 ± 54 end of helix H4 5 
151  ± 5 20 (77%) 82 ± 53 Helix H3 6 
190  ± 10 17 (65%) 98 ± 33 end of helix HB 7 
211  ± 6 16 (62%) 77 ± 42 HelixH2 8 
232  ± 5 26 (100%) 152 ± 62 HelixH1 9 
Table 4. Contour lengths, peak occurrence, average forces, and positions of potential barriers 
in Aqp1 topology by SMFS experiments (additional link to Fig. 8 – topology).   
 
 
Fig. 8. Topology model of Aqp1: Shown are the secondary structure elements in the lipid 
bilayer, as described by the 3D structure. Numbers in ovals represent the numbers of 
proposed potential barrier of table 4.  
Interesting are the two long loops, with formed helices in the transmembrane region. A view 
of the structure of aquaporin-1 quickly shows the role of both helices (HB and HE). The 
residues Asn 72 (part of HB) and Asn 192 (part of HE) arrange the immediate place of the 
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Fig. 9. Structure of aquaporin-1: Left side loop regions E and B (transmembrane helices HE 
and HB highlighted in red), right: Interface with conserved residues Asn 192 and Asn 76.       
This important functional and structural feature corresponds to two unfolding events in 
aquaporin-1. The major force peak appeared within the noisy region but at a tip–membrane 
separation of about 20 nm. The WLC fit (Fig. 7 red line – 58 aa) showed an average contour 
length of 58±6 amino acids, while the rupture event exhibited an average force of 
147±49 pN.  According to the topology shown in Fig. 8, the extracellular end of helix HE is 
separated from the C-terminal end. Thus, this adhesion peak is likely to reflect the unfolding 
of HB. We can observe an analog situation for the loop B and the corresponding helix HB. 
The force peaks found at a contour length of 190±10 amino acids (Fig.7) exhibit an average 
rupture force of 98±33 pN. This distance from the C-terminus corresponds to helix HB, 
which dips into the membrane from the cytoplasmic side and is only 11 amino acids long. 
Thus, this adhesion peak is likely to reflect the unfolding of HB.  
3.2 Unfolding characteristic of aquaporin-2 and aquaporin-3 
On the basis of known structures of aquaporin-1,-4 and -5 and the models of the aquaporin-2 
and -3 we created a multiple structure alignment using the PDBeFold service of the EMBL-EBI. 
We clustered the resulting q-scores of all pair wise structural alignments by applying the 
UPGMA method (Unweighted Pair Group Method with Arithmetic Mean) to get a rooted tree 
(see Fig. 10, left). The inner node of the tree indicates that the known structures of aquaporin-5 
and the glycerol channel (PDB_ID 1ldf) are almost identical in protein fold. The direct 
neighborhood of the aquaporin-1 structure and the models of aquaporin-2 and -3 give a strong 
hint for the unfolding characteristics of aquaporin-2. Due to their high structural similarity we 
postulate that aquaporin-2,-3 have a similar unfolding characteristic in comparison to 
aquaporin-1. The pair wise structural alignment of aquaporin-2 and -3 is shown in Fig. 10, 
right. The structure of aquaporin-4 shares a high similarity to the other structures. 
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A lot of tools and methods in the field of bioinformatics and structural biology are based on 
structure and/or sequence comparison. In this section we demonstrate a new method based 
on so called energy profiles for analyzing protein structure stability. Those profiles are 
 




Fig. 10. Left: tree of the q-scores resulting from the PDBeFold service using Unweighted Pair 
Group Method with Arithmetic Mean (UPGMA) hierarchical clustering. Right: A structural 
alignment of aquaporin-1 structure (orange) and the model of aquaporin-2 (cyan). 
calculated by coarse grained models. Based on the residue contacts in known protein 
structures, we calculated the potential for pair wise residue-residue-interactions. An energy 
profile is a schematic plot of the interaction energy of each residue as a function of the 
residue position in the sequence.  
4.1 Theory of energy profiles  
In this section, we show the theoretical aspects and calculation of so called protein energy 
profiles. The aspects explained in this section are essential in understanding the energy 
profile based methods we applied to the aquaporin proteins.  
Energy profiles are derived by coarse-grained amino acid interaction models based on 
information of known protein structures. In general, the energy of any protein is given by 
equation (1), where e*ij acts as the interaction energy between two amino acids ai and aj. The 
function f(rij) quantifies e*ij by the Euclidean distance rij. The solvent interaction energy of an 
amino acid ai is given by e’i0 and is relativized by expression g(i), which describes the solvent 
accessibility state of ai. 
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Based on (1), we designed a coarse grained interaction scheme, which uses the Cα and Cβ 
coordinates of the amino acids. Furthermore we redefined g(i) and f(rij). Instead of using a 
continuous space, f(rij) acts as Boolean function. That means, depending on rij, amino acid ai 
is either interacting with amino acid aj or it is not. Based on the work of (Dressel et al. 2007; 
Wertz & Scheraga, 1978) we defined a cut-off threshold for rij of 8Å. That leads to the 
equation (2). 
 














Fig. 9. Structure of aquaporin-1: Left side loop regions E and B (transmembrane helices HE 
and HB highlighted in red), right: Interface with conserved residues Asn 192 and Asn 76.       
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ÅFurthermore we introduced an amino acid specific inside/outside-property which reflects 
the orientation of the amino acid side chains with respect to the center of mass of the 
neighboring residues and was defined in the following way: 
A residue is declared as inside, if 
 ( )( )5 0C c C C C cα α β α− < ∨ − − <
      (3) 
α/βC

 are the vectors of the Cα/β atoms, c
 is the center of mass of all amino acids in a 
surrounding sphere with a radius of 5Å. For determining the center of mass only Cα atoms 
are taken into account. Using this property the inverse Boltzmann equation can be applied 















The parameters n(i,in) and n(i,out) are equal to the number of inside and outside occurrences 
of amino acid ai, respectively. These parameters are derived by known globular and 
membrane protein structures. In our coarse grained model, the interaction energy eij 
between two amino acids ai and aj is equal to the summation of ei and ej. Finally, let S be a 
set of amino acids, let k =|S| and ai is defined as the observed amino acid. For each ja S∈  is rij ≤ 8Å. Then the total energy Ei of ai equals (5). By iterating over all amino acids in a 
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Additionally, it needs to be said that we discard further solvent interaction calculation (seen 
in the second summation in equation 1) because these information is modeled by the amino 
acid specific inside/outside-property. In addition, we declared T as constant which leads to 
discarding the constant –kBT in the energy profile calculation. Thus the energies, which 
result by our model, are arbitrary unit entities [a.u.] and are direct proportional to energies 
given in [J] or [kcal.mol-1]. 
In conclusion, by calculating the total energy of an amino acid in a protein structure, 
physicochemical and structural information are abstracted to one single value. 
The relation of amino acid stability and amino acid energy is explainable by the folding of 
the protein and its energy landscape. As one of the last steps in protein biosynthesis the 
polypeptide folds into the native protein structure state spontaneously which is equal to 
the proteins most stable fold. This process can be described as a function of the loss of the 
Helmholtz free energy within an amino acid interaction energy state. Commonly a folded 
protein in its stable state holds the minimized amount of free energy. The energy profile is 
a transformation of the energy landscape of the protein at the point of minimized free 
energy, which leads to the conclusion that the energy value of an amino acid ai given by 
an energy profile is a transformation of the stability of the amino acid ai in the structure. 
Figure 11 illustrates the resulting energy profile (right) of the structure model of 
aquaporin-2 (left).   
 





Fig. 11. Left: Structure model of aquaporin-2 and the corresponding energy profile (right) of 
this model.  
4.2 Energy profiles analyses of the investigated aquaporins 
On the basis of the so-called energy profiles we can compare the structures and models of all 
investigated aquaporins, well-defined mutations and the influences of mutations for the 
stability of the aquaporins. 
4.2.1 Energy profiles of the investigated aquaporins 
For calculating the energy profiles we used the structures given in table 1 and table 2. To 
evaluate the energy profiles we checked the already existing aquaporin models concerning 
their reliability. As shown, the best matching structures were used as template structures for 
homology modeling. On the level of energy profiles we can confirm our hypothesis that all 
investigated aquaporins have the same stability characteristics. For this purpose we created 
a multiple energy profile alignment (MEPAL). We adapted standard algorithms in clustering 
and deriving consensus profiles and energy conservation. Figure 12 shows the MEPAL for all 
of the involved aquaporins in Diabetes Insipidus and the human aquaporin-1. 
The MEPAL method is based on classical multiple sequence alignment algorithms using 
modified scoring functions optimized for energy profile comparison. The tree (see Fig. 13) is 
calculated by applying the UPGMA clustering method to the pair wise distance scores 
which are calculated by the MEPAL algorithm. Furthermore, the graphical alignment output 
(Figure 12) consists of three parts. The upper row shows the energetically aligned energy 
profiles represented by the amino acids of the protein sequence which are colored 
depending on their energy. The greater the energy of an amino acid the greater is the red 
color content. The middle row shows the consensus profile. In the consensus profile, each 
energy at position i is derived by calculating the pair wise distance sores of all aligned energies 
at position i. The energy with the lowest average distance is representing the consensus profile 
at position i. Finally, the bottom row shows the conservations at each alignment position. Each 
conservation value is calculated by the sum of pair wise energy distances and is normalized by 
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homology modeling. On the level of energy profiles we can confirm our hypothesis that all 
investigated aquaporins have the same stability characteristics. For this purpose we created 
a multiple energy profile alignment (MEPAL). We adapted standard algorithms in clustering 
and deriving consensus profiles and energy conservation. Figure 12 shows the MEPAL for all 
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Fig. 12. MEPAL output for the energy profile alignment of aquaporin-1, -2,- 3 and -4. The 
Asn-Pro-Ala motifs are highlighted by red boxes.  
 




Fig. 13. UPGMA tree, based on energy profiles of aquaporin-1, -2, -3 and -4. 
The energy profile alignment based UPGMA Tree, which was calculated by MEPAL 
indicates high similarities between the energy profiles of aquaporin-1,-2 and -4 and is seen 
in figure 13. The distance of 3.92 between aquaporin-3 and the other structures corresponds 
to significant similarity. The graphical output of the MEPAL illustrates several highly 
energetically conserved amino acids and regions. Two of these conserved regions 
correspond to the opposite orientated Asn-Pro-Ala motifs in helix HB and helix HE (see 
section 2.1). These two motifs are highlighted by red boxes in Fig. 12. The energetic 
conservation of these motifs and their surrounding amino acids confirms the importance of 
these residues in water transport in aquaporin. Additionally the residues Gly 188, Phe 56, 
Cys 189, Ile 191 and His 180, which are involved in water transport as well, show differences 
in sequential and energetic conservation. In detail the conserved amino acids Gly 188 and 
Phe 56 show slight divergences or no divergences at all concerning their calculated energy. 
Cys 189 and Ile 191 show no conservation in aquaporin 1-4; but these changes have no effect 
on the level of energy profiles. Missing in aquaporin-3, His 180 shows sequential and 
energetic conservation in the other aquaporins. We postulate that these slight divergences 
do not affect the water flux significantly. 
A further point of interest lies in Arg 195. This residue is conserved in all four proteins 
but varies energetically. These divergences arise from conformational changes of the 
residue and the structural environment. Based on the facts we referred to in section 2.1, 
we postulate that these divergences between aquaporin 1-4 lead to a change in  
the secondary free-energy barrier influencing the transport selectivity and the water  
flux. It also needs to be said that the significant differences in the energy profile 
progression between aquaporin-3 and the other structures (see Fig. 13) might result by the 
less reliable aquaporin-3 model. Despite these divergences, we can confirm our postulated 
similarities concerning the unfolding characteristics of the aquaporins involved in 
Diabetes Insipidus.  
4.2.2 Energy profiles and stability of the mutants of aquaporin-2 
For comparison on the level of energy profiles we generated aquaporin-2 models with the 
two mutations: D150E and G196D.  Based on all three models we calculated the energy 
profiles and created a MEPAL. The results lead to a distance tree and can be discussed on 
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A: The UPGMA tree of the resulting distance scores of the energy profiles calculated by MEPAL. The 
inner node indicates that these point mutations lead similar energy profiles. 
B: The MEPAL output of the investigated energy profiles. The point mutations induce various energetic 
changes which are highlighted by arrows. The red rectangle illustrates the Asn-Pro-Ala motif. 
Fig. 14. Results from the analyses of the energy profile of aquaporin-2 and the investigated 
mutants.  
The energy profile based UPGMA tree (see Fig. 14, A) indicates strong similarities between the 
energy profiles of the two modelled aquaporin-2 mutants. This leads to the conclusion that 
both mutants induce the same energetic, structural and functional changes. While both 
mutations led to energetic variations in the entire energy profiles we focused our discussion on 
the mutations sites (see Fig. 14, B - red arrows). It needs to be said that because of the 
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modelling procedure and the energy profile calculation the resulting energy profile covers not 
all amino acids of the mutated sequence. In this case, this leads to an index indention of 3 
amino acids. The mutation D150E (see Fig. 14, B - at the top) induces an energetically increase 
of the two surrounding residues decreasing the energetic conservation at these positions. 
Interestingly, in this region the mutation G196D induces almost the same energetic increase as 
D150E. At the mutation site of the modelled G196D variant (see Fig. 14, B - at the bottom), the 
mutation induces slight energetic divergences in the region where the mutation site is located. 
Furthermore, in this region the G196D mutation leads to the same energetic variations as the 
D150E mutation. This observation can be confirmed at nearly all positions in the energy 
profiles of the modelled aquaporin mutations. Interestingly, both mutations do not affect the 
energetic conservation of the Asn-Pro-Ala motif (highlighted by a red rectangle in Fig. 14, B at 
the bottom). 
Additionally, we point to the energetic changes of Gly 188 (highlighted by an orange arrow 
in 14 B at the bottom). As mentioned in section 2.1 this residue is involved in water 
transport. Both mutations lead to an energetically increase of Gly 188 and reduce the 
energetic conservation in these three investigated energy profiles. Thus, we postulate that 
the mutations D150E and G196D affect the transecullar water transport. 
4.3 Energy profiles analyses of the V2 receptor 
For investigating energetic influences, binding capabilities and the effect of mutations in the 
V2 receptor we generated a V2 receptor model by molecular modeling. This model was used 
to calculate the energy profile of this receptor. Furthermore, we used the Molecular Docking 
Server to process a docking simulation of the V2 receptor model and the arginine 
vasopressin hormone. The structure of the model and its hormone in docked state was used 
for further analyses. Both models are illustrated in Fig. 5 in subsection 2.2. We calculated the 
energy profile of the V2 receptor model in docked state to detect energetic divergences 
induced by conformational changes and the hormone itself. Thus, AVP is an oligopeptide it 
can be integrated into the energy profile calculation in the way it is explained in section 4.1.  
To detect docking induced energetic changes both derived energy profiles were aligned 
using the MEPAL method. The alignment revealed energetic divergences in the 
surrounding of the amino acids Ala 84 (Fig. 15, A), Ile 130 (Fig. 15, B) and Pro 322 (Fig. 15, 
C). This leads to the conclusion that these amino acids are involved in hormone binding. 
Mutations of these amino acids are well described in literature and are causing a loss in 
functionality and hormone affinity (see table 3). Our novel energy profile based approach 
brought more evidence to these described mutations. 
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5. Discussion of the stability of the investigated membrane proteins 
The antidiuretic hormone, ADH, also called vasopressin and arginine-vasopressin, is a 
nanopeptide (nine amino acids) synthesized in the hypothalamus, transported to and stored 
in the posterior lobe of the pituitary gland which releases it into the blood circulation. It has 
antidiuretic and vasopressor actions. The effects of vasopressin result from stimulation of V1 
and V2 receptors, V1 mainly responsible for vasoconstriction, V2 for the antidiuretic effect 
V1 receptors are coupled by G-protein to phospholipase C. V2 receptors are coupled by G- 
protein to adenylcyclase. Its activation elicits an increase in cAMP which, via protein 
kinases, induces the activation of aqueous channel aquaporin-2 -mainly located in the renal 
collecting duct. Under the influence of vasopressin aquaporin-2 migrates from the 
cytoplasm to the apical membrane. In nephrogenic diabetes insipidus there are aquaporin-
2 alterations.  
Aquaporin-3 is constitutively expressed in the basolateral membrane of the cell. When water 
floods into the cell through aquaporin-2 channels, it can rapidly exit the cell through the 
aquaporin-3, 4 channels and flow into blood. 
We investigated the stability of membrane proteins on the basis of experimental and 
theoretical assumptions. Membrane proteins play essential roles in cellular processes. 
These mutations cause structural instabilities in a transmembrane protein leading it to 
unfold or missfold in an alternative conformation. By the structural comparison of the 
aquaporin-1, investigated by SMFS, with the involved proteins and protein models, we can 
postulate that aquaporin-2,-3 and -4 exhibit similarities in unfolding characteristics. This 
assumption can be confirmed by our theoretical approach. These theoretical methods are 
based on the so called energy profile calculation which is explained in this work. On the 
basis of stability analyses and the application of energy profile based methods we were 
able to enforce evidence for water flux reduction induced by well described mutations. 
Furthermore the correlation of residue conservation and energetic conservation of amino 
acids involved in water transport was detected. Especially the role of the two conserved 
helices HB and HE could be detected and described on the basis of experimental and 
theoretical methods. 
For analyzing the V2 receptor we derived a structure model by molecular modeling and 
processed AVP docking simulations. As a main part we focused on selected point mutations 
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Mutation  Effect  
N22Q N-linked glycosylation at asparagine 22, Mutagenesis of asparagine 22 to 
glutamine abolished N-linked glycosylation of the V2 receptor (N22Q-V2R), 
without altering its function or level of expression. (pubmed_Id 10362843) 
L44F the mutant L44F and the in vitro mutant S167A were expressed in their 
mature form at wild-type levels (pubmed_Id 8863826) 
L44P mutants L44P, W164S, S167L, and S167T lacked complex glycosylation  
and were expressed at low levels, mutants misfolded (pubmed_Id 
8863826,16006591) 
S45C Strong beta-catenin (CTNNB1) expression in the tumor cells and identified a 
heterozygote missense Ser45Cys mutation of exon 3 of CTNNB1 (pubmed_Id 
19294427). 
I46K Functional analysis of I46K and I130F revealed reduced maximum agonist-
induced cAMP responses as a result of an improper cell surface targeting 
(pubmed_Id 10770218) 
L62P core-glycosylated mutants L62P and V226E were excluded from lysosomes 
(pubmed_Id 18048502) 
A84D this mutation not only affects receptor folding in such a way as to lead to its 
retention inside the intracellular compartments but, as expected, also has 
profound effects on its binding and coupling properties (pubmed_Id 
10820167). 
A98P the cell-surface expressions of mutant receptors were totally (A98P and 
L274P) (pubmed_Id 17371330) 
W99R Mutation of a tryptophan located at the beginning of the first extracellular 
loop (W99R) that greatly impaired the binding properties of the receptor and 
had a minor effect on its intracellular routing (pubmed_Id 10820167). 
F105V the F105V mutation is delivered to the cell surface and displayed an 
unchanged maximum cAMP response, but impaired ligand binding abilities 
of F105V were reflected in a shifted concentration-response curve toward 
higher vasopressin concentrations. As the extracellularly located F105 is 
highly conserved among the vasopressin/oxytocin receptor family, 
functional analysis of this residue implicates an important role in high affinity 
agonist binding. (pubmed_Id 10770218) 
R113W The cell-surface expressions of mutant receptors were totally (A98P and 
L274P) or partially (R113W) absent. V2R-R113W, -G201D, and -T204N were 
expressed in the ER and in the basolateral membrane as immature, high-
mannose glycosylated, and mature complex-glycosylated proteins. The 
immature forms of V2R-R113W and -T204N, but not V2R-G201D, were 
rapidly degraded. The mature forms varied extensively in their stability and 
were degraded by only lysosomes (V2R-T204N and wild-type V2R) or 
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I130F Functional analysis of I46K and I130F revealed reduced maximum agonist-
induced cAMP responses as a result of an improper cell surface targeting 
(pubmed_Id 10770218,16006591) 
R137C (R137C) in the second intracellular loop, which has been associated with 
constitutive activation of the AVPR2. In conclusion, adults with intermittent, 
severe hyponatraemia may have a constitutively activating mutation in the 
AVPR2 with resultant nephrogenic syndrome of inappropriate antidiuresis. 
R137C gain-of-function mutation was detected by means of mutation analysis 
of the V2R gene. (pubmed_Id 18753429,18622631,16843086,19179480,17229917) 
R137L V2R-R137L mutant interacts with beta-arrestins in an agonist-independent 
manner resulting in dynamin-dependent internalization. V2R-R137L mutant 
traffic considerably more efficiently to the plasma membrane than V2R-
R137H, identifying this as a potentially important mutation-dependent 
difference affecting V2R function. (pubmed_Id 19179480,16843086) 
R143P R143P and delta V278 mutants are retained within the cytoplasmic 
compartment. (pubmed_Id 7560098)
S167A The mutant S167A was functionally active, (pubmed_Id 8863826) 
R181C 
G185C 
loss of receptor function (pubmed_Id 15841479)
G201D the complex-glycosylated mutant G201D were partially located in lysosomes, 
G201D was expressed in the ER and in the basolateral membrane as 
immature, high-mannose glycosylated, and mature complex-glycosylated 
proteins. (pubmed_Id 18048502,16006591) 
R202C R202C mutant reaches the cell surface, a simple binding impairment at the 
cell surface (pubmed_Id 7560098) 
T204N degraded by only lysosomes, T204N was expressed in the ER and in the 
basolateral membrane as immature, high-mannose glycosylated, and mature 




-for Y205C the lack of a Tyr residue at position 205 is responsible for the 
abolished receptor function rather than the formation of a disastrous second 
disulfide bond. Y205C mutant was almost inactive.  
-Analysis of the intermolecular interaction of the Tyr-205 hydrogen group by 
molecular modeling showed that Tyr-205 was located in transmembrane 
domain (TM) 5, and that its hydroxy group formed a hydrogen bond with 
Leu-169 main-chain =O located in TM 4. The mutation of Tyr-205 to 
phenylalanine would cause loss of this hydrogen bond and decrease or 
change the interaction between these TM coils, thus affecting the ability of 
AVP to bind to the receptor. According to this molecular model of AVPR2, 
the Y205F mutation would cause nephrogenic diabetes insipidus.  
- the loss of receptor function of Y205H, NDI-causing mutation Y205H which 
affects a codon frequently found to be mutated to Cys in NDI patients. 
(pubmed_Id 15841479,11026555, 17216256,) 
V206D stimulation of the V206D mutant increased the cAMP accumulation only 
slightly, V206D was mainly expressed in the endoplasmic reticulum (ER) as 
immature proteins. (pubmed_Id 11026555,16006591) 
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F287L F287L mutant in COS-7 cells revealed significant dysfunction and accumulate 
intracellular cyclic adenosine monophosphate in response to AVP hormone 
stimulation. (pubmed_Id 11916004) 
P322S P322S mutation of AVPR2 gene leads to a mild form of CNDI. (pubmed_Id 
10026830,9402087) 
S363A The S363A mutation that confers recycling to the V2R did not alter its 
interaction with arrestins. (pubmed_Id 11353798) 
Table appendix: Overview of mutations in the V2 receptor and a short description of 
functional and structural influences. 
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1. Introduction 
Diabetes insipidus in pregnancy (diabetes insipidus gravidarum, gestational diabetes insipidus 
or pregnancy-related diabetes insipidus) is considered to be a rare disease complicating up 
to 1 in 25000-30000 pregnancies; however, emerging evidence suggests that often the disease 
is under-diagnosed (Aleksandrov et al., 2010). As stated by the Italian E. Momigliano, in 
1929, in his first monograph on 31 cases of pregnancy-related diabetes insipidus 
(Momigliano, 1929), the disease may occur in an apparently healthy woman, during any 
stage of pregnancy, usually in the latter half, or may aggravate during pregnancy when 
previously diagnosed. As a paradox, the disorder may disappear days to weeks after 
delivery, or may alleviate, or remain unaltered (Bleakley, 1938). Moreover, aggravated 
recurrence of the disorder in successive pregnancies is recognized (Blotner & Kunkel, 1942).      
Interest towards pregnancy-related diabetes insipidus revived about 20-30 years ago, once it 
became apparent that this clinical condition is closely associated with liver disease, HELLP 
syndrome and the wide spectrum of preeclampsia, all with potentially serious consequences 
on the maternal course of gestation and fetal health and development.  
The aim of the present book chapter is to review the body water homeostasis during 
pregnancy as well as to insist on clinical conditions associated with the occurrence of 
diabetes insipidus in pregnancy and the early postpartum period. Not only true gestational 
diabetes insipidus will be addressed but, notably, maternal hypothalamic-pituitary diseases 
associated with diabetes insipidus presenting high incidence during pregnancy and the 
postpartum period will be detailed. It is the author’s hope that at the end of the chapter, the 
reader will find answers to hot questions on the intimate mechanisms facilitating gestational 
diabetes insipidus, the need to screen or not for alterations in water metabolism in pregnant 
women at risk, the challenges in differential diagnosis of arginin-vasopressin (AVP) 
disturbances in a pregnant women and the associated clinical conditions including 
preeclampsia, acute fatty liver and HELLP (Hemolysis-Elevated Liver enzymes-Low Platelets) 
syndrome.  
In addition, etiological considerations on AVP deficiency or defective hormone action in the 
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2. General adaptations of the endocrine system and the maternal 
hypothalamic-pituitary axis to pregnancy  
The fetal-placental unit develops as a unique endocrine organ in pregnancy to account for 
various endocrine changes. It synthesizes large amounts of hormones; in turn, these 
synthesis products are secreted into the fetal and maternal circulation. After 8 weeks of 
gestation, the placenta is the main source of progesterone, which derives from maternal 
LDL-cholesterol. Most of placental progesterone enters the maternal circulation and hence 
maternal progesterone plasma concentrations gradually raise during pregnancy up to 150 
ng/ml. Likewise, 17ß-estradiol and estrone are produced by the placenta via conversion 
from both maternal and fetal DHEA-S, whereas estriol is formed in the placenta from fetal 
adrenal DHEA-S as the primary source. In both mother and child, serum human chorionic 
gonadotropin (hCG) levels increase progressively to reach a peak at 10-14 weeks of 
pregnancy and thereafter fall until delivery. Undoubtedly, hCG is involved in 
steroidogenesis and maintenance of the corpus luteum activity during the first weeks of 
gestation. Unlike hCG, the plasma levels of human placental lactogen hormone (hPL) 
increase throughout the pregnancy to plateau at term. Human PL is secreted mostly into 
maternal circulation to induce lipolysis, resulting in increased availability of free fatty acids; 
it inhibits glucose uptake and gluconeogenesis in the mother, all these metabolic effects 
predisposing to maternal insulin resistance and hyperinsulinemia. Recently, human 
placental growth hormone (hPGH) synthesis was certified in pregnant women; it gradually 
replaces pituitary GH during pregnancy and is supposed to promote placental and fetal 
growth (Chellakooty et al., 2002).  
In order to adapt to fetal requirements, pregnancy per se is associated with considerable 
changes in the maternal endocrine status, including physiological changes of the 
osmoregulatory system. Some of the most significant changes occur in the anterior pituitary 
and thyroid glands to meet the nutritional needs of the fetus. The pituitary gland enlarges 
during normal gestation due to estrogen- and to a lesser extent progesterone-induced 
hyperplasia of lactotroph cells, explaining 10-fold increased maternal prolactin (PRL) levels 
by the end of pregnancy. By the 6th to 7th week of pregnancy, basal and stimulated GH 
release from the maternal pituitary is suppressed via placental GH-induced IGF-1 synthesis 
(Chellakooty et al., 2002). By the same time, follicle-stimulating (FSH) and luteinizing 
hormone (LH) levels start to decrease along to their response to gonadotropin-releasing 
hormone (GnRH) stimulation.  
Iodine requirements are increased in the pregnant woman up to 200-300 µg daily due to 
accelerated renal clearance and transplacental passage of inorganic iodine to supply fetal 
needs. Additional mechanisms consist of increased thyroid hormones demands to 
compensate for high thyroxin binding globulin (TBG) levels in the mother, stimulation of 
the thyroid gland by the thyrotropin-like activity of hCG, and activity of the type 3 placental 
deiodinase (Glinoer, 1997).  
The hypothalamic-pituitary-adrenal axis is subjected to significant changes during 
pregnancy as evidenced by increased maternal cortisol levels, mainly because of an increase 
in the concentration of corticosteroid binding globulin (CBG), and reduced cortisol 
clearance. But it is also observed that free cortisol levels are higher during the second 
trimester and plateau in the third. Several mechanisms are thought to be involved: an 
altered set point for ACTH, effects of placental ACTH on adrenal hormone production, 
antiglucocorticoid actions of progesterone, and cortisol resistance (Karaca et al., 2010). 
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Notably, the placental 11ß-hydroxysteroiddehydrogenase efficiently protects the fetus from 
maternal hypercortisolism by cortisol inactivation. In addition, placental synthesis of CRH is 
demonstrated. Placental CRH is under the control of cortisol by positive feed-forward and 
behaves as a determinant of onset of parturition (Kalantaridou et al., 2003). 
Both estrogen and progesterone activate synthesis of renin and, subsequently, production of 
angiotensin II and aldosterone, respectively. Nevertheless, the maternal vasculature 
becomes refractory to the pressor effects of angiotensin II, a phenomenon essential to blood 
volume expansion during pregnancy. Moreover, the physiological action of aldosterone is 
counteracted by progesterone, a competitive inhibitor of aldosterone in the distal tubule. 
3. Water balance, arginin-vasopressin metabolism, aquaporin-2 expression 
and vasopressinase activity in pregnancy 
3.1 Hemodynamic changes and water metabolism in normal pregnancy 
Pregnancy is a physiological condition associated with water retention which is especially 
prominent in the last trimester. Studies of body fluid volume regulation in normal human 
pregnancy pointed out towards water retention leading subsequently to increased total 
blood volume and decreased plasma osmolality. In both humans and rats, a 30–50% increase 
in extracellular fluid, plasma and blood volume was reported (Schrier & Briner, 1991). At 6 
weeks of pregnancy, an early decrease in systemic and renal vascular resistance with under-
filling of the arterial system is documented. As compensatory mechanisms, this will induce 
sympathetic system stimulation and enhanced cardiac output as well as activation of the 
renin-angiotensin-aldosterone (RAA) system with associated renal sodium and water 
retention, leading to the abovementioned expansion of total plasma volume. Evidence of 
arterial vasodilatation as a primary event of the hyper-dynamic circulatory status in 
pregnancy is offered by animal studies, such as the rat. Indeed, this appears to be a 
hormone-triggered mechanism, since up-regulation of endothelial nitric oxide synthase 
(eNOS) by estradiol has been documented. In line with this finding, increased expression of 
the eNOS gene in the aorta wall, and elevated plasma nitrite and nitrate levels were detected 
in pregnant rats. Moreover, neural NOS expression was also found to be increased in the 
hypothalamus of pregnant rats. In turn, inhibition of the NOS activity has been shown to 
result in a reverse of renal and systemic vascular changes and normalization of cardiac 
output (Schrier & Ohara, 2010). 
Pregnancy-mediated vasodilatation itself results in non-osmotic AVP release from the 
hypothalamus. During pregnancy, the osmotic threshold at which pregnant women 
manifest thirst and release AVP is shifted to a level lower to that of non-pregnant women 
(Lindheimer & Davison, 1995). Subsequently, a decrease of about 10 mOsm/kg in plasma 
osmolality ensues starting with the 6th week of pregnancy. Similar changes may be induced 
in non-pregnant women in whom exogenous hCG is administered (Davison et al., 1988).  
Thus, reduction in arterial pressure of more than 10-20% releases AVP from the posterior 
pituitary by lowering the osmoregulatory system set point, an effect mediated by 
stimulation of baroreceptors located in the walls of the left atrium and large arteries and 
leading via the glossopharyngeal and vagal nerve to the CNS and then the hypothalamus. 
Nevertheless, non-osmotic AVP release is not unique during physiological pregnancy but 
also occurs in adrenal insufficiency, pathological low-output congestive cardiac failure or 
liver cirrhosis, in the last triggered by splanchnic arterial vasodilatation. Likewise, orally 
active non-peptide-selective V2 receptor antagonists administered to patients with cardiac 
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filling of the arterial system is documented. As compensatory mechanisms, this will induce 
sympathetic system stimulation and enhanced cardiac output as well as activation of the 
renin-angiotensin-aldosterone (RAA) system with associated renal sodium and water 
retention, leading to the abovementioned expansion of total plasma volume. Evidence of 
arterial vasodilatation as a primary event of the hyper-dynamic circulatory status in 
pregnancy is offered by animal studies, such as the rat. Indeed, this appears to be a 
hormone-triggered mechanism, since up-regulation of endothelial nitric oxide synthase 
(eNOS) by estradiol has been documented. In line with this finding, increased expression of 
the eNOS gene in the aorta wall, and elevated plasma nitrite and nitrate levels were detected 
in pregnant rats. Moreover, neural NOS expression was also found to be increased in the 
hypothalamus of pregnant rats. In turn, inhibition of the NOS activity has been shown to 
result in a reverse of renal and systemic vascular changes and normalization of cardiac 
output (Schrier & Ohara, 2010). 
Pregnancy-mediated vasodilatation itself results in non-osmotic AVP release from the 
hypothalamus. During pregnancy, the osmotic threshold at which pregnant women 
manifest thirst and release AVP is shifted to a level lower to that of non-pregnant women 
(Lindheimer & Davison, 1995). Subsequently, a decrease of about 10 mOsm/kg in plasma 
osmolality ensues starting with the 6th week of pregnancy. Similar changes may be induced 
in non-pregnant women in whom exogenous hCG is administered (Davison et al., 1988).  
Thus, reduction in arterial pressure of more than 10-20% releases AVP from the posterior 
pituitary by lowering the osmoregulatory system set point, an effect mediated by 
stimulation of baroreceptors located in the walls of the left atrium and large arteries and 
leading via the glossopharyngeal and vagal nerve to the CNS and then the hypothalamus. 
Nevertheless, non-osmotic AVP release is not unique during physiological pregnancy but 
also occurs in adrenal insufficiency, pathological low-output congestive cardiac failure or 
liver cirrhosis, in the last triggered by splanchnic arterial vasodilatation. Likewise, orally 
active non-peptide-selective V2 receptor antagonists administered to patients with cardiac 
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failure or cirrhosis of the liver increase urinary water excretion while reversing 
hyponatremia (Schrier et al., 1998). Eventually, the non-osmotic AVP stimulation during 
pregnancy will promote water retention and increased body fluid volume with plasma 
hypoosmolality. Figure 1 presents hemodynamic changes and adaptations of water and 
AVP metabolism during normal pregnancy.  
 
 
Fig. 1. Hemodynamic changes and adaptations of water and AVP metabolism in normal 
pregnancy. 
3.2 Aquaporin-2 and vasopressinase activity in normal pregnancy 
Water molecules transport across membranes is mediated by water channel proteins called 
aquaporins. Of the several isoforms of aquaporins identified in the kidney and other organs 
(brain, liver, pancreas, colon, spleen, lung, submandibular gland, testes, leukocytes), 
aquaporin-2 is abundant in the collecting duct principal cells and is the main target for AVP 
effects to mediate water transport across the apical membrane of the renal collecting duct. In 
response to AVP, aquaporin-2 is translocated from cytoplasmic vesicles to apical plasma 
membranes by shuttle trafficking to increase water permeability of the membrane. After 
ending AVP stimulation, aquaporin-2 is redistributed and stored into cytoplasmic vesicles.  
Excretion of aquaporin-2 in the urine can be quantified and it appears that urinary 
aquaporin-2 may reflect the levels and/or activity of aquaporin-2 in the apical plasma 
membrane of the collecting duct. Analysis of urinary aquaporin-2 concentrations shows 
acute or long-term changes of the protein in a number of clinical conditions associated with 
water balance disorders. In that sense, low aquaporin-2 expression has been described in 
forms of nephrogenic diabetes insipidus (e.g. hypokalemia, hypercalcemia, lithium therapy, 
post-obstructive polyuria) as a mechanism for the inability of the kidney to concentrate 
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urine in these conditions. In the pregnant rat, up-regulation of aquaporin-2 expression and 
aquaporin-2 trafficking was described. Administration of the V2 receptor antagonist in 
pregnant rats suppressed the increase in aquaporin-2 mRNA and aquaporin-2 protein levels 
despite normal levels of plasma vasopressin thus suggesting that in pregnancy the up-
regulation of aquaporin-2 contributes to water retention in part through a V2 receptor-
mediated effect. In addition, vasopressin-independent factors (such as oxytocin) may be 
important for this up-regulation. 
Likewise, in pregnant women, up-regulation of aquaporin-2 expression and enhanced 
urinary protein levels have been substantially documented (Frokier et al., 1998); 
accordingly, this effect on aquaporin-2 is reversed by a V2 receptor antagonist (Schrier, 
2010). In a study of healthy pregnant primiparas, urinary aquaporin-2 excretion, plasma 
oxytocin and atrial natriuretic peptide but not plasma AVP levels were significantly higher 
in all three trimesters of pregnancy compared to age-matched non-pregnant women (Buemi, 
2001) thus suggesting possible effects of an AVP-independent factor to stimulate renal 
aquaporin-2 expression during pregnancy. 
In healthy adults, AVP circulates in an unbound state and equilibrates within minutes 
between plasma and the extracellular fluid. Its concentration in these compartments 
decreases with an average half-time of approximately 20 minutes. Normally, AVP is 
clearanced by the kidney or degraded by the liver; only a small quantity of AVP is taken up 
and stored by the platelets. During pregnancy, the increased AVP secretion is countered by 
a 3-fold to 6-fold increase in the metabolic clearance rate of vasopressin which is due to an 
enzyme, the vasopressinase. Vasopressinase is a plasmatic leucyl-cystinyl-aminopeptidase 
that degrades both AVP and oxytocin produced by the syncytiotrophoblast of the placenta. 
Because the placental trophoblastic mass increases about 1000-fold from 6 to 24 weeks of 
gestation, plasma vasopressinase levels may be 20-fold higher by the third trimester of 
pregnancy (Soule et al., 1995). Aside to vasopressinase, another enzyme of placental origin, 
leucine-aminopeptidase (oxytocinase) appears to contribute to AVP degradation during 
pregnancy. Plasma concentrations of leucine-aminopeptidase gradually increase during 
pregnancy until delivery, acting as an anti-uterotonic agent by degrading uterotonic 
peptides. Recently, preeclampsia was associated to low leucine-aminopeptidase levels 
(Landau et al., 2010). The accelerated AVP degradation resolves about 40 days post-delivery. 
Despite the increase in the clearance of AVP due to vasopressinase activity, in normal 
pregnancies, AVP levels remain unchanged thus suggesting a compensatory increase in 
synthesis and release. Nevertheless, it has to be pointed out that these adaptations are of no 
particular clinical relevance unless a pathological process is present.  
Genetically AVP-deficient homozygous Brattleboro (BB) rats suffer from severe diabetes 
insipidus. The pregnant BB rat may serve as an animal model of central diabetes insipidus 
associated to pregnancy. Early studies have shown that the osmotic threshold for AVP 
during pregnancy is lower in both BB rats and controls and that, in the homozygous animal, 
chronic vasopressin treatment increased urine osmolality less compared with virgins 
(Barron et al., 1985). Nevertheless, the model does not apply to true gestational diabetes 
insipidus since this is induced by enhanced vasopressinase activity and metabolic AVP 
clearance. Besides AVP, oxytocin and relaxin may play a role in controlling water balance 
during physiological pregnancy. BB rats were found to significantly concentrate their urine 
upon severe dehydration, and the plasma level of oxytocin was found to be about 6-fold 
higher under these circumstances (Edwards & LaRochelle, 1984). An antidiuretic effect of 
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failure or cirrhosis of the liver increase urinary water excretion while reversing 
hyponatremia (Schrier et al., 1998). Eventually, the non-osmotic AVP stimulation during 
pregnancy will promote water retention and increased body fluid volume with plasma 
hypoosmolality. Figure 1 presents hemodynamic changes and adaptations of water and 
AVP metabolism during normal pregnancy.  
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pregnancy. 
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(brain, liver, pancreas, colon, spleen, lung, submandibular gland, testes, leukocytes), 
aquaporin-2 is abundant in the collecting duct principal cells and is the main target for AVP 
effects to mediate water transport across the apical membrane of the renal collecting duct. In 
response to AVP, aquaporin-2 is translocated from cytoplasmic vesicles to apical plasma 
membranes by shuttle trafficking to increase water permeability of the membrane. After 
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aquaporin-2 may reflect the levels and/or activity of aquaporin-2 in the apical plasma 
membrane of the collecting duct. Analysis of urinary aquaporin-2 concentrations shows 
acute or long-term changes of the protein in a number of clinical conditions associated with 
water balance disorders. In that sense, low aquaporin-2 expression has been described in 
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urine in these conditions. In the pregnant rat, up-regulation of aquaporin-2 expression and 
aquaporin-2 trafficking was described. Administration of the V2 receptor antagonist in 
pregnant rats suppressed the increase in aquaporin-2 mRNA and aquaporin-2 protein levels 
despite normal levels of plasma vasopressin thus suggesting that in pregnancy the up-
regulation of aquaporin-2 contributes to water retention in part through a V2 receptor-
mediated effect. In addition, vasopressin-independent factors (such as oxytocin) may be 
important for this up-regulation. 
Likewise, in pregnant women, up-regulation of aquaporin-2 expression and enhanced 
urinary protein levels have been substantially documented (Frokier et al., 1998); 
accordingly, this effect on aquaporin-2 is reversed by a V2 receptor antagonist (Schrier, 
2010). In a study of healthy pregnant primiparas, urinary aquaporin-2 excretion, plasma 
oxytocin and atrial natriuretic peptide but not plasma AVP levels were significantly higher 
in all three trimesters of pregnancy compared to age-matched non-pregnant women (Buemi, 
2001) thus suggesting possible effects of an AVP-independent factor to stimulate renal 
aquaporin-2 expression during pregnancy. 
In healthy adults, AVP circulates in an unbound state and equilibrates within minutes 
between plasma and the extracellular fluid. Its concentration in these compartments 
decreases with an average half-time of approximately 20 minutes. Normally, AVP is 
clearanced by the kidney or degraded by the liver; only a small quantity of AVP is taken up 
and stored by the platelets. During pregnancy, the increased AVP secretion is countered by 
a 3-fold to 6-fold increase in the metabolic clearance rate of vasopressin which is due to an 
enzyme, the vasopressinase. Vasopressinase is a plasmatic leucyl-cystinyl-aminopeptidase 
that degrades both AVP and oxytocin produced by the syncytiotrophoblast of the placenta. 
Because the placental trophoblastic mass increases about 1000-fold from 6 to 24 weeks of 
gestation, plasma vasopressinase levels may be 20-fold higher by the third trimester of 
pregnancy (Soule et al., 1995). Aside to vasopressinase, another enzyme of placental origin, 
leucine-aminopeptidase (oxytocinase) appears to contribute to AVP degradation during 
pregnancy. Plasma concentrations of leucine-aminopeptidase gradually increase during 
pregnancy until delivery, acting as an anti-uterotonic agent by degrading uterotonic 
peptides. Recently, preeclampsia was associated to low leucine-aminopeptidase levels 
(Landau et al., 2010). The accelerated AVP degradation resolves about 40 days post-delivery. 
Despite the increase in the clearance of AVP due to vasopressinase activity, in normal 
pregnancies, AVP levels remain unchanged thus suggesting a compensatory increase in 
synthesis and release. Nevertheless, it has to be pointed out that these adaptations are of no 
particular clinical relevance unless a pathological process is present.  
Genetically AVP-deficient homozygous Brattleboro (BB) rats suffer from severe diabetes 
insipidus. The pregnant BB rat may serve as an animal model of central diabetes insipidus 
associated to pregnancy. Early studies have shown that the osmotic threshold for AVP 
during pregnancy is lower in both BB rats and controls and that, in the homozygous animal, 
chronic vasopressin treatment increased urine osmolality less compared with virgins 
(Barron et al., 1985). Nevertheless, the model does not apply to true gestational diabetes 
insipidus since this is induced by enhanced vasopressinase activity and metabolic AVP 
clearance. Besides AVP, oxytocin and relaxin may play a role in controlling water balance 
during physiological pregnancy. BB rats were found to significantly concentrate their urine 
upon severe dehydration, and the plasma level of oxytocin was found to be about 6-fold 
higher under these circumstances (Edwards & LaRochelle, 1984). An antidiuretic effect of 
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oxytocin was evidenced in both normal individuals and central diabetes insipidus. Oxytocin 
has an affinity for the V2 receptor two orders magnitude lower compared to that of l-
desamino-8-D-arginine (DDAVP). However, in a small study of healthy and diabetic men, 
oxytocin infusion resulted in decreased urine outflow and free water clearance and 
increased urine osmolality and aquaporin-2 urinary excretion (Koo et al., 2003) thus 
suggesting that, in man, the antidiuretic effect of oxytocin may be mediated by regulation of 
aquaporin-2 levels in the collecting duct.  
Relaxin is characterized as a pregnancy-related hormone secreted by the corpus luteum 
involved as a key player in maternal systemic and renal vasodilatation during pregnancy, as 
revealed by the vasodilatation obtained in non-pregnant rats in response to intravenous 
relaxin administration. In human, emerging evidence suggests that the effect of relaxin is 
mediated by the relaxin/insulin-like family peptide 1 receptor, RFXP1, through a Gα-
protein coupled to phosphatidylinositol-3kinase/Akt (protein kinase B)-dependent 
phosphorylation and activation of endothelial nitric oxide synthase to induce nitric oxide 
synthesis and, hence, important vasodilatation (Conrad, 2011).  
4. Etiology and clinical presentation of pregnancy-related diabetes insipidus 
4.1 Etiology of polyuria in pregnancy 
Table 1 depicts potential causes of polyuria in pregnant women. 
 
Solute Diuresis Water Diuresis 
Diabetes mellitus Primary polyuria 
Salt-losing tubulopathy Diabetes insipidus 
Saline loading Hyperkalemia 
Post-obstructive diuresis Hypercalcemia 
Osmotic iatrogenic diuresis  Primary or secondary tubulopathies 
 Sickle cell anemia 
Table 1. Causes of polyuria in pregnancy (adapted after Barbey et al., 2010). 
Etiologic characterization of diabetes insipidus during pregnancy is complex and, in some 
cases, difficult to ascertain to one or the other related clinical conditions. Should diabetes 
predate pregnancy, in either overt or sub-clinical form, any disorder causing AVP-
deficiency or AVP-resistance has to be taken into account. On the other hand, pregnancy 
itself may prone to development of pathological conditions of inadequate AVP synthesis or 
action, usually in a transient form during pregnancy and postpartum, but, occasionally, 
persisting thereafter. In synthesis, diabetes insipidus during pregnancy may reveal itself as: 
• Pre-gestational diabetes insipidus, either central (AVP-deficient) or nephrogenic (AVP-
resistant)  
• Latent (sub-clinical) central or nephrogenic diabetes insipidus, unmasked by both increased 
vasopressinase activity and diminished renal responsiveness to vasopressin (Iwasaki et 
al., 1991) 
• True gestational diabetes insipidus, as  
• Transient gestational diabetes insipidus which manifests in pregnancy and usually 
resolves 3-6 weeks after delivery. Multiple pregnancy acts as a risk factor. Transient 
gestational diabetes insipidus may be associated with preeclampsia, acute fatty 
liver disease or HELLP syndrome, or unmask prevalent liver disease such as in 
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hemochromatosis (Krysiak et al., 2010). As abovementioned, an underlying sub-
clinical deficiency in AVP may also be involved in some, if not all, patients.  
• Recurrent diabetes insipidus of pregnancy due to increased vasopressinase activity has 
been reported in subsequent pregnancies in several women. Both transient and 
recurrent gestational diabetes insipidus are vasopressin-resistant but respond well 
to desmopressin (DDAVP). 
• Transient, vasopressin- and DDAVP-resistant gestational diabetes insipidus which is a 
consequence of the physiological increase in the concentration of prostaglandin E2 
in the kidney during gestation leading to inhibition of AVP action at the level of its 
receptor (Jin-No et al., 1998) 
• Postpartum diabetes insipidus (i.e. lymphocytic hypophysitis, pituitary apoplexy, 
histiocytosis X, pituitary tumor, Sheehan’s syndrome). Even though these pathological 
conditions clearly predominate within the first year after birth (postpartum period), 
concomitance with pregnancy is not excluded in any of them, except for Sheehan’s 
syndrome. 
In rare cases, gestational diabetes insipidus may develop as nephrogenic form manifested in 
pregnancy and complicated by preeclampsia (Goodman et al., 1984; Korbet et al., 1985). 
Diabetes insipidus may persist postpartum or may be a transient latent form of the disease. 
4.2 Clinical features of pregnancy-related diabetes insipidus, and associated 
conditions 
Clinical presentation of pregnancy-related diabetes insipidus is usually acute with 
symptoms developing in a few days. An abrupt change in the voiding pattern during the 
last trimester of pregnancy manifesting as hypotonic polyuria, and excessive water intake 
represent the hallmark of the disease. Fatigue, nausea, weight loss, and reduced skin turgor 
may be seen. Women in whom diabetes insipidus is associated to a more complex morbid 
status may present additional symptoms and clinical signs.  
4.2.1 Pregnancy-related liver disease 
Pregnancy-related liver disease comprises a large spectrum of liver disturbances specifically 
to pregnancy, with variable outcome potential. While liver dysfunction is transient and 
usually mild in hyperemesis gravidarum and intra-hepatic cholestasis of pregnancy, women 
with acute fatty liver disease or HELLP syndrome are at high risk to concomitantly develop 
preeclampsia and a less favorable prognosis. Differential diagnosis between pregnancy-
related liver disease and preexistent or simultaneous hepatic disorder unrelated to 
pregnancy is mandatory and sometimes difficult.  
Nevertheless, rarely, liver biopsy is employed as an ultimate differential diagnosis tool. 
Association of de novo diabetes insipidus with liver injury in pregnant women is suggested 
by polyuria and polydipsia syndrome and epigastric pain, nausea, vomiting, pruritus and 
jaundice. At least in some patients, acute fatty liver disease can be considered as an atypical 
form of preeclampsia because 30-40% of women with acute fatty liver also develop 
preeclampsia. In that sense, onset of diabetes insipidus in patients with acute fatty liver may 
highly indicate the likelihood of preeclampsia. Hence, early delivery and supportive care 
may considerably improve the overall prognosis of these individuals. Pathogenesis of 
diabetes insipidus in pregnant women with acute fatty liver can be easily explained by 
enhanced vasopressinase activity subsequent to liver dysfunction. Commonly, diabetes 
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oxytocin was evidenced in both normal individuals and central diabetes insipidus. Oxytocin 
has an affinity for the V2 receptor two orders magnitude lower compared to that of l-
desamino-8-D-arginine (DDAVP). However, in a small study of healthy and diabetic men, 
oxytocin infusion resulted in decreased urine outflow and free water clearance and 
increased urine osmolality and aquaporin-2 urinary excretion (Koo et al., 2003) thus 
suggesting that, in man, the antidiuretic effect of oxytocin may be mediated by regulation of 
aquaporin-2 levels in the collecting duct.  
Relaxin is characterized as a pregnancy-related hormone secreted by the corpus luteum 
involved as a key player in maternal systemic and renal vasodilatation during pregnancy, as 
revealed by the vasodilatation obtained in non-pregnant rats in response to intravenous 
relaxin administration. In human, emerging evidence suggests that the effect of relaxin is 
mediated by the relaxin/insulin-like family peptide 1 receptor, RFXP1, through a Gα-
protein coupled to phosphatidylinositol-3kinase/Akt (protein kinase B)-dependent 
phosphorylation and activation of endothelial nitric oxide synthase to induce nitric oxide 
synthesis and, hence, important vasodilatation (Conrad, 2011).  
4. Etiology and clinical presentation of pregnancy-related diabetes insipidus 
4.1 Etiology of polyuria in pregnancy 
Table 1 depicts potential causes of polyuria in pregnant women. 
 
Solute Diuresis Water Diuresis 
Diabetes mellitus Primary polyuria 
Salt-losing tubulopathy Diabetes insipidus 
Saline loading Hyperkalemia 
Post-obstructive diuresis Hypercalcemia 
Osmotic iatrogenic diuresis  Primary or secondary tubulopathies 
 Sickle cell anemia 
Table 1. Causes of polyuria in pregnancy (adapted after Barbey et al., 2010). 
Etiologic characterization of diabetes insipidus during pregnancy is complex and, in some 
cases, difficult to ascertain to one or the other related clinical conditions. Should diabetes 
predate pregnancy, in either overt or sub-clinical form, any disorder causing AVP-
deficiency or AVP-resistance has to be taken into account. On the other hand, pregnancy 
itself may prone to development of pathological conditions of inadequate AVP synthesis or 
action, usually in a transient form during pregnancy and postpartum, but, occasionally, 
persisting thereafter. In synthesis, diabetes insipidus during pregnancy may reveal itself as: 
• Pre-gestational diabetes insipidus, either central (AVP-deficient) or nephrogenic (AVP-
resistant)  
• Latent (sub-clinical) central or nephrogenic diabetes insipidus, unmasked by both increased 
vasopressinase activity and diminished renal responsiveness to vasopressin (Iwasaki et 
al., 1991) 
• True gestational diabetes insipidus, as  
• Transient gestational diabetes insipidus which manifests in pregnancy and usually 
resolves 3-6 weeks after delivery. Multiple pregnancy acts as a risk factor. Transient 
gestational diabetes insipidus may be associated with preeclampsia, acute fatty 
liver disease or HELLP syndrome, or unmask prevalent liver disease such as in 
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hemochromatosis (Krysiak et al., 2010). As abovementioned, an underlying sub-
clinical deficiency in AVP may also be involved in some, if not all, patients.  
• Recurrent diabetes insipidus of pregnancy due to increased vasopressinase activity has 
been reported in subsequent pregnancies in several women. Both transient and 
recurrent gestational diabetes insipidus are vasopressin-resistant but respond well 
to desmopressin (DDAVP). 
• Transient, vasopressin- and DDAVP-resistant gestational diabetes insipidus which is a 
consequence of the physiological increase in the concentration of prostaglandin E2 
in the kidney during gestation leading to inhibition of AVP action at the level of its 
receptor (Jin-No et al., 1998) 
• Postpartum diabetes insipidus (i.e. lymphocytic hypophysitis, pituitary apoplexy, 
histiocytosis X, pituitary tumor, Sheehan’s syndrome). Even though these pathological 
conditions clearly predominate within the first year after birth (postpartum period), 
concomitance with pregnancy is not excluded in any of them, except for Sheehan’s 
syndrome. 
In rare cases, gestational diabetes insipidus may develop as nephrogenic form manifested in 
pregnancy and complicated by preeclampsia (Goodman et al., 1984; Korbet et al., 1985). 
Diabetes insipidus may persist postpartum or may be a transient latent form of the disease. 
4.2 Clinical features of pregnancy-related diabetes insipidus, and associated 
conditions 
Clinical presentation of pregnancy-related diabetes insipidus is usually acute with 
symptoms developing in a few days. An abrupt change in the voiding pattern during the 
last trimester of pregnancy manifesting as hypotonic polyuria, and excessive water intake 
represent the hallmark of the disease. Fatigue, nausea, weight loss, and reduced skin turgor 
may be seen. Women in whom diabetes insipidus is associated to a more complex morbid 
status may present additional symptoms and clinical signs.  
4.2.1 Pregnancy-related liver disease 
Pregnancy-related liver disease comprises a large spectrum of liver disturbances specifically 
to pregnancy, with variable outcome potential. While liver dysfunction is transient and 
usually mild in hyperemesis gravidarum and intra-hepatic cholestasis of pregnancy, women 
with acute fatty liver disease or HELLP syndrome are at high risk to concomitantly develop 
preeclampsia and a less favorable prognosis. Differential diagnosis between pregnancy-
related liver disease and preexistent or simultaneous hepatic disorder unrelated to 
pregnancy is mandatory and sometimes difficult.  
Nevertheless, rarely, liver biopsy is employed as an ultimate differential diagnosis tool. 
Association of de novo diabetes insipidus with liver injury in pregnant women is suggested 
by polyuria and polydipsia syndrome and epigastric pain, nausea, vomiting, pruritus and 
jaundice. At least in some patients, acute fatty liver disease can be considered as an atypical 
form of preeclampsia because 30-40% of women with acute fatty liver also develop 
preeclampsia. In that sense, onset of diabetes insipidus in patients with acute fatty liver may 
highly indicate the likelihood of preeclampsia. Hence, early delivery and supportive care 
may considerably improve the overall prognosis of these individuals. Pathogenesis of 
diabetes insipidus in pregnant women with acute fatty liver can be easily explained by 
enhanced vasopressinase activity subsequent to liver dysfunction. Commonly, diabetes 
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insipidus responds well to DDAVP therapy and spontaneously resolves with delivery or 
may persist postpartum for another few weeks.  
Recently, it has been found that acute fatty liver of pregnancy is associated with a defect of 
long-chain 3-hydroxyacyl coenzyme A dehydrogenase in the fetus with c1528G>C point 
mutation as the main cause (Guttiérez Junquera et al., 2009). Therefore, genetic testing can 
be taken into consideration in both the mother and the fetus.  
Association of advanced hepatocytolysis, hemolysis and thrombocytopenia gives birth to 
the HELLP syndrome, one component of systemic preeclampsia and eclampsia, often 
conjoined with diabetes insipidus, hypertension and cerebral edema. HELLP syndrome 
occurs in 10-20% of pregnancies with severe preeclampsia. The majority of cases (70%) 
develop in advanced pregnancy, between the 27th and 37th gestational week, and seldom 
later; the reminder within 48 hours after delivery, usually in women who developed 
proteinuria, hypertension, edema and excessive weight gain prior to delivery. 
Recent studies hypothesized genetic predisposition as a risk factor for HELLP syndrome, 
mainly under the form of various disturbances in the process of blood coagulation. 
Therefore, some clinical studies investigated the association between hereditary 
thrombophilia and HELLP syndrome but results remain controversial (Ganzevoort et al., 
2007; Larciprete et al., 2010). Several reports confirmed statistically higher incidence of 
antithrombin-III deficiency in patients with HELLP syndrome (Larciprete et al., 2010; Dogan 
et al., 2011). Apparently, women with elevated antiphospholipid antibodies titers are at risk 
to develop severe preeclampsia and HELLP syndrome (Heilmann et al., 2011).  
Onset of HELLP syndrome is within days or weeks with headache, visual symptoms, 
malaise, nausea and vomiting and fluctuating abdominal pain. Most symptoms exacerbate 
during night. Para-clinical investigations will exhibit proteinuria, low hemoglobin levels 
and increased serum lactate dehydrogenase (LDH) concentrations to attest for onset of 
microangiopathic hemolytic anemia (Haram et al., 2009) in these patients. Elevated levels of 
liver enzymes (ASAT, ALAT and α-glutathione-S-transferase-a1) are documented. 
Thrombocytopenia is the result of subsequent increased platelet consumption and, thus, 
platelet turnover. If diabetes insipidus is present, hypernatremia, hemoconcentration and 
diminished urine/plasma osmolality ratio is expected. Table 2 summarizes the diagnosis 







Platelet count ≤50 x 109/L 
AST or ALT ≥70 IU/L 
LDH ≥600 IU/L 
Platelet count ≤100 x 109/L 
AST ≥70 IU/L 
LDH ≥600 IU/L 
Table 2. Current diagnosis criteria for the HELLP syndrome. 
Based on the platelet count, the Mississippi system categorizes the disorder into class 1 
HELLP (table 2) and class 2 HELLP syndromes (i.e. platelet count ≤100 x 109/L and >50 x 
109/L, serum liver enzymes ≥70 IU/L and serum LDH ≥600 IU/L). In addition, class 3 
HELLP syndrome is defined according to Mississippi classification as platelet count ≤150 x 
109/L and >100 x 109/L, serum liver enzymes ≥40 IU/L and serum LDH concentration ≥600 
IU/L (Martin et al., 1999). Class 3 HELLP syndrome is considered a transitional group.  
The clinical significance of HELLP syndrome is based upon severe maternal and 
fetal/neonatal complications that may occur in affected pregnancies. Biochemical 
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abnormalities associated with increased risk of maternal complications consist of serum 
LDH levels >1400 IU/L, serum AST >150 IU/L, serum ALT >100 IU/L and serum uric acid 
levels >7.8 mg% (Magann & Martin, 1999). In the mother, life-threatening complications are 
abruptio placentae, disseminated intravascular coagulation, cerebral or brain stem 
hemorrhage, cerebral edema and spontaneous rupture of subcapsular liver hematoma. 
Purtscher-like retinopathy can result in permanent visual loss (Stewart et al., 2007).  
Newborns from women with HELLP syndrome delivered before the 32th to 34th gestational 
week are at risk for intrauterine growth restriction, cardiovascular (i.e. persisting ductus 
arteriosus) and respiratory complications, and perinatal death due to prematurity, abruptio 
placentae or cerebral hemorrhage (i.e. caused by neonatal thrombocytopenia). Notably, 
complications in the newborn appear to be rather related to prematurity than to HELLP 
syndrome itself. 
In women developing HELLP syndrome after the 34th week of pregnancy, vaginal delivery 
is the method of choice. Before the 34th gestational week, a single course of 12 mg 
betamethasone twice, 24 hours apart, is recommended to induce lung maturation. Repeated 
glucocorticoid courses may be more effective; however, they may lead to fetal growth 
restriction and prolonged adrenal suppression. High-dose dexamethasone treatment has 
been proposed as an alternative to improve maternal outcome, especially before 27th week of 
pregnancy, but there is no evidence of benefits compared to immediate delivery and thus 
should be individually addressed (Fonseca et al., 2005; Haram et al., 2009).  
4.2.2 Lymphocytic (autoimmune) hypophysitis 
Lymphocytic hypophysitis is a rare inflammatory disorder of the pituitary gland thought to 
have an autoimmune basis with predilection for women during the postpartum period and 
the late stage of pregnancy. Although lymphocytic hypophysitis should be always 
considered in the differential diagnosis of pituitary masses and/or pituitary insufficiency in 
women who are pregnant or in the early postpartum period, a definitive diagnosis of the 
disease requires pituitary biopsy. Nevertheless, a presumptive diagnosis of lymphocytic 
(autoimmune) hypophysitis is possible based on a history of gestational or postpartum 
pituitary insufficiency, rapid development of hypopituitarism in up to 75-80% of cases with 
early loss of adrenocorticotrophic hormone (ACTH) and TSH, and imagistic appearance of 
the pituitary gland and stalk including variable enlargement of the hypophysis with 
homogenous appearance and intact sella floor. Cystic appearance of the pituitary gland on 
magnetic resonance imaging (MRI), although rare, is not excluded in patients with 
autoimmune hypophysitis (Flanagan et al., 2002). In hypophysitis, the pituitary stalk is 
thickened but not displaced, an aspect that is opposed to the MRI of the displaced 
hypophyseal stalk that is described in macroadenomas with supra-sellar enlargement. A 
strong, homogenous enhancement of the anterior pituitary after gadolinium infusion, even 
though suggests inflammation, is not specific enough to differentiate between hypophysitis 
on one hand and pituitary adenoma on the other hand.  
Autoimmune inflammation of the pituitary gland presents commonly as lymphocytic 
adenohypophysitis. The clinical presentation of autoimmune adenohypophysitis includes 
headache, pituitary insufficiency and central diabetes insipidus. Visual disturbances 
comprise visual field defects due to compression of the optic chiasm and diplopia due to 
compression of III, IV and VI cranial nerves by parasellar expansion of the autoimmune 
inflammatory process towards the cavernous sinus. Diabetes insipidus may be a component 
of pure lymphocytic adenohypophysitis because of inhibition of the axonal transport of 
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insipidus responds well to DDAVP therapy and spontaneously resolves with delivery or 
may persist postpartum for another few weeks.  
Recently, it has been found that acute fatty liver of pregnancy is associated with a defect of 
long-chain 3-hydroxyacyl coenzyme A dehydrogenase in the fetus with c1528G>C point 
mutation as the main cause (Guttiérez Junquera et al., 2009). Therefore, genetic testing can 
be taken into consideration in both the mother and the fetus.  
Association of advanced hepatocytolysis, hemolysis and thrombocytopenia gives birth to 
the HELLP syndrome, one component of systemic preeclampsia and eclampsia, often 
conjoined with diabetes insipidus, hypertension and cerebral edema. HELLP syndrome 
occurs in 10-20% of pregnancies with severe preeclampsia. The majority of cases (70%) 
develop in advanced pregnancy, between the 27th and 37th gestational week, and seldom 
later; the reminder within 48 hours after delivery, usually in women who developed 
proteinuria, hypertension, edema and excessive weight gain prior to delivery. 
Recent studies hypothesized genetic predisposition as a risk factor for HELLP syndrome, 
mainly under the form of various disturbances in the process of blood coagulation. 
Therefore, some clinical studies investigated the association between hereditary 
thrombophilia and HELLP syndrome but results remain controversial (Ganzevoort et al., 
2007; Larciprete et al., 2010). Several reports confirmed statistically higher incidence of 
antithrombin-III deficiency in patients with HELLP syndrome (Larciprete et al., 2010; Dogan 
et al., 2011). Apparently, women with elevated antiphospholipid antibodies titers are at risk 
to develop severe preeclampsia and HELLP syndrome (Heilmann et al., 2011).  
Onset of HELLP syndrome is within days or weeks with headache, visual symptoms, 
malaise, nausea and vomiting and fluctuating abdominal pain. Most symptoms exacerbate 
during night. Para-clinical investigations will exhibit proteinuria, low hemoglobin levels 
and increased serum lactate dehydrogenase (LDH) concentrations to attest for onset of 
microangiopathic hemolytic anemia (Haram et al., 2009) in these patients. Elevated levels of 
liver enzymes (ASAT, ALAT and α-glutathione-S-transferase-a1) are documented. 
Thrombocytopenia is the result of subsequent increased platelet consumption and, thus, 
platelet turnover. If diabetes insipidus is present, hypernatremia, hemoconcentration and 
diminished urine/plasma osmolality ratio is expected. Table 2 summarizes the diagnosis 







Platelet count ≤50 x 109/L 
AST or ALT ≥70 IU/L 
LDH ≥600 IU/L 
Platelet count ≤100 x 109/L 
AST ≥70 IU/L 
LDH ≥600 IU/L 
Table 2. Current diagnosis criteria for the HELLP syndrome. 
Based on the platelet count, the Mississippi system categorizes the disorder into class 1 
HELLP (table 2) and class 2 HELLP syndromes (i.e. platelet count ≤100 x 109/L and >50 x 
109/L, serum liver enzymes ≥70 IU/L and serum LDH ≥600 IU/L). In addition, class 3 
HELLP syndrome is defined according to Mississippi classification as platelet count ≤150 x 
109/L and >100 x 109/L, serum liver enzymes ≥40 IU/L and serum LDH concentration ≥600 
IU/L (Martin et al., 1999). Class 3 HELLP syndrome is considered a transitional group.  
The clinical significance of HELLP syndrome is based upon severe maternal and 
fetal/neonatal complications that may occur in affected pregnancies. Biochemical 
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abnormalities associated with increased risk of maternal complications consist of serum 
LDH levels >1400 IU/L, serum AST >150 IU/L, serum ALT >100 IU/L and serum uric acid 
levels >7.8 mg% (Magann & Martin, 1999). In the mother, life-threatening complications are 
abruptio placentae, disseminated intravascular coagulation, cerebral or brain stem 
hemorrhage, cerebral edema and spontaneous rupture of subcapsular liver hematoma. 
Purtscher-like retinopathy can result in permanent visual loss (Stewart et al., 2007).  
Newborns from women with HELLP syndrome delivered before the 32th to 34th gestational 
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arteriosus) and respiratory complications, and perinatal death due to prematurity, abruptio 
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betamethasone twice, 24 hours apart, is recommended to induce lung maturation. Repeated 
glucocorticoid courses may be more effective; however, they may lead to fetal growth 
restriction and prolonged adrenal suppression. High-dose dexamethasone treatment has 
been proposed as an alternative to improve maternal outcome, especially before 27th week of 
pregnancy, but there is no evidence of benefits compared to immediate delivery and thus 
should be individually addressed (Fonseca et al., 2005; Haram et al., 2009).  
4.2.2 Lymphocytic (autoimmune) hypophysitis 
Lymphocytic hypophysitis is a rare inflammatory disorder of the pituitary gland thought to 
have an autoimmune basis with predilection for women during the postpartum period and 
the late stage of pregnancy. Although lymphocytic hypophysitis should be always 
considered in the differential diagnosis of pituitary masses and/or pituitary insufficiency in 
women who are pregnant or in the early postpartum period, a definitive diagnosis of the 
disease requires pituitary biopsy. Nevertheless, a presumptive diagnosis of lymphocytic 
(autoimmune) hypophysitis is possible based on a history of gestational or postpartum 
pituitary insufficiency, rapid development of hypopituitarism in up to 75-80% of cases with 
early loss of adrenocorticotrophic hormone (ACTH) and TSH, and imagistic appearance of 
the pituitary gland and stalk including variable enlargement of the hypophysis with 
homogenous appearance and intact sella floor. Cystic appearance of the pituitary gland on 
magnetic resonance imaging (MRI), although rare, is not excluded in patients with 
autoimmune hypophysitis (Flanagan et al., 2002). In hypophysitis, the pituitary stalk is 
thickened but not displaced, an aspect that is opposed to the MRI of the displaced 
hypophyseal stalk that is described in macroadenomas with supra-sellar enlargement. A 
strong, homogenous enhancement of the anterior pituitary after gadolinium infusion, even 
though suggests inflammation, is not specific enough to differentiate between hypophysitis 
on one hand and pituitary adenoma on the other hand.  
Autoimmune inflammation of the pituitary gland presents commonly as lymphocytic 
adenohypophysitis. The clinical presentation of autoimmune adenohypophysitis includes 
headache, pituitary insufficiency and central diabetes insipidus. Visual disturbances 
comprise visual field defects due to compression of the optic chiasm and diplopia due to 
compression of III, IV and VI cranial nerves by parasellar expansion of the autoimmune 
inflammatory process towards the cavernous sinus. Diabetes insipidus may be a component 
of pure lymphocytic adenohypophysitis because of inhibition of the axonal transport of 
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AVP by swelling of the pars tuberalis of the adenophypophysis which covers the 
infundibulum anterolaterally. From the clinical viewpoint, diabetes insipidus can be masked 
by coexistence of glucocorticoid deficiency in lymphocytic adenohypophysitis which is 
associated with stimulation of ADH release and aquaporin-2 synthesis (Caturegli et al., 
2005) and is often revealed by glucocorticoid hormones replacement therapy. Long-term 
imagistic observation of few cases with a medical history of lymphocytic hypophysitis 
during pregnancy suggested that this clinical condition may evolve with pituitary atrophy 
and empty sella. Hence, it is believed that at least some cases with postpartum pituitary 
insufficiency (even Sheehan’s syndrome) and empty sella may actually include lymphocytic 
adenohypophysitis (Ishihara et al., 1996).  
Rarely, autoimmune inflammation of the pituitary gland may be limited to the posterior 
pituitary lobe and infundibular stem and termed lymphocytic infundibulo-hypophysitis. 
Lymphocytic infundibulo-hypophysitis has been reported as a cause of central diabetes 
insipidus in the postpartum period (VanHavenbergh et al., 1996). On MRI, infundibulo-
hypophysitis is suspected on enlargement of the posterior pituitary lobe and thickening of 
the pituitary stalk greater than 3 mm at the level of the median eminence of the 
hypothalamus (Caturegli et al., 2005). Although loss of physiological T1 hyper-intensity in 
the posterior pituitary is suggestive, specificity of this aspect is low.     
4.2.3 Pituitary apoplexy 
Hemorrhagic or ischemic pituitary apoplexy is a rare neuro-endocrine emergency with a 
potentially severe outcome resulting even in hyponatremic coma and death. The main 
clinical symptoms are thunderclap headache, nausea and vomiting, fever, loss of 
consciousness, ophtalmoplegia, visual field impairment, monocular blindness and neck 
stiffness (meningeal irritation). The diagnosis is most challenging in apparently healthy 
subjects (Georgescu et al., 2009) in whom neurological complications such as stroke, 
meningitis, diffuse subarachnoid hemorrhage or optic tract hemorrhage may develop. 
Occasionally, pituitary apoplexy may present as isolated unilateral or bilateral IIIrd or VIth 
nerve palsy. 
In most cases, pituitary apoplexy complicates the evolution of previously diagnosed 
adenomas. In a retrospective review of 28 cases with pituitary adenoma, 14% of patients 
were incidentally diagnosed after pituitary apoplexy (Dekkers et al., 2007) and in a follow-
up of 42 patients with incidentally found non-functioning pituitary adenoma, apoplexy 
complicated the natural course of the disease in 9.5% of cases. On the other hand, in a large 
series of 45 cases of subjects with pituitary apoplexy, only 18% were known to have 
pituitary adenoma at presentation (Sibal et al., 2004). Likewise, in a larger series of 62 
patients with this clinical condition, 81% of subjects had no previous medical history 
suggesting pituitary tumor (Semple et al., 2005).  
Pituitary apoplexy in pregnancy and postpartum is even more rarely encountered with less 
than 50 cases reported in the medical literature. Occasionally, spontaneous abortion 
develops during the follow-up (Krull et al., 2010). To confirm diagnosis, pituitary hormones 
evaluation and MRI assessment of the hypothalamus-pituitary region is mandatory. MRI is 
revealing a sellar mass with fluid level or central component suggesting hemorrhage. 
Extrasellar expansion is common resulting in pituitary stalk displacement and optic chiasm 
compression.  
Pituitary insufficiency of various degrees follows the onset of pituitary apoplexy. Note 
worthily, the association of pituitary apoplexy with permanent or transient diabetes 
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insipidus is rather rare, irrespective of gender and physiological status; in two larger 
studies, of 62 and 40 patients, respectively, only 8% of subjects developed AVP deficiency 
(Semple et al., 2005; Lubina et al., 2005). Artery surgery, other major surgery, pregnancy, 
gamma knife irradiation, anticoagulant therapy, and coagulopathy secondary to liver failure 
were identified as precipitating factors for pituitary apoplexy. Specific information on the 
prevalence of diabetes insipidus in women developing pituitary apoplexy in pregnancy and 
postpartum is not yet available.  
With except of cases developing compression of the optic chiasm or severe neurological 
status, pituitary apoplexy in pregnancy should be treated preferably conservatively with 
high-dose glucocorticoid therapy and hormone replacement therapy including AVP- or 
DDAVP medication if diabetes insipidus is diagnosed. Monitoring by MRI is recommended. 
In advanced gestation delivery is preferred.   
4.2.4 Sheehan’s syndrome 
Sheehan’s syndrome describes postpartum pituitary necrosis; however, the exact pathogenic 
mechanism of the syndrome is not well understood because such endocrine abnormalities 
are not obvious in most women with severe hemorrhage in pregnancy and delivery. 
Although not a typical feature of Sheehan’s syndrome, early postpartum diabetes insipidus 
may accompany postpartum pituitary necrosis in about 5% of cases and even more when 
systematically looked for. In a study on posterior pituitary function in 26 women with 
Sheehan’s syndrome by both water deprivation and 5% hypertonic saline infusion test, 
partial diabetes insipidus was diagnosed in 29.6% of patients (Atmaca et al., 2007). Likewise, 
plasma AVP measurements after the 5% hypertonic saline infusion test in women with 
postpartum hypopituitarism but absent polyuria revealed, in 10 of 12 patients, the presence 
of various degrees of subnormal AVP responses to the increase in plasma osmolality 
(Iwasaki et al., 1989). Higher osmotic threshold for thirst perception was described in 
Sheehan’s syndrome patients in comparison to controls; thus, besides AVP insufficiency, 
ischemic damage of the thirst center may contribute to increased osmotic threshold for the 
onset of thirst in Sheehan’s syndrome (Atmaca et al., 2007).  
Occasionally, in women with pre-pregnancy diagnosis of Sheehan’s syndrome, latent central 
diabetes insipidus may became manifest during pregnancy (Briet et al., 1998) to be corrected 
with vasopressin therapy. Water metabolism disturbances in patients with Sheehan’s 
syndrome depend on several factors such as the degree of pituitary damage, the time of 
onset since the pituitary injury, association of co-morbidities and/or concomitant 
medication. Emerging evidence shows that Sheehan’s syndrome with or without diabetes 
insipidus is increasingly reported in association with antiphospholipid syndrome (Mehdi et 
al., 2011). In addition, in advanced pregnancy, contribution of enhanced vasopressinase 
activity to disturbed water balance should be considered and is suggested by incomplete 
response of polyuria and polydipsia to vasopressin but adequate control by desmopressin. 
Exceptionally, postpartum Sheehan’s syndrome may evolve to acute renal failure.  
5. Impact of pregnancy-related diabetes insipidus on maternal and fetal 
health 
Pre-pregnancy confirmed, therapeutically controlled diabetes insipidus has normally no 
significant impact on pregnancy outcome and health status of the fetus. On the contrary, 
gestational diabetes insipidus is potentially related to a series of maternal-fetal 
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AVP by swelling of the pars tuberalis of the adenophypophysis which covers the 
infundibulum anterolaterally. From the clinical viewpoint, diabetes insipidus can be masked 
by coexistence of glucocorticoid deficiency in lymphocytic adenohypophysitis which is 
associated with stimulation of ADH release and aquaporin-2 synthesis (Caturegli et al., 
2005) and is often revealed by glucocorticoid hormones replacement therapy. Long-term 
imagistic observation of few cases with a medical history of lymphocytic hypophysitis 
during pregnancy suggested that this clinical condition may evolve with pituitary atrophy 
and empty sella. Hence, it is believed that at least some cases with postpartum pituitary 
insufficiency (even Sheehan’s syndrome) and empty sella may actually include lymphocytic 
adenohypophysitis (Ishihara et al., 1996).  
Rarely, autoimmune inflammation of the pituitary gland may be limited to the posterior 
pituitary lobe and infundibular stem and termed lymphocytic infundibulo-hypophysitis. 
Lymphocytic infundibulo-hypophysitis has been reported as a cause of central diabetes 
insipidus in the postpartum period (VanHavenbergh et al., 1996). On MRI, infundibulo-
hypophysitis is suspected on enlargement of the posterior pituitary lobe and thickening of 
the pituitary stalk greater than 3 mm at the level of the median eminence of the 
hypothalamus (Caturegli et al., 2005). Although loss of physiological T1 hyper-intensity in 
the posterior pituitary is suggestive, specificity of this aspect is low.     
4.2.3 Pituitary apoplexy 
Hemorrhagic or ischemic pituitary apoplexy is a rare neuro-endocrine emergency with a 
potentially severe outcome resulting even in hyponatremic coma and death. The main 
clinical symptoms are thunderclap headache, nausea and vomiting, fever, loss of 
consciousness, ophtalmoplegia, visual field impairment, monocular blindness and neck 
stiffness (meningeal irritation). The diagnosis is most challenging in apparently healthy 
subjects (Georgescu et al., 2009) in whom neurological complications such as stroke, 
meningitis, diffuse subarachnoid hemorrhage or optic tract hemorrhage may develop. 
Occasionally, pituitary apoplexy may present as isolated unilateral or bilateral IIIrd or VIth 
nerve palsy. 
In most cases, pituitary apoplexy complicates the evolution of previously diagnosed 
adenomas. In a retrospective review of 28 cases with pituitary adenoma, 14% of patients 
were incidentally diagnosed after pituitary apoplexy (Dekkers et al., 2007) and in a follow-
up of 42 patients with incidentally found non-functioning pituitary adenoma, apoplexy 
complicated the natural course of the disease in 9.5% of cases. On the other hand, in a large 
series of 45 cases of subjects with pituitary apoplexy, only 18% were known to have 
pituitary adenoma at presentation (Sibal et al., 2004). Likewise, in a larger series of 62 
patients with this clinical condition, 81% of subjects had no previous medical history 
suggesting pituitary tumor (Semple et al., 2005).  
Pituitary apoplexy in pregnancy and postpartum is even more rarely encountered with less 
than 50 cases reported in the medical literature. Occasionally, spontaneous abortion 
develops during the follow-up (Krull et al., 2010). To confirm diagnosis, pituitary hormones 
evaluation and MRI assessment of the hypothalamus-pituitary region is mandatory. MRI is 
revealing a sellar mass with fluid level or central component suggesting hemorrhage. 
Extrasellar expansion is common resulting in pituitary stalk displacement and optic chiasm 
compression.  
Pituitary insufficiency of various degrees follows the onset of pituitary apoplexy. Note 
worthily, the association of pituitary apoplexy with permanent or transient diabetes 
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insipidus is rather rare, irrespective of gender and physiological status; in two larger 
studies, of 62 and 40 patients, respectively, only 8% of subjects developed AVP deficiency 
(Semple et al., 2005; Lubina et al., 2005). Artery surgery, other major surgery, pregnancy, 
gamma knife irradiation, anticoagulant therapy, and coagulopathy secondary to liver failure 
were identified as precipitating factors for pituitary apoplexy. Specific information on the 
prevalence of diabetes insipidus in women developing pituitary apoplexy in pregnancy and 
postpartum is not yet available.  
With except of cases developing compression of the optic chiasm or severe neurological 
status, pituitary apoplexy in pregnancy should be treated preferably conservatively with 
high-dose glucocorticoid therapy and hormone replacement therapy including AVP- or 
DDAVP medication if diabetes insipidus is diagnosed. Monitoring by MRI is recommended. 
In advanced gestation delivery is preferred.   
4.2.4 Sheehan’s syndrome 
Sheehan’s syndrome describes postpartum pituitary necrosis; however, the exact pathogenic 
mechanism of the syndrome is not well understood because such endocrine abnormalities 
are not obvious in most women with severe hemorrhage in pregnancy and delivery. 
Although not a typical feature of Sheehan’s syndrome, early postpartum diabetes insipidus 
may accompany postpartum pituitary necrosis in about 5% of cases and even more when 
systematically looked for. In a study on posterior pituitary function in 26 women with 
Sheehan’s syndrome by both water deprivation and 5% hypertonic saline infusion test, 
partial diabetes insipidus was diagnosed in 29.6% of patients (Atmaca et al., 2007). Likewise, 
plasma AVP measurements after the 5% hypertonic saline infusion test in women with 
postpartum hypopituitarism but absent polyuria revealed, in 10 of 12 patients, the presence 
of various degrees of subnormal AVP responses to the increase in plasma osmolality 
(Iwasaki et al., 1989). Higher osmotic threshold for thirst perception was described in 
Sheehan’s syndrome patients in comparison to controls; thus, besides AVP insufficiency, 
ischemic damage of the thirst center may contribute to increased osmotic threshold for the 
onset of thirst in Sheehan’s syndrome (Atmaca et al., 2007).  
Occasionally, in women with pre-pregnancy diagnosis of Sheehan’s syndrome, latent central 
diabetes insipidus may became manifest during pregnancy (Briet et al., 1998) to be corrected 
with vasopressin therapy. Water metabolism disturbances in patients with Sheehan’s 
syndrome depend on several factors such as the degree of pituitary damage, the time of 
onset since the pituitary injury, association of co-morbidities and/or concomitant 
medication. Emerging evidence shows that Sheehan’s syndrome with or without diabetes 
insipidus is increasingly reported in association with antiphospholipid syndrome (Mehdi et 
al., 2011). In addition, in advanced pregnancy, contribution of enhanced vasopressinase 
activity to disturbed water balance should be considered and is suggested by incomplete 
response of polyuria and polydipsia to vasopressin but adequate control by desmopressin. 
Exceptionally, postpartum Sheehan’s syndrome may evolve to acute renal failure.  
5. Impact of pregnancy-related diabetes insipidus on maternal and fetal 
health 
Pre-pregnancy confirmed, therapeutically controlled diabetes insipidus has normally no 
significant impact on pregnancy outcome and health status of the fetus. On the contrary, 
gestational diabetes insipidus is potentially related to a series of maternal-fetal 
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complications, of maximum severity in cases associated with HELLP syndrome and pre-
eclampsia. Maternal complications may include severe hypernatremia, eclampsia, hepatic 
insufficiency and disseminated intravascular coagulation. In several cases, premature 
delivery of the fetus avoids fetal hypoxia and intrauterine fetal death (Wiser et al., 2008).  
Generally, transient diabetes insipidus recovers about 4-6 weeks after delivery. Rarely, 
permanent central diabetes insipidus with or without definitive pituitary insufficiency of 
various degrees may occur in the mother, depending on the underlying clinical condition of 
pregnancy-related diabetes.  
Gestational diabetes insipidus may associate in utero fetal complications such as 
oligohydramnios or polyhydramnios. Rapid-onset polyhydramnios and fetal polyuria were 
recently described by Weinberg (Weinberg et al., 2010) in a singleton pregnancy developing 
transient third trimester gestational diabetes insipidus in the mother. Nevertheless, the 
mechanism of fetal polyuria remains elusive in this case. The authors’ speculated on either 
maternal over-hydration or an effect on fetal vasopressin of the increased maternal 
vasopressinase, for which transplacental passage has been described.  
6. Fetal disorders/conditions associated with disturbances in ADH 
production or activity and their repercussions on the pregnancy course 
Both AVP and oxytocin are synthesized by the hypothalamic supraoptic and 
paraventricular nuclei during the first weeks of fetal life. AVP is found in high 
concentrations in fetal plasma and neonate umbilical cord blood and thought to be 
involved in blood pressure regulation. The main stimulus of AVP release in the fetus is 
hypoxia but also hypotension, acidosis and hypercarbia may play a role. Aquaporin-2 
metabolism in the fetus and neonate is not fully understood. Researches in both preterm 
and at term infants suggested that in early postnatal life aquaporin-2 urinary levels cannot 
serve as a marker of AVP renal action and renal capacity to concentrate urine (Nyul et al., 
2002; Zelenina et al., 2006) although opposing results were reported (Iacobelli et al., 2006). 
Nevertheless, in the same studies urinary aquaporin-2 concentrations correlated 
adequately with the overall maturity of tubular renal function and decreased in 
conditions of impaired kidney activity. In the fetus and newborn, diabetes insipidus is a 
rare disorder with a complex pathogenesis (table 3).  
Most cases of central diabetes insipidus are secondary to a known etiology while defective 
AVP action is often related to a pathological condition and/or specific medication in the 
pregnant mother. 
Clinically, diabetes insipidus may be suspected in newborns presenting during the first days 
of life with polyuria and weight loss, and is confirmed by hypernatremia, high plasmatic 
osmolality and low urine osmolality and a good response to desmopressin. Nevertheless, 
diagnosis during the neonatal period may be difficult because of frequent lack of polyuria 
due to the decreased renal glomerular filtration that exists during the neonatal period. The 
increase in the glomerular filtration rate thereafter unmasks the later polyuria. Moreover, 
the low osmolarity of the breast milk may mask specific features of diabetes insipidus in 
neonates that are exclusively breastfed. The disorder may be suspected in infants with 
unexplained fever, irritability, lack of weight gain, hypernatremia. Often, the child can be 
calmed with water but not with milk. Rapid management is required to prevent potentially 
lethal complications such as intracranial bleeding and renal vein thrombosis. 
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Central diabetes insipidus Nephrogenic diabetes insipidus 
Perinatal asphyxia Medication (in the mother) (e.g. lithium, 
angiotensin-converting enzyme inhibitors, 
angiotensin type 1 receptor blockers)  
Intracranial hemorrhage (e.g. vitamin K defi-
ciency) 
Familial or sporadic congenital 
nephrogenic diabetes insipidus 
Infection (e.g. congenital toxoplasmosis, con-
genital cytomegalovirus infection, meningitis: 
streptococcal, meningococcal, listeria menin-
gitis, brain abscess) 
 
Congenital defects in the brain/pituitary 
morphogenesis (e.g. pituitary agenesis/hypo-
genesis, septo-optic dysplasia,  holoprosence-
phaly, congenital nasal pyriform aperture 
stenosis, cleft lip/palate, meningomyelocele, 
hydrocephalus, facial diplegia (Mobius 
syndrome), Delleman syndrome, Kabuki 
syndrome etc.  
 
Cranio-cerebral trauma  
Intracranial tumors (e.g. teratoma, craniopha-
ryngioma)  
Cysts  
Familial central diabetes insipidus  
Wolfram syndrome*   
Table 3. Etiology and pathogenesis of diabetes insipidus in the fetus and neonate.*onset of 
diabetes insipidus is confirmed after the age of 3 month.  
6.1 Central diabetes insipidus in the fetus and neonate 
Congenital isolated central diabetes insipidus may be of idiopathic nature (Bianchi, 2010) or 
due to various underlying pathological states (Table 3). Idiopathic central diabetes insipidus 
has been particularly reported in preterm very low birth weight infants (Stapleton & Di 
Geronimo, 2000). Central diabetes insipidus appears as a component of congenital 
anomalies, in particular midline developmental defects or genetic syndromes, of which the 
most important are represented by: 
• midline craniofacial malformations (holoprosencephaly)  
• septo-optic dysplasia (De Morsier’s syndrome) is a complex disorder that consists in 
incomplete development of midline cranial structures such as hypoplasia/aplasia of the 
optic nerves, hypoplasia/absence of the septum pellucidum and/or pituitary 
hypoplasia/aplasia, with isolated or combined pituitary hormone deficiencies 
including AVP deficiency and in particular growth hormone deficiency. HESX1 gene 
mutations have been associated with septo-optic dysplasia. 
• Delleman syndrome associating somatic changes such as macrocephaly, micrognathia, 
anophtalmia, cleft lip and palate, cutis aplasia, diabetes insipidus and 
panhypopituitarism (Leichtman et al., 1994) 
• Kabuki syndrome, a multiple malformation disorder caused by mutations in the MLL2 
gene (Ng et al., 2010), a histone methyltransferase ubiquitary expressed among adult 
 
Diabetes Insipidus 90
complications, of maximum severity in cases associated with HELLP syndrome and pre-
eclampsia. Maternal complications may include severe hypernatremia, eclampsia, hepatic 
insufficiency and disseminated intravascular coagulation. In several cases, premature 
delivery of the fetus avoids fetal hypoxia and intrauterine fetal death (Wiser et al., 2008).  
Generally, transient diabetes insipidus recovers about 4-6 weeks after delivery. Rarely, 
permanent central diabetes insipidus with or without definitive pituitary insufficiency of 
various degrees may occur in the mother, depending on the underlying clinical condition of 
pregnancy-related diabetes.  
Gestational diabetes insipidus may associate in utero fetal complications such as 
oligohydramnios or polyhydramnios. Rapid-onset polyhydramnios and fetal polyuria were 
recently described by Weinberg (Weinberg et al., 2010) in a singleton pregnancy developing 
transient third trimester gestational diabetes insipidus in the mother. Nevertheless, the 
mechanism of fetal polyuria remains elusive in this case. The authors’ speculated on either 
maternal over-hydration or an effect on fetal vasopressin of the increased maternal 
vasopressinase, for which transplacental passage has been described.  
6. Fetal disorders/conditions associated with disturbances in ADH 
production or activity and their repercussions on the pregnancy course 
Both AVP and oxytocin are synthesized by the hypothalamic supraoptic and 
paraventricular nuclei during the first weeks of fetal life. AVP is found in high 
concentrations in fetal plasma and neonate umbilical cord blood and thought to be 
involved in blood pressure regulation. The main stimulus of AVP release in the fetus is 
hypoxia but also hypotension, acidosis and hypercarbia may play a role. Aquaporin-2 
metabolism in the fetus and neonate is not fully understood. Researches in both preterm 
and at term infants suggested that in early postnatal life aquaporin-2 urinary levels cannot 
serve as a marker of AVP renal action and renal capacity to concentrate urine (Nyul et al., 
2002; Zelenina et al., 2006) although opposing results were reported (Iacobelli et al., 2006). 
Nevertheless, in the same studies urinary aquaporin-2 concentrations correlated 
adequately with the overall maturity of tubular renal function and decreased in 
conditions of impaired kidney activity. In the fetus and newborn, diabetes insipidus is a 
rare disorder with a complex pathogenesis (table 3).  
Most cases of central diabetes insipidus are secondary to a known etiology while defective 
AVP action is often related to a pathological condition and/or specific medication in the 
pregnant mother. 
Clinically, diabetes insipidus may be suspected in newborns presenting during the first days 
of life with polyuria and weight loss, and is confirmed by hypernatremia, high plasmatic 
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Central diabetes insipidus Nephrogenic diabetes insipidus 
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optic nerves, hypoplasia/absence of the septum pellucidum and/or pituitary 
hypoplasia/aplasia, with isolated or combined pituitary hormone deficiencies 
including AVP deficiency and in particular growth hormone deficiency. HESX1 gene 
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anophtalmia, cleft lip and palate, cutis aplasia, diabetes insipidus and 
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human tissues; affected individuals may present with strabismus, long palpebral 
fissures, large ears, cardiac and immunological anomalies, dwarfism and mental 
retardation. Diabetes insipidus may develop. 
In fact, any severe defect of brain development can be associated to diabetes insipidus due 
to alterations in pituitary embryogenesis.  
• Pituitary agenesis/hypogenesis with absence of the pituitary stalk 
• Wolfram syndrome or DIDMOAD with an autosomal recessive transmission pattern,  
which combines diabetes insipidus, diabetes mellitus, optic atrophy, deafness, atonia of 
the bladder, hydronephrosis, neurological and gastrointestinal anomalies, 
hypogonadotropic hypogonadism and depression. In contrast to diabetes mellitus 
which develops early, even during neonatal life, diabetes insipidus appears in up to 
75% of affected individuals, with a peak incidence at age 15 (range 3 months - 40 years). 
Desmopressin treatment adequately controls diabetes insipidus. The gene involved in 
most Wolfram syndrome cases is called WFS1 and located in the chromosomal region 
4p16.1. The WFS1 protein, also known as wolframin, appears to be involved in cell cycle 
regulation and apoptosis. Recently, another mutation associated with the WSF2 locus 
on chromosome 4 has been identified in patients suffering from Wolfram syndrome 
(Amr et al., 2010).  
• Familial central diabetes insipidus may be transmitted autosomal dominant, autosomal 
recessive or X-linked with variable penetrability. 
Congenital toxoplasmosis may result in central diabetes insipidus. In that case, the serum 
and cerebrospinal fluid samples of the patient test positive for toxoplasmosis. Alternatively, 
etiology is suggested by cranial computed tomography revealing obstructive hydrocephalus 
and cranial disseminated calcifications. Anterior pituitary insufficiency is occasionally cited 
in neonates with congenital toxoplasmosis with central adrenal insufficiency and central 
hypothyroidism (Siahanidou et al., 2006). One case of prolonged fever, attributed to 
hypothalamic dysfunction (hypothalamic fever) has been reported in association to diabetes 
insipidus in a newborn diagnosed with congenital toxoplasmosis (Siahanidou et al., 2006). 
Tumors of the hypothalamus-pituitary region may account for onset of central fetal/neona-
tal diabetes insipidus. Neonatal craniopharyngioma has been repeatedly reported as a 
suprasellar tumor with partially cystic appearance in MRI and variable outcome after 
radical neurosurgery (Müller et al., 2000). Arachnoid cysts with suprasellar localization may 
manifest with pituitary insufficiency and central diabetes insipidus when the cyst reaches a 
sufficient size. In Langerhans cell histiocytosis early infiltration of the hypothalamus and 
pituitary stalk causes central diabetes insipidus. Combined Langerhans cell histiocytosis and 
DiGeorge Syndrome displaying multisystemic involvement of Letterer-Siewe disease at 
birth has been reported (Levendoglu et al., 1996). Transiently, central diabetes insipidus in 
the neonate is described in association with hypotonia, dysmorphism and marked speech 
delay due to 22q13 deletion syndrome (Barakat et al., 2004).  
6.2 Nephrogenic diabetes insipidus in the fetus and neonate 
Congenital nephrogenic either sporadic or familial diabetes insipidus is caused in 90% of 
cases by X-linked transmitted mutations in the AVP receptor 2 gene that encodes for the 
AVP type 2 receptor. Until now, five types of molecular defects in the protein synthesis or 
action have been described. The other 10% of cases result from mutations in the aquaporin-2 
gene. Autosomal recessive inheritance of the mutation results in proteins that remain 
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trapped in the endoplasmic reticulum and are rapidly degraded, whereas autosomal 
dominant inheritance results in synthesis of structurally normal proteins but inable to 
ensure intracellular transport within the tubular renal cell. In few cases of congenital 
nephrogenic diabetes insipidus neither the AVP gene nor the aquaporin-2 gene are affected.  
Note worthily, nephrogenic diabetes insipidus in the fetus may be a result of maternal 
medication such as lithium, angiotensin-converting enzyme inhibitors or angiotensin type 1 
receptor blockers. Lithium is commonly used in the treatment of psychiatric disorders, 
specifically bipolar depression. Lithium causes polyhydramnios from fetal diabetes 
insipidus in utero. Clinical presentation of infants with in utero lithium exposure comprises 
transient neuro-developmental deficiencies such as hypoglycemia, hyperbilirubinemia, 
hypotonia, respiratory distress syndrome, cyanosis, lethargy, and weak suck and Moro 
reflexes in the neonatal period. Additionally, large-for-gestational age and prematurity, 
Ebstein’s anomaly, cardiovascular toxicity and endocrine complications have been reported. 
Of endocrine disorders, newborns are at risk to develop nephrogenic diabetes insipidus and 
thyroid dysfunction (Kozma et al., 2005).  
Alternatively, other congenital tubulopathies can associate a partial defect in the capacity to 
concentrate urine and usually present with a low degree of polyuria (e.g. Bartter syndrome, 
Fanconi syndrome, nephronophtisis, polycystic kidneys, obstructive nephropathy, nephritis, 
renal insufficiency).  
7. Diagnostic challenges in pregnancy-related diabetes insipidus 
Whatever etiology of diabetes insipidus, the main feature consists of excretion of high 
amounts of dilute, flavorless, hypotonic urine. Irrespective of the pathogenesis of the 
disorder (i.e. central, gestational or nephrogenic diabetes insipidus), a primary deficiency in 
urinary concentration will result in a rise of urine flow that produces a slight (1% to 2%) 
decrease in body water and a commensurate rise in basal plasma osmolality and sodium. 
Therefore, high urine output with low urine specific gravity (<1005) and low urine 
osmolality (50-300 mOsm/kg) in the presence of normal or elevated sodium (148 mmol/l) 
or plasma osmolality strongly suggests diabetes insipidus. Exclusion of other causes of 
polyuria such as diabetes mellitus, renal failure, hypokalemia, hypercalcemia and tubular 
renal acidosis is made by determination of fasting glucose and oral glucose tolerance test, 
urea, creatinine, creatinine clearance and electrolytes in blood and urine. Adrenal function 
tests, thyroid tests and basal and dynamic tests of pituitary function should be considered. 
The practice of relating plasma to urine osmolality is useful; it can quickly differentiate 
diabetes insipidus from parenteral fluid excess. The urine osmolality is a measure of the 
concentration of the urine and is determined by AVP concentration. In a hypernatremic 
patient, a urine osmolality below that of the plasma suggests diabetes insipidus.  
In contrast to women with primary polyuria, women with diabetes insipidus will not 
concentrate their urine osmolality during the water deprivation test. However, differential 
diagnosis from primary polydipsia may be difficult in women with partial AVP deficiency 
since fluid restriction can increase AVP secretion sufficiently to concentrate the urine. 
Additionally, the water deprivation test performed during pregnancy needs closed 
observation of the patient and may be problematic because the resulting plasma volume 
may lead to important dehydration and may increase the risk of utero-placental 
insufficiency. In this case diagnostic tests may be limited to measurement of urine and 
plasma osmolality and AVP or DDAVP administration.  
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Partial or mild forms of diabetes insipidus, however, cannot be clearly differentiated by 
indirect tests. In these cases, plasma AVP measurement with a high sensitivity assay, before 
and after water deprivation or osmotic stimulation during infusion of hypertonic 5% saline 
increases diagnosis accuracy (Zerbe & Robertson, 1981). Using a nomogram, AVP remains low 
after hypertonic saline infusion in patients with cranial diabetes insipidus while it increases 
normally in relation to plasma osmolality in patients with primary polyuria. Pregnant women 
with pre-existing central diabetes insipidus will respond by increased urine osmolality after 
intranasal delivery of AVP or AVP injection, as will patients developing hypothalamus-
pituitary disorders during pregnancy. In contrast, vasopressin resistance is well-described in 
transient or recurrent gestational diabetes insipidus due to vasopressinase, however, patients 
will adequately respond to DDAVP. If there is a normal response to AVP or DDAVP that is 
urine osmolality obtained 30–60 min after injection increases, nephrogenic diabetes insipidus 
can be ruled out. All pregnant women with diabetes insipidus of unclear etiology should 
undergo magnetic resonance imaging of the hypothalamus-pituitary region to establish 
coexistence of disorders that may have affected AVP-producing neurons.  
Notably, differential diagnosis of diabetes insipidus in pregnant women without pre-dating 
disease may be challenging and, occasionally, certainty with regard to the etiopathogeny is 
obtained after delivery. However, it has to be kept in mind that persistence of polyuria and 
polydipsia more than 6 weeks postpartum questions the diagnosis of true gestational 
diabetes insipidus and needs re-evaluation of the case. 
8. Therapy of diabetes insipidus in pregnancy and lactation 
Once the diagnosis is established, close monitoring of vital signs, fetal status, fluid balance, 
body weight and renal function are essential. Fluid intake must approximate urine volume 
and other fluid losses. Many patients require parenteral treatment, which usually consists of 
5% glucose and normal saline infusion. Vaginal delivery with regional analgesia or, in the 
case of cesarean section, spinal anesthesia, are the methods of choice. 
Earlier pituitary extracts of AVP contained oxytocin and precipitated uterine contractions 
and preterm labor. Chlorpropamide can stimulate secretion of AVP and potentiate its effects 
but it can cause fetal hypoglycemia and neonatal diabetes insipidus.  
Because AVP degradation by vasopressinase is initiated by clipping the first amino-acid of 
the hormone, whereas its analog called DDAVP (1-deamino-8-D-arginine vasopressin, 
desmopressin acetate) is devoid of the first amino acid of AVP, the treatment of choice in 
patients with pregnancy-related diabetes insipidus is DDAVP. In contrast to the naturally 
occurring hormone, arginine-vasopressin, DDAVP exhibits practically no pressor activity 
and a prolonged antidiuretic activity lasting from 8 to 12 h (Fjellestad-Paulsen et al., 1993). 
There are several routes of administration of DDAVP. In pregnancy, the intranasal, oral or 
sublingual routes are preferred (Table 4).  
 
Intransal Oral Sublingual (Melt) 
Spray Drops Tablets Tablets 
- 5 µg 100 µg 60 µg 
10 µg 10 µg 200 µg 120 µg 
20 µg 20 µg 400 µg 240 µg 
Table 4. Dose comparison of different DDAVP (desmopressin acetate) formulations. 
 
New Insights into the Diagnosis and Management of Pregnancy-Related Diabetes Insipidus 95 
Decreased response to nasal DDAVP may occur during episodes of rhinitis. In these cases or 
when oral administration is not possible, and in the postoperative period, the parenteral 
form (4 µg/ml, intravenously, intramuscularly or subcutaneously) is preferred.  
Experience with the use of DDAVP during pregnancy is increasing; it is safe for both the 
mother and the fetus. In fact, DDAVP appears not to cross the placenta within detectable 
limits (Ray et al., 2004). To be mentioned, however, there is large individual variation in the 
amplitude and duration of effect. Hence, doses have to be tailored individually for optimal 
efficacy.  
Hyponatremia is reported to occur after first doses of DDAVP in patients who do not 
restricte oral water intake; therefore, desmopressin carries the potential hazard of dilutional 
hyponatremia if the patient continues to drink inappropriately despite persistent 
antidiuresis. Lower extremity edema and signs of water intoxication may develop in cases 
with excessive dosage.  
9. Conclusion  
Diabetes insipidus in pregnancy and postpartum is an endocrine disorder with potentially 
serious consequences on the maternal course of gestation and on fetal development and 
health when occurring in association with life-threatening clinical conditions such as 
preeclampsia, HELLP syndrome or pituitary insufficiency. Although described more than 
one hundred years ago, the disease is not fully understood from the pathophysiological 
point of view and appears to be under-diagnosed. Basically, most information available in 
this area of knowledge resulted from isolated case reports or case series reviews, while on 
the contrary few conclusions were drawn from systematic studies documenting disease 
prevalence and therapy. To improve knowledge in the diagnosis and multispecialty 
management of women with pregnancy-related diabetes insipidus and their offspring, 
further studies are warranted. 
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1. Introduction  
Cade described the effects of lithium on manic episodes in 1949.  Schou confirmed these 
initial observations in 1954. From 1949 until today we can speak of the history of 
psychopharmacology, in fact it is the oldest drug in mental disorders that is still in full use 
(Johson, 2006).  
The Food and Drug Administration (FDA) approved it in 1970 for the treatment of acute 
mania and in 1974 for the prophylaxis of bipolar disorder.  
Today lithium valid indications remain in force: acute mania, bipolar depression, prophylaxis 
and maintenance of bipolar disorder and unipolar depression. Moreover, its use has also been 
extended to many diseases: personality disorders, aggression, anxiety, etc. (Freeman, 2006). 
However, it is a drug whose management requires detailed knowledge of their numerous 
side effects (Table 1), as well as drug interactions (Table 2), contraindications and special 
situations (Álvarez, 2000). The fact that it is a drug with a very narrow therapeutic window, 
requires frequent monitoring plasma determinations. 
We report a case that has, in principle, one of the most common side effects of using this 
drug, 25 to 35 percent of patients have polyuria and polydipsia (Sadock, 2004), a person who 
concurrently also presents serious illnesses which require special surveillance. But a close 
examination proved to be another slightly different pathology documented. 
Central diabetes insipidus (CDI) is a condition characterized by polyuria, polydipsia, and 
nocturia and is due to deficiency of arginine vasopressin (AVP). 
The case has already been published four years ago in a Spanish journal (Gil-Díez, 2007), but 
we consider it of interest in order to report on the progress of the disease and a bibliographic 
update.  
2. Case report 
A 61 year old woman diagnosed with bipolar disorder since the age of 18. She was 
frequently hospitalized due to depressive episodes and treated with lithium for about 19 
years with excellent results.        
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Cardiovascular system Sinus Node dysfunction 
ECG changes 
Myocardial disorders (myocarditis) 
Kidney On Glomerular Filtration Rate (GFR) 
On Serum Creatinine 
On Distal Tubular function 
Renal Tubular acidosis 
Proteinuria 
Morphologic changes 
Body weight Increase 
Nervous System Acute toxicity 
Permanent cognitive impairment 
Cognitive functions altered 
Haematology Leukocytosis 




Endocrinous System Hypothyroidism 
Increased Calcium plasma levels 
Glycemic disorders 




Sexual function Sexual dysfunction  
Table 1. Main Lithium side effects. 
Family history: A mother and a brother diagnosed with affective disorder who died by 
suicide. 
Significant medical history and treatment with various specialists: Primary autoimmune 
hypothyroidism with an adequate replacement therapy treatment, Diabetes mellitus type 2 
with current good metabolic control, hypercholesterolemia and obesity. 
She was continuously treated with lithium 600 mg three times a day, with appropriate 
lithemia plasma levels. 
Concomitant treatment: Risperidone 3 (0 – 0 - 1/2), Quetiapine 200 (0 - 0 - 1), Levothyroxine 
100 (1 before breakfast), Glycazide 30 (1/2 – 1/2 – 0) and Symvastatine 40 (1 at bedtime). 
In July 2006, she was admitted for severe depressive episode with suicidal ideation and 
Paroxetine was added to her treatment. A few days later she suffered from fever, stupor, 
and myoclonus. Among the studies carried out a plasma lithemia of 1.03 mEq/l was 
highlighted. Psychotropic treatment was discontinued and she was referred to the Internal 
Medicine Department. Facing the possibility of a meningo-encephalitis, laboratory tests and 
CT scan were performed. She was treated empirically with acyclovir, ceftriaxone, and 
ampicillin, which lead to the disappearance of the fever and other satisfactory outcomes. 
Micrococcus sp was isolated from blood cultures. 
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Calcium Channel Blockers 





Risk: (1) Interaction risk, use only if necessary, surveillance; (2) potentially hazard, 
surveillance; (3) safe, mild discomfort 
Table 2. Lithium interactions with other psychotropic drugs 
In this context, high blood sodium levels (164 mEq/l), polyuria and polydipsia were 
presented. The urine had an osmolarity of 369, lower than would correspond to blood 
osmolarity of 353 mOsm/kg. The values of 24-hour urine cortisol were increased but with 
normal baseline figures for plasma cortisol. Also presenting: ADH: 2.8 pg/ml, aldosterone: 
273 pg/ml, renin: 0.7 ng/ml/h. Abdominal CT is performed to assess adrenal glands and 
new determinations of urinary cortisol, ACTH and DHEA plasma levels, all within the 
normal range. It was thought in diabetes insipidus and detailed assessment was made of 
Nephrology and Endocrinology Services, to confirm whether it was central or nephrogenic 
diabetes.  
The results of analytical determinations carried out are detailed as follows: 
Serum chemistries:  
- Blood glucose (82 mg/dl.), Urea (38 mg/dl.), Creatinine (0.66 mg/dl.), Uric acid (5.9 
mg/dl.), Triglycerides (151 mg/dl.), Cholesterol (265 mg/dl.), HDL-cholesterol (53 
mg/dl.), LDL-cholesterol (182 mg/dl.), Electrolytes (BUN, creatinine, Na, K, Cl all 
within normal range), Calcium (9.2 mg/dl.), Phosphorus (3.6 mg/dl.), transaminases 
(normal), blood osmolarity (296 mOsm/Kg.), urine osmolarity in 24 hours (197 
mOsm/Kg.), diuresis (4500ml.),  
- Nugent test: after administration of 1 mg of Dexamethasone, Cortisol levels post-
dexametasone 0.63 mcg/dl. 
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- Cortisol in urine 24 hours (65 mcg.),  
- Estradiol (29 pg/ml.), 
- Growth Hormone (baseline: 0.4 ng/ml. – After 15’ lower than 0.3 ng/ml.), 
- Prolactin (previous baseline values: 9.1 and 5.8 ng/ml.) 
The water deprivation test (WDT) is performed followed by desmopressin injection 
(DDAVP test). Both test results (table 3) were compatible with partial central diabetes 
insipidus, due to the appearance of urine concentration after a desmopressin injection as 
shown in the following results: 
- Blood osmolarity at 08:30 h: 297 mOsm/kg.; at 11:30 h: 304 mOsm/kg.; at 14:00 h: 300 
mosm/kg. 
- In urine from 07:30 to 08:30 h: 138 mOsm/Kg.; from 10:30 h to 11:30 h: 197 mOsm/kg.; 
from 13:30 h to 14:30 h: 154 mOsm/kg. 
- At 14:30 h (with an increased urine osmolality less than 30 mOsm/kg, blood 
osmolarity> 290 and urine> 300), 2 mcg desmopressin was injected subcutaneously. 
- Urine osmolality from 14:30 to 15:30 h: 300 mOsm/kg; from 15:30 to 16:30 h: 402 
mOsm/kg.; from 16:30 to 17:30: 351; from 17:30 to 18:30: 269 mOsm/kg.  
- Osmolality (4 h after desmopressin injecticon): 295 mOsm/kg; ADH: 1.6 pg/ml. Study 
being compatible with partial central diabetes insipidus presenting partial 
concentration of the urine after injection of DDAVP. 
In addition, there were no changes in kidney function.  
 
 Blood Urine 
Osmolality 296 mOsm/Kg 197 mOsm/Kg 
   
Water Deprivation Test   
Osmolarity (mOsm/Kg)at 08:30 h. 297 138 
 11:30 h. 304 197 
 14:00 h. 300 154 
    
DDVP test    
(2 mcgr. Dessmopresin injec.)    
Osmolarity (mOsm/Kg) at 15:30 h.  300 
 16:30 h.  402 
 17:30 h.  351 
 18:30 h. 295 269 
Table 3. Water Deprivation and Vassopresin tests results 
In the WDT (Muller test), urine osmolality is not modified neither in Central Diabetes  
Insipidus nor in Nephrogenic Diabetes Insipidus. 
In DDVP test, urine osmolality is increased > 9% in Central Diabetes Insipidus. 
MRI of the brain and pituitary findings: Partially empty sella, small laminar pituitary gland 
covering the sella’s floor, centred pituitary stalk, no abnormalities suggesting a pathology 
were showed after contrast administration. 
The patient medical history was completed with the following diagnosis: Diabetes insipidus. 
Partially empty sella. Normal pituitary function. 
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Desmopressin therapy was prescribed 0.1 mg every 8 hours. A few days later, the volume of 
urine collected in 24 hours was within acceptable range. 
Since our first study, four years ago, the patient has continued to balance 
psychopathologically and no episodes of mental illness were presented. During this time the 
patient has been treated with lithium and it’s lithemia plasma levels have always been 
within therapeutic range. 
Current treatment: 
Lithium 400 mg (1-1-1),  Clonazepan 2 mg ( ½ - ½ -1),  Escitalopram 15 (1-0 -0), Quetiapine 
100 (0-0-1), Desmopressin 0.1 mg (1-1-1), Levothyroxine 100 (1-0-0), Simvastatin 40 mg (0-0-
1), Gliclazide 30 mg (½ tablet od -breakfast-). 
During this period the patient attended frequent medical controls with analytical testing. In 
all cases the patient has remained stable. Related to central diabetes insipidus has remained 
asymptomatic, with mild polyuria and polydipsia and analytical testing within normal 
range limits. She continued with desmopressin. 
However, the patient was admitted twice for a few days because of respiratory failure and 
moderate pulmonary hypertension. Treatment includes oxygen therapy, tiotropium 18 mcgr 
(one puff od), budesonide and formoterol fumarate 160/4.5 mcgr (one puff bd) and 
torasemide 10 mg (od at breakfast). 
3. Discussion 
Central diabetes insipidus (CDI) is a condition characterized by polyuria and polydipsia due 
to the presence of inadequate secretion of antidiuretic hormone (ADH) or vasopressin by the 
neurohypophysis or posterior pituitary; in the absence of ADH polyuria, itoccurs because 
the patient is unable to concentrate urine.  
Any cause damaging or altering the neurohypophyseal system can lead to CDI (Casanueva, 
1998). Traumatic brain injury or neurosurgery are the most frequent causes, there are also 
primary and inherited forms (Table 4). However, it should be noted that in 25% of cases in 
adults the etiology remains unknown (Catalá, 2007).  
In nephrogenic diabetes insipidus (NDI) lithium interferes with the action of ADH at distal 
tubule and collector level by reducing the sensitivity of adenylate cyclase to vasopressin and 
consequently interfering with the formation of intracellular cAMP.  As some authors 
describe, 10% of patients with the chronic treatment of lithium may develop NDI (Pérez-
Blanco, 2000). 
Differential diagnosis of diabetes insipidus is complex and involves analytical testing (Table 
5) and hypothalamic-pituitary magnetic resonance imaging (MRI), together with the 
consideration of history and the exclusion of other causes (hyperglycemia, hypercalcemia, 
etc.). 
Whilst nephrogenic diabetes insipidus is considered as a possible and relatively common 
effect of lithium, this drug in central diabetes insipidus is rarely involved in its origin. 
According to other authors, the lithium can induce a partial CDI (Pérez-Blanco, 2000). We 
have found few cases documented and the mechanism of action is not known. In all 
references found the population studies are people with lithium treatment who develop 
symptoms of diabetes insipidus by the simultaneous presence of other pathologies: trauma 
(Olson, 2004), aortic stenosis (Hensen, 1997), cavernous sinus thrombosis (Kamijo, 2003). The 
role of lithium in the regulation of ADH release is discussed due to its participation in 
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Genetic or familial: autosomal 
Dominant (mutations of the gene encoding the AVP-neurophysin II) 
Recessive 
Gene mutations inactivating AVP 
X Q28 linked (gene not identified) 
Deletion of chromosome 7q 










- craniopharyngioma, pituitary adenoma, pinealoma, dysgerminoma, meningioma, 
- metastasis (carcinoma of the lung in male and female breast) 
- hematologic: lymphoma, leukemia 
- granulomas, histiocytosis, Wegener granulomatosis, sarcoidosis 
- infections: chronic meningitis, tuberculosis, syphilis, viral encephalitis, 
toxoplasmosis 
- vascular diseases: Sheehan syndrome, internal carotid aneurysm, bypass surgery, 
hypoxic encephalopathy 
- autoimmune: lymphocytic infundibulohipofisitis  
- inflammatory: lupus erythematosus, scleroderma 
- toxins: Tetrodotoxin, snake venom 
- drugs: ethanol, phenytoin, corticosteroids, alpha agonists 
- idiopathic 
Modified from: Catalá Bouset et al. Guía clínica del diagnóstico y tratamiento de los trastornos de la 
neurohipófisis. Endocrinol Nutr. 2007;54(1):23-33 
Table 4. Etiology of central diabetes insipidus. Modified from Bauset M. (2007) 
 
 Normal Central Diabetes Insipidus 
Nephrogenic 
Diabetes Insipidus 
Plasma Osmolality (mOsm/Kg) Normal Increased Increased 
Urine Osmolality (mOsm/Kg) Normal Decreased Decreased 
Urine Osmolality (mOsm/Kg) after water 
deprivation > 750 < 300 < 300 
Urine Osmolality (mOsm/Kg) after AVP > 750 > 750 < 300 




Table 5. Diabetes Insipidus differential diagnoses 
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In our case it is appropriate to note the existence of viral encephalitis in the appearance of 
the picture, so it is worth recalling the pathological images of sella and pituitary findings. 
Anyway, the case illustrates the difficulties of management of some patients with lithium, 
and the need for a differential diagnosis in the presence of diabetes insipidus (Posner, 1996) 
The treatment is also completely different. In central diabetes insipidus desmopressin is the 
drug of choice for treatment. It is a synthetic analogue of vasopressin, which has a potent 
antidiuretic effect. In our case, over 4 years has been effective, and did not change the serum 
sodium levels (one of the risks of use) (Catalá, 2007). 
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1. Introduction 
Diabetes insipidus (DI) is a clinical condition characterized by excretion of large volume of 
low specific gravity urine (1). Diabetes insipidus can be central in which there is deficient 
production of arginine vasopressin (AVP) also known as anti-diuretric hormone (ADH) or 
nephrogenic in which there is end organ resistance to ADH action (1).   
2. Classification 
Etiological classification of diabetes insipidus is as follows. 
1. Central Diabetes Insipidus (CDI) 
A. Idiopathic  
B. Familial 
C. Structural Causes  
i. Congenital: Septo-optic dysplasia 
  Tuber cinereum Hamartoma 
ii. Traumatic: Iatrogenic, head trauma  
iii. Inflammatory: Tuberculous Meningitis 
 Sarcoidosis   
 Wegener’s granulomatosis 
 Lymphocytic Hypophysitis 
iv. Neoplastic:  
a. Pediatric:  
 Hypothalamic glioma 
 Craniopharyngioma 
 Intracranial Germ Cell Tumors 
 Teratoma 
 Langerhans Histiocytosis 
b. Adult: Metastasis 
2. Psychogenic: Compulsive intake of large amounts of fluid leading to inhibition of 
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2. Psychogenic: Compulsive intake of large amounts of fluid leading to inhibition of 
normal vasopressin (2). 
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3. Nephrogenic Diabetes Insipidus (NDI) 
A. Primary 
B. Secondary: Polycystic kidney disease, drug toxicity such as Lithium toxicity, analgesic 
nephropathy, reflux nephropathy, amyloidosis, acute tubular nephropathy (1) 
3. Etiopathogenesis 
Central diabetes insipidus is characterized by decreased secretion of ADH that results in 
polyuria and polydipsia by diminishing the patient’s ability to concentrate urine. Diminished 
or absent ADH can be the result of a defect in one or more sites involving the hypothalamic 
osmoreceptors, supraoptic or paraventricular nuclei, or the supraopticohypophyseal tract. In 
contrast, lesions of the posterior pituitary rarely cause permanent diabetes insipidus, because 
the ADH is produced in the hypothalamus and still can be secreted into the circulation (1, 3).  
Psychogenic diabetes insipidus is caused by compulsive intake of large amounts of fluid 
leading to inhibition of normal vasopressin (2). 
Nephrogenic diabetes insipidus is characterized by a decrease in the ability to concentrate 
the urine due to resistance to ADH action in the kidney. NDI can be observed chronic renal 
insufficiency, Lithium toxicity, Hypocalcaemia and tubular interstitial disease (1, 4, 5). 
4. Relevant anatomy 
Sella turcica is a saddle shaped fossa located in the sphenoid bone. It is bounded by the 
prechiasmal sulcus, tuberculum sella and by the anterior clinoid processes. Sphenoid sinus 
lies below and anterior to it. The bony margins of sella are best seen with computed 
tomography (CT scan). The fatty bone marrow of the bones of the sella creates hyperintense 
T1 signal on magenetic resonance imaging (MRI). Suprasellar cistern is a CSF space located 
just above the sella and contains vessels forming the circle of Willis. Optic chiasm is located 
within the center of suprasellar cistern. On lateral aspect, pair of cavernous sinuses exist 
which contain internal carotid artery along with oculomotor, trochlear and abducent nerves 
in addition to the first and second divisions of trigeminal nerve (6, 7). 
The pituitary gland occupies the sella turcica and consists of two parts called as anterior 
(adenohypophysis) and posterior (neurohypophysis) pituitary. These lobes are 
developmentally and functionally different. Anterior pituitary is formed from the 
evagination of oral ectodermal tissue called Rathke’s pouch, which is derived from the 
nasopharyngeal tissue during the embryonic period. Posterior pituitary is derived from 
diencephalic neuroectoderm and is connected to the hypothalamus via pituitary stalk. 
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Normal precontrast sagittal(1c), coronal (1d), post contrast sagittal (1e) and coronal (1f) MRI of pituitary 
stalk and pituitary gland 
Fig. 1. Normal CT sagittal post contrast soft tissue window (1a) and bone algorithm (1b) 
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The hypothalamus is the ventral part of diencephalon and extends from lamina terminalis to 
a vertical plane posterior to the mamillary bodies and from hypothalamic sulcus to the pial 
surface of the floor of the third ventricle (5-6).  
Posterior lobe of the pituitary has rich and direct blood supply which explains extensive 
immediate contrast enhancement of posterior lobe. Anterior pituitary is supplied by the 
portal pituitary system which explains delay in contrast accumulation in anterior pituitary 
lobe compared to the posterior pituitary lobe. Similarly, due to relatively deficient vascular 
supply of anterior lobe, it is more vulnerable to ischemic insults such as Sheehan’s 
syndrome and pituitary apoplexy (6). 
Dimensions and shape of pituitary are variable during different physiological states. At 
birth, pituitary is usually globular in shape and reveals hyperintensity on T1 weighted 
images in both anterior and posterior lobe. At about 6 weeks of postnatal life, anterior lobe 
loses hyperintensity and become isointense to that of cerebral white matter. On the other 
hand, posterior pituitary retains its hyperintensity which serves as an important landmark 
throughout the life. Pituitary is usually larger in size in female and further increases during 
pregnancy. Also at adolescent, pituitary size increases physiologically. Despite variations in 
size, shape and height, pituitary gland should fill the whole sella turcica with variations in 
height (6-8).  
5. Role of imaging 
MR imaging is the modality of choice for evaluating central diabetes insipidus due to its 
multiplanar imaging capability, better tissue contrast resolution and capability to selectively 
suppress individual tissue signal like fat. CT scan is better than MRI for detecting 
calcifications, bone destruction and osteolytic lesions (6-8). 
5.1 MR imaging protocol 
Coronal T1, coronal  T2, small field of view sagittal T1 weighted images of the sella with and 
without fat saturation are obtained.,  After injection of the intravenous contrast, fat 
suppressed sagittal and coronal T1 weighted images of the sella are also obtained. MRI of 
the brain with and without contrast is also performed for a comprehensive evaluation of the 
pituitary, sellar and parasellar region (6).  
Nephrogenic diabetes insipidus is characterized by a decrease in the ability to concentrate 
urine due to resistance to ADH action in the kidney. Diagnosis of NDI is often clinical and 
laboratory based and imaging has marginal benefit in this group of DI (1, 4, 5). 
6. Central Diabetes Insipidus (CDI) 
6.1 Idiopathic Central Diabetes Insipidus 
It is the most common type of diabetes insipidus (DI) and is seen in 30-50 % of patients 
diagnosed with CDI. It has been suggested that idiopathic CDI is an autoimmune disease 
characterized by the lymphocytic infiltration of posterior pituitary and pituitary stalk. The 
role of autoimmunity is evident from the association of this disease with other autoimmune 
conditions and presence of cytoplasmic antibodies against the vasopressin. On MRI, 
posterior pituitary and pituitary stalk often appear thickened and enlarged, particularly 
during the early stage. Such presentation is more common in young female patients. 
However, thickening of pituitary is a non specific finding since patient having such 
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presentation on the MRI, may develop germinoma or histiocytosis. Particularly, progressive 
thickening of pituitary stalk in pediatric patients on serial MRIs is often due to germinoma. 
In addition, other endocrine abnormalities are also seen in such patients including 
suppressed release of growth hormone (GH), thyroid stimulating hormone (TSH) and 
adrenocorticotropic hormone (ACTH) (3).  
6.2 Familial Central Diabetes Insipidus 
Familial CDI or familial neurohypophyseal diabetes insipidus (FNDI) is often an autosomal 
dominant disease which is caused by mutations in the arginine-vasopressin gene (AVP). 
This mutation leads to accumulation of misfolded arginine-vasopressin fibrillar aggregates 
within the endoplasmic reticulum and causes death of the magnocellular neurons of SOP 
and PVN nuclei of hypothalamus. This phenomenon is called toxic gain of function and is 
also seen in other neurodegerative conditions such as Huntington disease and Parkinson 
disease. However, it is unclear how these aggregates cause death of magnocellular neurons. 
Children born with autosomal dominant disease often develop symptoms several months or 
years following the birth (9). 
6.3 Structural causes 
6.3.1 Congenital 
Septo-optic Dysplasia: 
Septo-optic Dysplasia (figure 2) is a disease spectrum with variable combination of the 
following components: 
• Optic nerve hypoplasia 
• Pituitary abnormality such as ectopic posterior pituitary 
• Absent septum pellucidum 
Septo-optic dysplasia is associated with abnormalities of cortical development and 
hypothalamic-pituitary dysfunction. Suppression of hypothalamic-pituitary axis leads to 
growth retardation secondary to suppressed release of growth hormone and TSH from the 
anterior pituitary. In addition, such involvement also affect serum level of ADH since ADH 
is released from the hypothalamus and stored in posterior pituitary before release into the 
circulation causing CDI. In addition, these children exhibit variable combinations of cleft 
palate, syndactyly, ear deformities, hypertelorism, optic atrophy, micropenis, and anosmia 
(10).  
Affected children have mutations in the HESX1 gene, which is involved in early 
development of the ventral prosencephalon. Pituitary dysfunction leads to diabetes 
insipidus, GH deficiency and short stature, and, occasionally, TSH deficiency (11). 
Posterior pituitary stores hormones released from the hypothalamic neurons which reach 
posterior pituitary via descending axons. These axons are covered by the ascending 
ectodermal cells of the Rathke’s pouch as they migrate towards the posterior pituitary 
during development. The development of posterior pituitary is complete by the end of first 
trimester. Abnormality of the migration can lead to ectopic posterior pituitary gland located 
either near the median eminence or along the pituitary stalk (12).  
Tuber Cinereum Hamartoma 
Tuber Cinerium Hamartoma is a congenital disorder of defective neuronal migration 
characterized by gray matter heterotopias, formation of which typically begins during the  
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(c) 
Fig. 2. MRI of Septo-Optic Dysplasia: Axial T2 (2a) shows bilateral optic nerve hypoplasia, 
right retinal detachment and right microophthalmia from retinopathy of prematurity. 
Coronal T1 (2b) shows absent septum pellucidum. Sagittal T1(2C) shows ectopic posterior 
pituitary bright spot.  
days 33-41 of gestational life. It is approximately 1-3 cm in size, nonneoplastic and 
disorganized collection of hypothalamic neurons, glia and fiber bundles. It is typically 
located on the floor of third ventricle within the tuber cinereum of the hypothalamus. 
Recent literature suggested that tuber cinereum hamartoma accounts for about 33% of all 
cases of true precocious puberty and is seen more commonly in boys than girls. The 
precocious puberty seen in these patients develops about 2 years earlier than in idiopathic 
precocious puberty and patients are often less than 3 years of age (13-14).  
The induction of precocious puberty is due to pulsatile release of GnRH from the 
hamartoma which leads to premature activation of hypothalamic-pituitary-gonadal axis. 
Occasionally patients present with acromegaly secondary to excessive growth hormone 
release from the Hamartoma. In addition to hormonal disturbances, patient often present 
with gelastic epilepsy (spasmodic or hysterical laughter) with interval irritability and 
depressed mood. In addition, several other malformations are also noted in association with 
tuber cinereum Hamartoma such as polydactyly, microgyria, hemispheric heterotopias, 
corpus callosum agenesis, mental retardation and behavioral problems. Occasionally, tuber 
cinereum hemartomas can be a part of Pallister-Hall syndrome which is caused because of a 
frameshift mutation of chromosome 7p13 and is characterized by multiple malformations, 
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such as polydactyly and imperforate anus. However, neurologic symptoms are less severe 
in patients with Pallister-Hall syndrome (13-14).  
With smaller (3-15 mm) pedunculated mass, patient is often asymptomatic or may only have 
central precocious puberty. However, with large (10-38 mm) and sessile lesions, patient 
often display multiple symptoms including seizures. Radiography in patients with tuber 
cinereum hamartoma and precocious puberty show advanced bone age, evidence of 
intracranial calcification, increased intracranial pressure and enlarged sella turcica. In 
addition, ultrasonography shows enlargement of ovaries accompanied by several small 
cysts/follicles, prominence/enlargement of uterus and well defined central endometrial 
lining.  CT has limited role due to decreased sensitivity at the level of sella turcica and 
shows isodense mass compared to the gray matter without any evidence of calcification and 
contrast enhancement. Therefore, MRI is the main modality for identifying hypothalamic 
hamartoma (figure 3) which shows isodense lesion to gray matter on T1 weighted images 
which do not enhance with contrast along with preservation of pituitary bright spot. On T2 
weighted images Hamartoma is either isointense or slightly hyperintense compared to gray 
matter. Particularly, lack of enhancement helps to differentiate hypothalamic Hamartoma 
from germ cell tumor, Langerhans cell histiocytosis and hypothalamic glioma which are also 
seen in the same location and show at least partial uptake of contrast (13-14).  
Recently, it has been reported that MR spectroscopy can also play an important role in 
diagnosis of tuber cinereum hamartoma with more information regarding the functional 
status of this mass. Since the mass is slow growing and rarely cause mass effect, initial 
treatment is symptomatic management and includes hormone suppressive therapy with 
leutenizing hormone antagonist such as leuprolide or continuous administration of GnRH 
analogs which effectively suppresses premature precocious puberty and seizures. Surgery is 
reserved for those patients having intractable seizures or rapid growth of mass with no 












Fig. 3. Hypothalamic Hamartoma. Precontrast coronal (3a) and sagittal (3b) images show 
isointense lesion in the region of hypothalamus. Post contrast image (3c) show lack of 
enhancement of the lesion. 
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6.3.2 Traumatic 
Iatrogenic injury from neurosurgical procedures especially after trans-sphenoidal surgery 
can lead to the CDI because of iatrogenic damage to the hypothalamus and posterior 
pituitary. For example, transsphenoidal removal of small tumors limited to sella has 
resulted in development of CDI. Whereas, removal of large tumors has been shown to 
precipitate CDI in as high as 60-80% of total patients. The incidence rate declines 
significantly in patients who have undergone minimally invasive endoscopic pituitary 
surgery (2.7% permanent and 13.6% transient). The likelihood of developing permanent CDI 
is higher if plasma sodium level reaches level higher than 145 mmol/L within the first five 
days postoperatively.   
Occasionally, neurosurgery or head trauma causes severe damage to the hypothalamus and 
pituitary stalk. In such scenarios, often triphasic response is seen. In the beginning, polyuric 
phase is present which lasts up to 4-5 days and is due to inhibition of ADH release from the 
hypothalamus.  This is followed by antidiuretic phase between days 6-11 that is 
characterized by the slow release of ADH from the posterior pituitary and leads to 
hyponatremia secondary to antidiuretic effects of ADH. Once the ADH store in posterior 
pituitary is depleted, patient develops permanent CDI. However, it is important to note that 
very often the damage to hypothalamic-pituitary axis is mild to moderate and does not 
cause permanent CDI. 3.4% of patients had transient polyuria and then transient 
hyponatremia. It is very important to realize that polyuria seen following a major surgery 
including neurosurgery is not always due to CDI and may result from excess IV fluids given 
during the surgery, and also from osmotic dieresis induced from administration of mannitol 
and glucocorticoid for minimizing the cerebral edema. These conditions can be 
differentiated from CDI by measuring urine osmolality and the response to water restriction 
and the administration of ADH. Usually, urine osmolality is less than plasma osmolality 
and less than 300 mOsm/kg and plasma AVP concentration is low in spite of high plasma 
osmolality in the CDI Rarely, patient develops combination of CDI and cerebral salt wasting 
following neurosurgery (15).  
6.3.3 Inflammatory 
Tuberculous meningitis 
Tuberculous meningitis is aseptic meningitis which is often caused because of the spread of 
infection from the pulmonary focus via hematogeneous route but can also occur because of 
contiguous spread from adjacent focus of infection. The most common endocrinal 
disturbance noted is hyperprolactinemia followed by cortisol deficiency and central 
hypothyroidism. In addition, isolated cases of SIADH and CDI have also been reported.  
Intracranial tuberculosis presents as sellar or suprasellar tuberculoma along with 
calcification, obstructive hydrocephalus, vasculitis or apoplexy. Characteristic MRI changes 
include sellar tuberculoma, osteomyelitis of adjacent bones, caseous necrosis, dural 
enhancement and exudates in and around the pituitary gland in addition to thickened 
pituitary stalk. Post contrast studies show nodularity or thickening of the stalk and 
infundibulum. The pituitary tuberculomas are heterogeneously isointense on T1 weighted 
imaging and hyperintense on T2 weighted imaging with intense enhancement with contrast. 
Occasionally, T1 weighted images show hyperintensity attributed to the high protein 
content and the non-enhancing areas are likely due to caseous necrosis (16). 
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Sarcoidosis 
Sarcoidosis is a chronic noncaseating granulomatous disease characterized by abnormal 
collection of chronic inflammatory cells including lymphocytes, macrophages and 
multinucleated giant cells at various locations including lungs, lymph node, skin and neural 
tissue. It is more common in African American female. Disease course is often insidious and 
patient may remain asymptomatic. Occasional spontaneous remissions and improvements 
have been reported but relapse rate of more than 50% is also seen.  About 10% patients 
develop serious morbidity due to pulmonary scarring and respiratory failure.  However, 
other nonspecific symptoms include fatigue, difficulty to sleep, lack of energy and 
motivation, joint swelling and pain, blurry vision, skin rash, shortness of breath. Skin lesions 
include rash, erythema nodosum (swelling in front of anterior tibia or shin) and lupus 
pernio. There are some variants of sarcoidosis. For example, triad of erythema nodosum, 
bilateral hilar lymphadenopathy and arthalgia is called Lofgren syndrome that has good 
prognosis compared to other variants. Involvement of CNS is referred as neurosarcoidosis 
and is noted in 5% of patients diagnosed with sarcoidosis. In addition, about 33% of patients 
diagnosed with neurosarcoidosis develop some degree of CDI. In addition, occasional 
hypothalamic disturbances and defects in anterior pituitary hormonal release are also noted 
in such patients. Neurosarcoidosis affects leptomeninges, vascular structures, cranial nerves, 
hypothalamus, infundibular stalk and pituitary gland. DI is suggested to be due to the either 
vasculitis or direct granulomatous effect.  
As with other inflammatory condition involving pituitary stalk, MRI shows uniformly 
thickened pituitary stalk but occasional involvement of adjacent hypothalamus and 
pituitary is seen. Similar to other granulomatous disease, strong contrast enhancement is 
also seen. Interestingly, such features on MRI are seen only in patients who have CDI for 
less than 2 years and are lost upon follow up suggesting that neurosarcoidosis induced DI is 
self limiting (17-18).  
Wegener's granulomatosis 
Wegener s granulomatosis (WG) is a systemic, necrotizing, granulomatous vasculitis of 
small and medium sized vessels that was first described in detail by Friedrich Wegener in 
1939. It is a chronic disease of unknown etiology and is closely associated with elevated 
serum levels of anti-neutrophil cytoplasmic antibody (ANCA). Once diagnosis is 
established, WG require lifelong immunosuppresion because of propensity to cause 
irreversible end organ damage.  It affects multiple organ systems, such as upper and lower 
airway involvement (sinusitis, epistaxis, dyspnea and cough), kidney (impaired kidney 
functioning, rapidly progressive glomerulonephritis and chronic kidney failure) and other 
organs. In about one third of patients, CNS is involved and patient exhibit features of 
peripheral neuropathy, mononeuritis multiplex, cranial nerve palsies, stroke, cerebral 
vasculitis and rarely CDI. Involvement of posterior pituitary in WG is very rare with only 
less than 50 cases described in literature so far since 1953. Due to rare association between 
WG and CDI, it is often missed during the early course of disease. Therefore, it is very 
important for physicians to suspect WG in any patient presenting with nasal congestion, 
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6.3.2 Traumatic 
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phase is present which lasts up to 4-5 days and is due to inhibition of ADH release from the 
hypothalamus.  This is followed by antidiuretic phase between days 6-11 that is 
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Sarcoidosis 
Sarcoidosis is a chronic noncaseating granulomatous disease characterized by abnormal 
collection of chronic inflammatory cells including lymphocytes, macrophages and 
multinucleated giant cells at various locations including lungs, lymph node, skin and neural 
tissue. It is more common in African American female. Disease course is often insidious and 
patient may remain asymptomatic. Occasional spontaneous remissions and improvements 
have been reported but relapse rate of more than 50% is also seen.  About 10% patients 
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pernio. There are some variants of sarcoidosis. For example, triad of erythema nodosum, 
bilateral hilar lymphadenopathy and arthalgia is called Lofgren syndrome that has good 
prognosis compared to other variants. Involvement of CNS is referred as neurosarcoidosis 
and is noted in 5% of patients diagnosed with sarcoidosis. In addition, about 33% of patients 
diagnosed with neurosarcoidosis develop some degree of CDI. In addition, occasional 
hypothalamic disturbances and defects in anterior pituitary hormonal release are also noted 
in such patients. Neurosarcoidosis affects leptomeninges, vascular structures, cranial nerves, 
hypothalamus, infundibular stalk and pituitary gland. DI is suggested to be due to the either 
vasculitis or direct granulomatous effect.  
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enhancement is seen. Loss of posterior pituitary bright spot is seen on T1 weighted images 
(likely due to significant decrease in arginine-vasopressin content in posterior pituitary) and 
no contrast enhancement is noted.  Occasionally, MRI failed to show any changes in 
pituitary in patients with proven clinical CDI and WG. In such patients, it has been 
suggested that CDI is caused because of small vessel vasculitis and therefore remain 
undetected. Treatment is often directed at immune suppression (19-20). 
Lymphocytic infundibuloneurohypophysitis and lymphocytic adenohypophysitis 
Lymphocytic Infundibuloneurohypophysitis and Lymphocytic Adenohypophysitis were 
initially identified as one of the most important causes of idiopathic DI. Lymphocytic 
Adenohypophysitis is a rare autoimmune disease which is seen more commonly in younger 
female of menstrual age and is acute in onset. Patients often have other autoimmune disease 
as well and are positive for autoantibodies against arginine-vasopressin secreting cells. It is 
not yet clear whether these antibodies are cytotoxic and cause DI via damaging the neural 
tissue. However, their presence indicates the high likelihood of development of overt DI in 
such patients. Such patients have long history of subclinical disease followed by clinically 
obvious DI.  
MRI in lymphocytic adenohypophysitis typically shows pituitary infundibulum thickening 
and neurohypophysis enlargement in such patients. During the early subclinical phase, 
posterior lobe of pituitary is often hyperintense on MRI but become normal again indicating 
the self-limiting nature of this disease. Upon biopsy, inflammatory infiltrate consisting of T 
lymphocytes and plasma cells is identified in the affected tissues with occasional presence of 
macrophages, neutrophils and eosinophils in the anterior pituitary. Interestingly, treatment 
with DDAVP leads to recovery of posterior pituitary function along with disappearance of 
autoantibodies.  
Lymphocytic Infundibuloneurohypophysitis presents with the combination of CDI and 
vision disturbances and might have serum positivity for autoantibodies against arginine-
vasopressin secreting cells. Lymphoplasmacytic infiltrate is seen in hypothalamus, pituitary, 
infundibulum, optic nerve, tract and chiasm. MRI imaging in these patients show normal 
pituitary with focal nodular thickening of the infundibulum, stalk thickening, and absence 
of hyperintense signal of neurohypophysis. Occasionally, anterior pituitary is also affected. 
Overall, it is also a self-limiting disorder and no treatment is needed except hormone 
replacement for short duration of time. In addition, glucocorticoid therapy is also given to 
decrease the intracranial pressure (21-22).  
6.3.4 Neoplastic 
6.3.4.1 Pediatric neoplastic causes 
Hypothalamic glioma 
Hypothalamic gliomas are low-grade tumors arising from glial cells and are classified as 
World Health Organization grade I tumors. Despite low grade, these tumors are associated 
with higher morbidity and mortality. Very often these tumors are located in optic 
chiasmatic/hypothalamic region but are also seen in the posterior fossa, temporal lobe and 
spinal cord. Hypothalamic gliomas are commonly seen in childhood and adolescent age 
group. However, hypothalamic gliomas are occasionally seen in adults and are more 
aggressive than their pediatric counterparts. Male and female are equally affected.  
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About one third of the hypothalamic gliomas are associated with neurofibromatosis 1, 
which is an autosomal dominant disease resulting from mutation on chromosome 17. 
Patients who have associated NF1 have been reported to have better prognosis than those 
without NF1 and are characterized by smaller, often non-cystic lesions with more frequent 
involvement of the orbital portion of optic nerve. On the other hand, gliomas without 
associated NF1 are larger, cystic and frequently affect hypothalamus and optic chiasm. In 
severe cases, calcification is noted within the stroma of hypothalamic glioma, making it hard 
to distinguish from craniopharyngioma. Clinical presentation includes headache, visual 
disturbances, failure to thrive, hyperactivity and endocrinal disturbances such as diabetes 
insipidus.  
On CT scans, hypothalamic gliomas are hypodense compared to the gray matter whereas on 
MRI, the mass (figure 4) is hypointense to isointense on T1 weighted images and 
hyperintensive on T2 weighted images. The contrast enhancement is variable but usually 
mildly homogeneous. Large gliomas may have cystic component that is hypodense on CT 
and hyperintense on T2 weighted MRI. T2 weighted images are useful for delineating the 
spread of tumor along the optic tract. Angiography is performed in case of giant and rapidly 
growing tumors with signs of malignant transformation identifying cerebral vessel 
displacement and enhancement of abnormal vascular tumor net. Treatment is based on the 
aggressiveness of the tumor and often involves the combination of surgery, chemotherapy 
and radiotherapy (23-24).  
Craniopharyngioma 
Craniopharyngioma (CPH) is a benign tumor, which derives from Rathke’s pouch. It is 
postulated to arise from cells of the embryonic epithelium lining the pharyngeal-pituitary 
passage extending from the bottom of third ventricle up to the wall of pharynx. It 
constitutes 10% of all pediatric brain tumors, 90% of all pituitary masses and 56% of all 
chiasmal-sellar tumors. Two varieties have been identified including cystic (or 
adamantinomatous) tumors (ACPs) and squamous-papillary variety that are markedly 
different both clinically and pathologically.  
ACP is more commonly seen and is often noted in pediatric patients (between 5-10 years of 
age). It is characterized by one or more large cysts with variable wall thickness and central 
proteinacious fluid that has machine oil consistency. In addition, it also has variable 
proportion of solid component. Overall, it is an inhomogeneous mass commonly associated 
with both solid and cystic component and some degree of calcification in more than 90% of 
cases. It is commonly seen in sellar and suprasellar location.  
Squamous papillary variant is often solid in nature and rarely present with cystic 
component. Calcification is not commonly seen. They are often large masses and lead to 
mass effect and location specific manifestations. Patient often develop Horner syndrome, 
neurological deficit, epilepsy, headache, pseudotumor cerebri and elevation in intracranial 
pressure. 
It is associated with CDI both before and after the curative surgery with higher incidence 
noted postoperatively. Interestingly, patients who underwent transfrontal removal of 
craniopharyngioma have no biologically active ADH in the serum despite elevated level of 
immunoreactive ADH. In addition, replenishment of ADH level is not effective. This 
presentation mimics nephrogenic DI. However, CDI in this setting is often transient. 
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Fig. 4. Hypothalamic Glioma: Precontrast sagittal T1 (a), axial T1 (b), post contrast axial T1 
(c) and coronal T1 (d) images of pilocytic astrocytoma involving hypothalamus 
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(c) and coronal T1 (d) images of pilocytic astrocytoma involving hypothalamus 
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Imaging is very important for identifying CPH, and for delineating the location and extent 
of craniopharyngioma (figure 5). For example, plain radiography reveals changes in shape 
and size of the sella turcica, deformity of the anterior clinoid process along with 
calcifications in the chiasmal–sellar region. In addition, calcification is often seen within the 
cavity of sella and often present as laminar pattern of calcification within the capsule. In 
majority of the patients with CPH, the dorsum sella turcica is shortened. Mass effect on the 
third ventricle causes increase in intra-ventricular pressure with dilatation of ventricular 
system and widening of bony sutures. CT and MRI provide more detailed and accurate 
description of CPH, including precise size of the tumor, proportion of solid and cystic 





Fig. 5. Sagittal T1W post contrast MR image shows a complex solid and cystic  sella-supra 
sellar enhancing mass. This was a proven Craniopharyngioma on histopathology. 
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On CT, it appears as a well defined mass with heterogeneous density. Solid part is isodense 
to the brain but cystic part is usually hypodense than that of brain. Density of solid 
component increases considerably upon contrast enhancement. CT may show hypodense 
lesion within the ventricles with peripheral rim of calcification. T1 weighted MR images of 
cystic component are often heterogeneous ranging from hypointense to hyperintense signal 
depending on the protein content of cyst whereas the solid or nodular part of tumor is 
usually isointense. On T2 weighted images, cystic area appears hyperintense with 
hypointense foci representing calcification. Proteinacious nature of the cystic fluid causes 
hyperintense signal on T1weighted images and mild hyperintensity on T2-weighted 
imaging at the periphery. On sagittal images, sedimentation phenomenon of cystic content 
can be seen. On MRI, intense contrast enhancement is seen in the wall of the cyst and also in 
the solid component of the tumor (25-26).  
Intracranial germ cell tumors 
Intracranial germ cell tumors often located close to the midline and could be both benign 
and malignant.  Germ cell tumors arise due to defective migration of primordial germ cells 
and are commonly seen within the gonads, mediastinum or in the pineal region. In fact 
more than 50% of tumors within the pineal regional are germ cell tumors. It usually presents 
between the age of 10-12 years and males are more frequently affected if tumor is located 
within the pineal regions whereas slight female preponderance is noted in case of 
suprasellar germ cell tumors. Most of the intracranial germ cell tumors are within the pineal 
region and 20% are seen in suprasellar region and few are identified in the pituitary fossa. 
AFP and b-HCG levels are elevated in patients with germ cell tumor and are routinely used 
for screening purpose and monitoring response to treatment. They constitute 3-5% of 
pediatric intracranial tumors and 0.5-1% of adult intracranial tumors. Common clinical 
features are endocrinal disturbances such CDI, precocious puberty and panhypopituitarism. 
In addition, obstructive hydrocephalus, visual defects and optic nerve atrophy are also seen.  
On CT, germ cell tumors (figure 6) appear as hyperdense lesions with homogeneous contrast 
enhancement. It often shows abnormal subtle pituitary stalk thickening and enhancement in 
patients with CDI. On MRI, germinoma are isointense or mildly hypointense on T1 weighted 
images and isointense or mildly hyperintense on T2 weighted images. Strong contrast 
enhancement is seen on both CT and MRI. Treatment of choice is radiotherapy with excellent 
prognosis. Chemotherapy is used in radiotherapy resistant tumors (27-28). 
Teratoma 
Teratomas are usually benign tumors which contain elements derived from all the three 
germ layers and are covered by a capsule. They are commonly seen in pediatric male 
patients. When located intracranially, these lesions have predilection for the midline and 
involve the pineal region, the third ventricle, and the infundibulochiasmal region. Rarely, 
intracranial suprasellar teratomas extend into the pituitary fossa, with enlargement of the 
sella turcica, thereby resulting in visual disturbance, DI, and hypopituitarism.  
Sella is often enlarged with widening of the entry and depression of the bottom. Often teeth 
like inclusions are seen with in the sella and around it. Occasionally, initial MRI may fail to 
identify the mass. However, upon follow up with T1- and T2-weighted MR imaging, high 
signal intensities representing fat components can be seen in sellar and suprasellar areas. 
Very often, MRI reveals teratomas as heterogeneous mass secondary to the presence of all 
three germ line structures which enhance following contrast administration (29-30).  
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Fig. 6. Hypothalamic Dermoid: Non-fat suppressed coronal T1 (a) and sagittal T1 (b,c) 
shows hyperintense T1 signal in the hypothalamic mass that suppresses on fat suppressed 
T1 sagittal (d ) image representing fat in the dermoid. 
 















Fig. 6. Hypothalamic Dermoid: Non-fat suppressed coronal T1 (a) and sagittal T1 (b,c) 
shows hyperintense T1 signal in the hypothalamic mass that suppresses on fat suppressed 
T1 sagittal (d ) image representing fat in the dermoid. 
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Langerhans cells histiocytosis 
Langerhans Cells Histiocytosis refers to the group of granulomatous disease characterized 
by abnormal activation and clonal proliferation of immune cells called histiocytes or 
Langerhans cells and is mostly seen in children between 1-4 years of age. These cells are 
bone marrow derived and are a variant of dendritic cells that normally reside in the skin. 
Upon entry of foreign antigen into body via breach of skin, these cells engulf and process 
these antigens and migrate to the nearby lymph node. They present these antigens to the 
macrophages and other immune cells and activate the cascades of both cellular and humoral 
immune response against the foreign antigen. However, upon abnormal activations, these 
cells can lead to the granumatous disease causing erosive and painful bone lesion in 
addition to effect on multiple other organ systems.  
There are three variants of histiocytosis including malignant (true histiocytic lymphomas), 
reactive (benign histiocytosis) and Langerhans cell histiocytosis (LCH). Depending upon the 
nature of bone involvement, LCH is further classified into three variants including unifocal, 
multifocal unisystem, and multifocal multisystem. In all these variants, LCH provokes 
nonspecific immune response and leads to painful bone swelling, erosive bone lesion and 
pathologic fractures, hepatosplenomegaly, lymphadenopathy, pancytopenia, infection, 
fever, skin rash, hormonal disturbances including diabetes insipidus, chronic cough, 
shortness of breath and granulomatous lung disease. LCH is commonly seen in pediatric 
patients and twice common in boys than girls.  
Frontal bone is most commonly involved however any bone can be affected and develops 
punched out lesions with sharp margins and no sclerosis. Particularly, chronic recurrent form 
is referred as Hand-Schuller-Christian disease which presents as a triad of Diabetes insipidus, 
proptosis and destructive bone lesions. On the other hand, acute form of disease is called as 
letterer-siwe disease which presents with hepatomegaly, splenomegaly, fever, eruptive skin 
lesion, thrombocytopenia and anemia. Diagnosis is established via biopsy and 
immunohistochemistry with positive reactivity for CD1a and S-100 proteins. In addition, 
electron microscopy shows abnormal membranous aggregates of endoplasmic reticulum in 
tennis racket shaped or rod shaped structures called birbeck granules or birbeck bodies (200-
400 nm in width). These bodies characteristically show central linear density and a striated 
appearance and are regarded as pathognomic of histiocytosis. It is reported that formation of 
these bodies is induced by Langerin (CD207), which is transmembrane II surface receptor 
present on the membrane of Langerhans cells. Clinically, several hormonal disturbances are 
seen but the most common is diabetes insipidus followed by growth retardation. In addition, 
galactorrhea, hypogonadism and hypopituitarism are also occasionally seen secondary to 
histiocytic infiltration of hypothalamus and partial or complete inhibition of the release of 
hypothalamic trophic hormones which subsequently suppresses pituitary hormonal release.   
On radiographs, variable sized lytic foci are seen with characteristic beveled edge 
appearance of lesion margin. Occasionally, focal residual bone lesion with button 
sequestrum is also seen lying centrally within the area of lytic lesion. On CT scan, button 
sequestrum lesions are seen as sharply defined hypodense intradiploic bony defects. In 
addition, lytic foci and erosive changes are also seen on CT scans. On MRI, button 
sequestrum lesion appears as low to intermediate intensity lesion on T1 weighted images 
and hyperintensity lesion on T2 weighted images. In addition, contrast enhancement with 
fat suppression enhances the diagnostic yield and helps identify the extent of lesion, 
invasion of adjacent epidural space, brain parenchyma or dural venous sinuses. In addition, 
scintigraphy is also helpful but show variable isotope uptake, such as smaller lesions show 
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enhanced uptake and less or no uptake in bigger lesions. This modality help identify 
multiple osseous and tissue lesions and is of use for narrowing the differential diagnosis. 





Fig. 7. Histiocytosis involving the pituitary infundibulum. Sagittal non contrast T1W MR 
image (top) shows absent posterior pituitary bright spot with thickened enhancing pituitary 
infundibulum on post contrast T1W sagittal MR image (bottom). 
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6.3.4.2 Adult neoplastic causes 
Metastasis 
Metastases to the pituitary-hypothalamic axis account for less than 1% of all the sellar 
masses. Breast cancer metastases are most common, accounting for 6-8% of all the metastasis 
to the pituitary followed by lung and GI cancers. When cancers metastasize to pituitary, 
most cancers involve the neurohypophysis but breast cancer demonstrates high affinity for 
the adenohypophysis. DI is the most common presenting symptoms in such patients and is 
seen in about 20% of such patients. Other manifestations include vision problems, anterior 
pituitary dysfunction, headache and ophthalmoplegia. It is permanent if SOP and PVN 
nuclei of hypothalamus are involved. If SON and PVN nuclei are spared and only posterior 
lobe of the pituitary is involved, than CDI is often transient.   
MRI is very useful for diagnosis and shows a destructive and inhomogeneously enhancing 
lesion extending across intrasellar and suprasellar location. In addition, diffuse enlargement 
of the gland, thickening of the pituitary stalk, invasion of the cavernous sinus, and sclerosis 
of the surrounding sella turcica can also be noted. If metastasis is localized to the skull base, 
sclerosis of sella turcica is more obvious. On the other hand, if metastasis is located within 
the pituitary parenchyma, sella turcica sclerosis is minimal (33).  
7. Psychogenic Diabetes Insipidus 
It is caused by compulsive intake of large amounts of fluid leading to inhibition of normal 
vasopressin. Obviously, there are no imaging features of this entity. Exclusion of any 
intracranial lesion by MRI of brain and sella with and without contrast might aid in its 
diagnosis (2). 
8. Nephrogenic Diabetes Insipidus (NDI) 
a. Primary: It is X-linked recessive condition with unresponsiveness of the tubules and 
collecting system to vasopressin. For obvious reasons there are no specific imaging 
features of this entity.  
b. Secondary: Polycystic kidney disease, drug toxicity such as Lithium toxicity, analgesic 
nephropathy, reflux nephropathy, amyloidosis, acute tubular nephropathy.  
Polycystic kidney disease 
Polycystic kidney disease (also known as PKD) is the most common life threatening genetic 
disorder of kidney can be either autosomal recessive (AR) or autosomal dominant (AD). 
Both ADPKD/ARPKD are characterized by the development of multiple cysts in both the 
kidneys, which are often fluid filled leading to increase in size of kidneys.  
ADPKD is the most common inherited kidney disease and is postulated to have begun 
during the embryonic life with fewer than 5% of nephrons being affected at the time of birth. 
Because of fluid accumulations, cysts continue to grow and cause pressure atrophy of renal 
parenchyma and worsening of renal failure.  Increase in serum creatinine is noted during 
the second and third decade of life with obvious renal failure during 6th-7th decade of life. 
Clinical features include abdominal discomfort and pain (most common), hematuria, 
urinary tract infection, high blood pressure, intracranial bleeding, nephrolithiasis, colon 
diverticulosis, hepatic cysts, pancreatic cysts, splenic cysts, cysts in seminal vesicle, cardiac 
cysts, arterial aneurysms (cranial vessels and aorta), abdominal wall hernias, aortic and 
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mitral valve abnormalities, end stage renal disease, kidney failure and occasionally 
nephrogenic diabetes insipidus (34-35).  
Autosomal recessive PKD (ARPKD) is also called infantile PKD since signs of kidney 
involvement are often identified even before the birth of child. Children often die within the 
first few days because of respiratory difficulties arising because of lung hypoplasia secondary 
to oligohydramnios. In addition, with increasing age, liver scarring is also noted in children.  
The diagnosis of PKD is established via imaging (figure 8). Expansile fluid filled cysts of 
various sizes along with distorted renal cortex and medulla in addition to stretching and 
elongation of kidney tubules and blood vessels are often noted. Ultrasound is recommended 
for the initial screening because of ease of performance, easy availability, low cost and no 
risk of radiation. But, the data obtained with ultrasound is often not reproducible and as 
accurate as compared to which is obtained via CT or MRI. Occasionally other complications 
also develop such as infection, hemorrhage, cyst rupture and peritonitis that can also be 
identified on cross sectional CT or MRI. CT is also useful for volume measurement and 
assessing structural defects in kidney, however, it involves the use of contrast and radiation.  
 
 
Fig. 8. Coronal HASTE (left) and axial TRUE-FISP (right) MR images show both kidneys 
completely replaced by cysts appearing as bright rounded structures. Notice non-
visualization of any normal renal parenchyma. The patient incidentally also had Polycystic 
Liver Disease. 
Recently, MRI has gained popularity for determining the kidney volume and estimation of 
disease progression. The data obtained via MRI is often reproducible and accurate in 
addition to excellent tissue contrast, high resolution 3D images and no need of contrast or 
radiation. Excellent visualization of renal cyst is obtained via coronal T2 weighted and axial 
fat saturated T2 weighted imaging showing hyperintense cysts throughout both kidneys. In 
addition, simple and complex cysts are easily differentiated with T1 weighted imaging. 
Contrast MRI enable better visualization of renal parenchyma however, use of gadolinium 
contrast can lead to development of nephrogenic systemic sclerosis in such patients with 
impaired kidney functions. In addition, MRI also evaluates the blood flow to the affected 
kidney, which is an important marker of disease progression. With increase in severity of 
disease, the renal blood flow decreases proportionally. In addition, imaging is also very 
important based on the reports that combined renal volume is a prognostic indicator of 
disease severity. CT and MRI are often used for volume measurement over the short period 
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ADPKD is the most common inherited kidney disease and is postulated to have begun 
during the embryonic life with fewer than 5% of nephrons being affected at the time of birth. 
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mitral valve abnormalities, end stage renal disease, kidney failure and occasionally 
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Autosomal recessive PKD (ARPKD) is also called infantile PKD since signs of kidney 
involvement are often identified even before the birth of child. Children often die within the 
first few days because of respiratory difficulties arising because of lung hypoplasia secondary 
to oligohydramnios. In addition, with increasing age, liver scarring is also noted in children.  
The diagnosis of PKD is established via imaging (figure 8). Expansile fluid filled cysts of 
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elongation of kidney tubules and blood vessels are often noted. Ultrasound is recommended 
for the initial screening because of ease of performance, easy availability, low cost and no 
risk of radiation. But, the data obtained with ultrasound is often not reproducible and as 
accurate as compared to which is obtained via CT or MRI. Occasionally other complications 
also develop such as infection, hemorrhage, cyst rupture and peritonitis that can also be 
identified on cross sectional CT or MRI. CT is also useful for volume measurement and 
assessing structural defects in kidney, however, it involves the use of contrast and radiation.  
 
 
Fig. 8. Coronal HASTE (left) and axial TRUE-FISP (right) MR images show both kidneys 
completely replaced by cysts appearing as bright rounded structures. Notice non-
visualization of any normal renal parenchyma. The patient incidentally also had Polycystic 
Liver Disease. 
Recently, MRI has gained popularity for determining the kidney volume and estimation of 
disease progression. The data obtained via MRI is often reproducible and accurate in 
addition to excellent tissue contrast, high resolution 3D images and no need of contrast or 
radiation. Excellent visualization of renal cyst is obtained via coronal T2 weighted and axial 
fat saturated T2 weighted imaging showing hyperintense cysts throughout both kidneys. In 
addition, simple and complex cysts are easily differentiated with T1 weighted imaging. 
Contrast MRI enable better visualization of renal parenchyma however, use of gadolinium 
contrast can lead to development of nephrogenic systemic sclerosis in such patients with 
impaired kidney functions. In addition, MRI also evaluates the blood flow to the affected 
kidney, which is an important marker of disease progression. With increase in severity of 
disease, the renal blood flow decreases proportionally. In addition, imaging is also very 
important based on the reports that combined renal volume is a prognostic indicator of 
disease severity. CT and MRI are often used for volume measurement over the short period 
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of time whereas in patients with long interval between consecutive follow up, ultrasound is 
the preferred modality. In addition, other quantitative imaging markers, which are often 
linked with disease progression, are size, number, spatial distribution, individual growth 
rate, and asymmetry of cysts. MRI is very often used for measuring and evaluating these 
markers of disease progression. In addition, family history and genetic testing are also 
important in diagnosing PKD. In addition, specific anatomic areas can also be evaluated 
with MRI. Review of literature suggests that kidneys can weigh as much as  8 kg (normal 
weight is 120-140 gram) secondary to the presence of multiple fluid filled cysts (measuring 
up o 3 cm) and have length up to 40 cm. In one recent study, it was found that volume of 
kidney affected by ADPKD was up to 1000 ml (in normal people, mean volume of kidney is 
150 ml). Overall, MRI is superior to ultrasonography and CT. MRI efficiently detects small 
renal cysts as small as 2 mm that are likely to be missed on CT and ultrasound (US). 
However, MRI is more expensive, less readily available, takes longer time to acquire images 
and is contraindicated in certain population such as those with pacemakers and other 
prosthesis. Some of these limitations should be overcome by technical advancements. In 
addition family history and genetic testing are also used for establishing the diagnosis (34-
35). 
Lithium nephropathy 
Lithium is a well established treatment for affective disorders. It has a narrow therapeutic 
window, ranging from 0.6 - 1.2 mMol/L. Lithium nephrotoxicity can be classified into 
nephrogenic diabetes insipidus, acute toxicity, and chronic renal disease. Nephrogenic 
diabetes insipidus is characterized by polyuria and polydipsia. Mild toxicity can be seen at 
serum lithium levels of 1.5 - 2.5 mMol/L, with moderate toxicity at levels of 2.5 - 3.5 
mMol/L (36).  
Lithium toxicity affects multiple organ systems, and may cause coarse tremors, 
neuromuscular excitability, muscle weakness, sluggishness, nausea, vomiting, diarrhea, and 
seizures. Rhabdomyolysis can also occur. Decreasing renal function, evidenced by 
increasing serum creatinine and decreased creatinine clearance, is seen in chronic lithium 
nephropathy. The only established risk factor is lithium therapy, and an increased duration 
of therapy increases the risk of progression to end-stage renal disease (ESRD). 
Discontinuation of lithium therapy does not ensure against progression to ESRD. Chronic 
lithium nephropathy is a progressive condition, and pathology demonstrates tubular 
atrophy, glomerulosclerosis, interstitial fibrosis, and distal tubular dilatation with microcyst 
formation. A recent study found that tubular microcysts were present in 62.5% of renal 
biopsies performed in patients treated with lithium, involved both the renal cortex  
and medulla, and measured 1-2 mm in diameter. A serum creatinine level of 2.5 mg/dL at 
the time of biopsy was found to be the only significant predictor of progression to ESRD 
(36).  
Renal cystic disease is commonly evaluated with US, computed tomography (CT), and MRI. 
US demonstrates well-circumscribed, anechoic cystic structures with posterior acoustic 
enhancement, and CT shows hypodense cystic structures measuring between -10 and +20 
Houndsfield units (HU). The number and nature of cystic lesions is best characterized by 
MRI, and T2-weighted imaging most accurately assesses the fluid content of lesions. MRI is 
a useful tool to evaluate the renal parenchyma, and when combined with magnetic 
resonance angiography (MRA), can effectively study the renal arteries. T2-weighted images 
demonstrate the microcysts of chronic lithium nephropathy as small hyperintense 1-2 mm 
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round lesions. In a patient with a history of lithium therapy, MR imaging of abundant 
microcysts within the kidneys bilaterally strongly supports the diagnosis of chronic lithium 
nephropathy, and may obviate the need for renal biopsy (36).  
Analgesic nephropathy 
Analgesic nephropathy is defined as damage to one or both kidneys resulting from chronic 
exposure to over the counter pain medications such as acetaminophen and NSAIDs or other 
medications containing phenacetin. It has been suggested that approximately 6 or more pills 
for 3 years significantly increases the risk for analgesic nephropathy. It is seen in 4 per 
100,000 thousand patients and is more common in female above 30 years of age, most of 
whom are self medicating for relief from chronic pain. It is more common in Europe, 
Australia and USA. However, its incidence has declined significant in the past few decades 
owing to decreased consumption of phenacetin containing compounds and public 
awareness (43-44). 
Initial changes include scarring of small blood vessels called capillary sclerosis which in turn 
lead to renal papillary necrosis and subsequently chronic interstitial nephritis. In the 
absence of treatment and avoidance of analgesics, patient develops pyelonephritis, renal 
failure, anemia, high blood pressure, NDI and end stage renal disease. These changes are 
postulated to result from decrease blood flow to the kidney because of vessel sclerosis and 
also because of inhibition of prostaglandin E2 production by NSAIDs, depletion of 
antioxidants and oxidative damage to the kidney.  
Both CT and US can be used for assessing kidney damage because of analgesic nephropathy 
and show bilateral decrease in renal volume combined with either bumpy contours or 
papillary calcifications. However, US has higher sensitivity than CT scan for detecting RPN 
due to analgesic nephropathy (37-38). 
Reflux nephropathy 
Reflux nephropathy (RN) caused because of reflux of urine back into kidneys instead of 
going forward into the bladder and then into urethra. It is caused because of defective valve 
at the site of insertion of ureter into bladder and the condition is vesico-ureteric reflux 
(VUR). Over the period of time, reflux of urine back into kidneys injures the parenchyma 
and causes small and scarred kidneys. Scarring is almost always seen and often develops 
within the first five years of life. In addition, patient also develops hypertension, hematuria, 
proteinuria, chronic renal failure, ESRD and NDI. Recurrent urinary tract infection  in male 
and female children raises the suspicion for RN and warrant further investigations. Initial 
investigations of choice are ultrasonogram, voiding cystourethrography and renal 
scientigraphy or nuclear cystography using Tc 99m dimercaptosuccinic acid (DMSA). 
DMSA scan is now regarded as the most sensitive and specific modality for detecting 
inflammatory changes within the kidney and also for identifying VUR, particulary the 
transient episodes and uses low radiation dose. In recent study it was found that DMSA 
scan was positive in children with negative vesicocysto urethrogram (VCUG), indicating 
higher sensitivity with DMSA scan. Chronic reflux nephropathy in adult can also be 
evaluated with IV excretory urography or nephropyelotomography or CT urography, which 
often reveals calyceal distortion with typical claviform morphology. In addition, dilatation 
of intra-renal urinary tract is also seen. On voiding cystourethrogram, backward flow of 
contrast from opacified bladder into the ureter is seen in patients with VUR. In addition, 
contrast enhanced CT or MRI can also show parenchymal changes such as decrease in renal 
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of time whereas in patients with long interval between consecutive follow up, ultrasound is 
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35). 
Lithium nephropathy 
Lithium is a well established treatment for affective disorders. It has a narrow therapeutic 
window, ranging from 0.6 - 1.2 mMol/L. Lithium nephrotoxicity can be classified into 
nephrogenic diabetes insipidus, acute toxicity, and chronic renal disease. Nephrogenic 
diabetes insipidus is characterized by polyuria and polydipsia. Mild toxicity can be seen at 
serum lithium levels of 1.5 - 2.5 mMol/L, with moderate toxicity at levels of 2.5 - 3.5 
mMol/L (36).  
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the time of biopsy was found to be the only significant predictor of progression to ESRD 
(36).  
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Houndsfield units (HU). The number and nature of cystic lesions is best characterized by 
MRI, and T2-weighted imaging most accurately assesses the fluid content of lesions. MRI is 
a useful tool to evaluate the renal parenchyma, and when combined with magnetic 
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also because of inhibition of prostaglandin E2 production by NSAIDs, depletion of 
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Both CT and US can be used for assessing kidney damage because of analgesic nephropathy 
and show bilateral decrease in renal volume combined with either bumpy contours or 
papillary calcifications. However, US has higher sensitivity than CT scan for detecting RPN 
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Reflux nephropathy (RN) caused because of reflux of urine back into kidneys instead of 
going forward into the bladder and then into urethra. It is caused because of defective valve 
at the site of insertion of ureter into bladder and the condition is vesico-ureteric reflux 
(VUR). Over the period of time, reflux of urine back into kidneys injures the parenchyma 
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within the first five years of life. In addition, patient also develops hypertension, hematuria, 
proteinuria, chronic renal failure, ESRD and NDI. Recurrent urinary tract infection  in male 
and female children raises the suspicion for RN and warrant further investigations. Initial 
investigations of choice are ultrasonogram, voiding cystourethrography and renal 
scientigraphy or nuclear cystography using Tc 99m dimercaptosuccinic acid (DMSA). 
DMSA scan is now regarded as the most sensitive and specific modality for detecting 
inflammatory changes within the kidney and also for identifying VUR, particulary the 
transient episodes and uses low radiation dose. In recent study it was found that DMSA 
scan was positive in children with negative vesicocysto urethrogram (VCUG), indicating 
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often reveals calyceal distortion with typical claviform morphology. In addition, dilatation 
of intra-renal urinary tract is also seen. On voiding cystourethrogram, backward flow of 
contrast from opacified bladder into the ureter is seen in patients with VUR. In addition, 
contrast enhanced CT or MRI can also show parenchymal changes such as decrease in renal 
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size and presence of notch of the renal parenchyma surface, parencymal scarring, ureteral 
dilatation and calyceal clubbing. Long standing reduction in renal mass often leads to 
glomerular injury and sclerosis. Contrast-enhanced voiding sonocystography is a newer 
modality and useful alternative. This modality is radiation free and uses microbubble-based 
contrast agents. Recently, it has been proposed that contrast-enhanced voiding 
sonocystographyshould be used for both diagnosis and follow up of patients with VUR 
since several recent studies have shown superiority of Contrast-enhanced voiding 
sonocystography over VCUG and nuclear cystography for detecting VUR. In addition, MR 
urography (MRU) is an excellent modality and provides detailed information regarding the 
anatomy (such as renal contour and caliceal configuration) and functioning of urinary tract. 
It is suggested that in many ways MRU is more useful than DMSA scan.  Recently, 
Lonergan et al. demonstrated that gadolinium-enhanced inversion-recovery MR imaging 
has higher sensitivity for detecting focus of infections within the urinary tract and offer 
greater reproducibility. In addition, MRU provides greater resolution, excellent tissue 
contrast, detailed analysis of tubular function without causing background artifact and 
radiation exposure. However, it is an expensive and time consuming modality and requires 
sedation, which negates its usefulness to some extent (39-41).   
Amyloidosis 
Amyloidosis is a group of heritable or acquired diseases characterized by the deposition of 
abnormal proteinacious material as beta-fibrillar sheets in the extracellular space. It can 
affect almost every organ system either alone or in combination. Primary amyloidosis 
develop secondary to immune disorder such as multiple myeloma where as secondary 
amyloidosis is often due to chronic inflammatory diseases such as rheumatoid arthritis. 
Definitive diagnosis is established with biopsy followed by tissue staining with special dyes. 
The commonly used staining agent is Congo Red Dye which causes apple green bifringence 
under polarized light and thioflavine-T (intense yellow-green fluorescence). In addition, 
imaging can also be crucial for managing patients affected with amyloidosis. Its utility 
however has been limited due to the fact that imaging findings are often nonspecific and 
diverse (42-43). 
Renal involvement in multiple myeloma (MM) and rheumatoid arthritis (RA) leads to small 
and contracted kidneys. CT may show either focal cortical mass with focal calcifications or 
diffuse infiltration in the kidney glomeruli or interstitium.  Variability in kidney size reflect 
the stage of disease. For example, during the acute stage, kidneys may be enlarged with 
smooth contour whereas in chronic phase kidneys are often shrunken with diffuse irregular 
contour, thinned cortex and hard texture (called as amyloid contracted kidneys). In 
addition, diffuse cortical thinning is also noted in chronic phase in addition to focal 
parenchymal nodules. Other findings noted in renal amyloidosis are amorphous 
calcification of renal parenchyma, filling defect in renal pelvis either because of blood clot or 
because of amyloid mass and perinephric mass with calcification. In addition, decreased 
renal perfusion and reduced elimination of contrast can also be seen on urography and/or 
angiography in these patients.   
On ultrasound, renal amyloidosis often meets the criteria for type 1 renal parenchymal 
disease. Increase in echogenecity of renal cortex is noted along with medullary prominence 
which is suggested to be due to the deposition of amyloid, calcium or acute parenchymal 
diseases. In addition, corticomedullary demarcation is often prominent and arcuate vessels 
are obscured (42-43).  
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Recently, it has been suggested that diffusion weighted MRI is also of use in evaluating 
renal amyloidosis in patient with familial Mediterranean fever. In addition, nuclear scan 
performed after administration of gallium show enhanced uptake in affected kidneys and is 
suggestive of disease activity. However, PET/CT failed to show enhanced uptake in case of 
cardiac and renal amyloidosis (42-44). 
Acute tubular necrosis 
Acute tubular necrosis or (ATN) is characterized by the death of tubular cells in kidney. 
Tubular cells constitute kidney tubules, which are key structures for transferring urine to the 
ureter. These cells also perform reabsorbtion of 99% of water filtered into Bowman’s capsule 
and concentrate the urine. Tubular cells possess regenerating capacity and continuously 
replace the old and dying cells. This is very important and allows for complete recovery 
from ATN if precipitating cause is eliminated. ATN often presents with ARF and is the most 
common cause of ARF. There are two varieties of ATN. One is ischemic ATN and another 
one in toxic ATN. Ischemic ATN occurs due to decreased perfusion (renal artery stenosis, 
shock, renal artery emboli) whereas toxic ATN occurs due to exposure to toxins (such as 
analgesics or antibiotics, hemoglobin, myoglobin, Bence Jones proteins of multiple 
myeloma, heavy metals, organic solvents, posion and several others). Since the damage 
occurs to the kidney, it is classified as renal cause of acute renal failure. Urinalysis often 
shows pathognomonic muddy brown epithelial cast in patients with ATN along with 
increased fractional excretion of sodium (>3%).  Histopathology shows tubulorrhexis, which 
is a localized necrosis of the epithelial cells lining the renal tubules. In addition, focal 
rupture or loss of basement membrane is also seen developing skip lesions through the 
tubules. Due to loss of basement membrane, regeneration is often unlikely in ischemic ATN. 
In toxic ATN, basement membrane is often intact and allows complete recovery if 
precipitating cause is removed in timely manner. However, in both types, dead or partially 
viable cells shed into tubular lumen and lead to obstruction and eventual renal failure. 
Ultrasound and renal scintigraphy are useful for evaluation and diagnosis of ATN. US show 
swollen and enlarged pyramids with decreased cortico-medullary differentiation and 
increased resistive index. On the other hand renal scintigraphy shows normal perfusion, 
increased retention and decreased excretion (45-46). 
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